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PREFACE 
The following thesis focuses on aspects of the replication of human 
immunodeficiency virus 1 (HIV -1), the causative agent of acquired immunodeficiency 
syndrome (AIDS). The studies described here may contribute to the development ofnew 
treatments to inhibit this virus. 
The main body of the thesis consists of two manuscripts. The frrst article 
"Functional evidence for the involvement of microtubules and dynein motor complexes 
in TRIM5a-mediated restriction of retroviruses", presented in Chapter II, was published 
in Journal of virology. This study demonstrates that the full ability of the restriction 
factor TRIM5a (tripartite motif-containing protein 5, isoform a) to inhibit retroviruses 
requires functional microtubules and dynein motor complexes. 
A similar study aimed at characterization of the involvement of microtubules and 
dynein motor complexes in owl monkey TRIMCyp-mediated restriction was also 
performed. We found that dependence on microtubules and dynein motor complexes in 
the full restriction mediated by TRIMCyp is cellular context-specific. This study, 
entitled "Inhibition of microtubules and dynein rescues HIV -1 from owl monkey 
TRIMCyp-mediated restriction in a cellular context-specific fashion" was published in 
Journal of General Virology and is presented here in Annex B. 
The second manuscript presented in Chapter III, which was in preparation at the 
time of thesis submission, discusses on the role of microtubules and dynein motor 
complexes in HIV-l core disassembly (uncoating). We found that these two cytoskeletal 
components promote uncoating of the HIV -1 capsid core. A part of this study that 
includes additional experiments was later published in Viruses ("Cytoplasmic Dynein 
promotes HIV -1 Uncoating") and is presented in Annex A. 
In conclusion, the studies presented in the following thesis provide novel insights 
into HIV -1 core uncoating and its restriction as mediated by TRIM5a. 
RÉSUMÉ 
L'infection au virus de l'immunodéficience humaine (VIH-1), l'agent causal du 
SIDA, reste incurable à ce jour. Par conséquent, il est essentiel de développer nos 
connaissances sur ses mécanismes de réplication et les stratégies d'inhibition possibles. 
Le VIH -1 appartient au groupe VI de la famille de virus Retroviridae, sous-famille 
des Lentiviridae. Le génome des rétrovirus est retrouvé sous forme d'ARN simple brin 
qui, au cours de l'infection, est réverse-transcrit en ADN double brin par l'enzyme virale 
transcriptase inverse. Cet ADN complémentaire (ADNc) est par la suite inséré dans 
l'ADN génomique de l 'hôte cellulaire par l'enzyme virale intégrase. La particularité des 
lentivirus est leur habilité à importer activement leur ADNc dans le noyau à travers les 
pores nucléaires. Suivant l'entrée dans la cellule, les étapes les plus précoces de la 
réplication du VIH sont le déshabillage de son cœur capsidique et la transcription 
inverse, et ces deux processus sont probablement interdépendants. On pense que le 
VIH-1 est transporté en direction du noyau via les complexes de dynéine associés aux 
microtubules (Fig. 1). 
TRIM5a. (tripartite motif-containing protein 5, isoform o.) est un facteur de 
restriction qui inhibe les étapes précoces de la réplication rétrovirale. TRIM5a. agit via 
une reconnaissance spécifique du cœur capsidique peu après l'entrée du virus et le 
déstabilise. TRIM5a. agit d'une façon spécifique à l'hôte et également au virus; TRIM5a. 
du singe Rhésus macaque inhibe le VIH-1 alors que TRIM5a. humain n'a pas d'action 
contre ce virus, mais inhibe d'autres rétrovirus tel que le virus de la leucémie murine 
N-tropique (N-tropic murine leukemia virus, N-MLV). Les protéines TRIM5a. forment 
des corps cytoplasmiques (CCs) qui sont associés aux microtubules (Fig. 1). 
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Schéma représentant les étapes précoces de la réplication du VIH-l et 
comment elles sont inhibées par les protéines TRIM5a. 
(1) Suivant l'entrée du virus qui est médiée par des récepteurs 
spécifiques, la capside du VIH-l (CA) s'associe aux microtubules et 
utilise les complexes moteurs de dynéine pour son transport vers le 
noyau. (2) Pendant ou après ce transport, le VIH-l accomplit la 
transcription inverse (reverse transcription, R T) et subit un déshabillage, 
deux étapes qui sont probablement interdépendantes. (3) Dans les cellules 
exprimant TRIM5a, le cœur viral est intercepté peu de temps après 
son entrée dans le cytoplasme par ce facteur de restriction. R TC, 
complexe de transcription inverse (reverse transcription comp/ex); PIC, 
complexe de pré-intégration (pre-integration comp/ex); MTOC, centre 
organisateur des microtubules (microtubu/e-organizing center). CC s, 
corps cytoplasmiques. 
Dans cette thèse, nous examinons si les microtubules et les complexes de dynéine 
ont un rôle dans (i) la restriction rétrovirale médiée par TRIM5a, et (ii) le déshabillage 
du VIH-l. Nous avons étudié ces deux processus par disruption pharmacologique ou par 
perturbation du transport médié par les complexes de dynéine. Les microtubules ont été 
inhibés par traitement au nocodazole ou au paclitaxel, et le transport dependant des 
VIl 
dynéines a été inhibé soit à l'aide d'un small interfering RNA (siRNA) ciblant la chaîne 
lourde des dynéines (dynein heavy chain, DHC), soit par sur-expression de la protéine 
p50/dynamitine, ou encore par un traitement pharmacologique au erythro-9-(2-hydroxy-
3-nonyl)adenine (ERNA). Pour analyser l'infectivité, nous avons utilisé des vecteurs 
rétroviraux exprimant la GFP. Nous avons utilisé l'imagerie à immunofluorescence pour 
observer les CCs formés par TRIM5a ainsi que les cœurs capsidiques dans les cellules 
infectées. Nous avons employé un test de «fate-of-capsid assay» qui permet l'isolation 
de cœurs capsidiques insolubles des cellules infectées, par ultracentrifugation à travers 
un coussin de sucrose. 
Dans la première partie, nous démontrons la dépendance de la restriction par 
TRIM5a aux microtubules et complexes de dynéine. La perturbation de ces deux 
composantes du cytosquelette résulte en un potentiel de restriction par TRIM5a 
significativement réduit. Cette perte de la restriction est observée soit suite à la 
perturbation des microtubules, ou bien suite à la perturbation de l'activité des complexes 
de dynéine, et n'est pas le résultat d'une diminution de la stabilité de TRIM5a ou d'une 
diminution de viabilité cellulaire. Les traitements au nocodazole ou la déplétion de DHC 
interfèrent tous deux avec la dynamique des CCs de TRIM5a, augmentant leur taille et 
altérant leur localisation intracellulaire, tel qu'observé par immunoflurorescence. De 
plus, dans le test de fate-of-capsid, les traitements au nocodazole ou au paclitaxel, et la 
déplétion de DHC augmentent la stabilité des cœurs viraUx de VIH-l dans les cellules 
infectées, fournissant une explication alternative pour la baisse de restriction. 
Dans la deuxième partie, nous avons observé que les microtubules et les 
complexes de dynéine sont probablement importants pour le déshabillage du VIH-l . 
Dans des expériences d'immunofluorescence, nous avons détecté une accumulation de 
foci de cœurs capsidiques dans les cellules infectées par le VIH-l et où le niveau 
d'expression de la DHC a été diminué ou traitées de façon à perturber les microtubules. 
Ces foci détectés dans des conditions d'infection aigüe sont probablement des cœurs 
capsidiques viraux individuels. En utilisant le fate-of-capsid assay pour analyser le 
déshabillage du cœur capsidique dans les cellules infectées, nous avons observé une 
Vlll 
augmentation des quantités de cœurs Vlraux insolubles suite aux traitements au 
nocodazole ou au paclitaxel, à la déplétion de la DHC et à la surexpression de 
p50/dynamitine. Nos résultats suggèrent qu'inhiber la dynamique des microtubules ou le 
transport médié par la dynéine interfère avec le déshabillage du VIH -1 dans le 
cytoplasme des cellules infectées, ce qui implique un lien fonctionnel entre le transport 
du VIH-1 et son déshabillage. 
En conclusion, les microtubules et les complexes de dynéine sont importants pour 
la restriction rétrovirale médiée par TRIM5a, possiblement en permettant un contact 
initial entre TRIM5a et sa cible virale. Les protéines TRIM5 contiennent possiblement 
un PMIM qui permet l'interaction directe avec les microtubules. De plus, le 
cytosquelette semble réguler la dynamique des CCs de protéines TRIM5a. Enfm, le 
réseau de microtubules et les complexes de dynéine sont importants pour la réplication 
du VIH-1 , en régulant son déshabillage en plus de son transport vers le noyau. 
Les études présentées dans cette thèse représentent des avancées importantes dans 
le domaine des interactions hôte-pathogène. Elles contribuent à augmenter l'état des 
connaissances sur la réplication du VIH-1 et le mécanisme d'inhibition par TRIM5a. Il 
est à espérer que ce travail pourra contribuer au développement futur de nouvelles 
approches pour traiter l'infection au VIH-1. 
ABSTRACT 
Infection with Human immunodeficiency virus 1 (HIV -1), the causative agent of 
acquired immunodeficiency syndrome (AIDS), remains incurable. Thus, it is essential to 
gain detailed knowledge about the mechanisms of its replication and possible ways to 
inhibit it. Following entry to the cell, HIV -1 undergoes many processes necessary for the 
productive infection, of which the earliest are uncoating and reverse transcription, which 
are likely inter-dependent. HIV-l is thought to traffic towards the nucleus using the 
microtubule-associated dynein motor complex. Tripartite motif-containing prote in 5, 
isoform a (TRIM5a) is a cellular restriction factor, found in cytoplasmic bodies (CBs), 
that inhibits the early steps of retroviral replication. TRIM5a acts through specifie 
recognition of incoming retroviral capsid (CA) cores and destabilizes them. 
Interestingly, TRIM5a CBs were found to associate with microtubules. The studies in 
the following thesis examine whether microtubules and dynein motor complexes play a 
role in (i) the retroviral restriction mediated by TRIM5a and (ii) HIV -1 core disassembly 
(uncoating). These two processes were monitored under either pharmacological 
disruption of microtubule dynamics or perturbation of dynein-mediated transport. 
Microtubule dynamics were inhibited using nocodazole or paclitaxel, while dynein 
mediated-transport was interrupted by either an siRNA targeting dynein heavy chain 
(DHC), p50/dynamitin over-expression or a pharmacological treatment using erythro-9-
(2-hydroxy-3-nonyl) adenine (EHNA). In the frrst study, we demonstrated the 
dependence of TRIM5a-mediated restriction on microtubules and dynein motor 
complexes. Disrupting these two cytoskeletal components resulted in a significantly 
decreased potential of TRIM5a to inhibit retroviral infection. The loss in restriction 
resulting from either perturbation of microtubules or disruption of dyne in motor activity 
was not due to differences in protein stability or cell viability. Both nocodazole 
treatment and DHC depletion interfered with the dynamics of TRIM5a CBs, increasing 
their size and altering their intracellular localization. In addition, nocodazole, paclitaxel 
and DHC depletion were aIl found to increase the stability of HIV -1 cores in infected 
cells, providing an alternative explanation for the decreased restriction. In the second 
study, we found that both microtubules and dynein motor complexes are likely to 
be important factors in HIV -1 uncoating. The immunofluorescence microscopy 
experiments allowed observation of an accumulation of CA/aci in HIV-l infected cells 
following DHC depletion or microtubule perturbation. Such CA/aci detected in infected 
cells are thought to be individual not-yet or partially uncoated viruses. Using a fate-of-
capsid assay to monitor HIV -1 CA core disassembly in infected cells, we observed an 
increase in the amounts of pelletable (particulate) CA cores following treatments with 
nocodazole or paclitaxel, as weIl as DHC depletion and p50/dynamitin over-expression. 
The results suggest that inhibiting the dynamics of microtubules or dynein-mediated 
transport interferes with HIV -1 uncoating in the cytoplasm of infected cells, implying a 
functionallink between HIV -1 transport and uncoating. In conclusion, microtubules and 
dynein motor complexes are important for the retroviral restriction mediated by 
TRIM5a, possibly by allowing the initial contact between TRIM5a and its viral target. 
Furthermore, it is likely that the cytoskeleton regulates the dynamics of the CBs formed 
x 
by TRIM5a proteins. Finally, the microtubule network and the dynein motor complex 
are important in RIV -1 replication regulating, in addition to the transport of its core 
towards the nucleus, its proper uncoating. 
Keywords: RIV -1, TRIM5a, uncoating, microtubules, dyne in, capsid 
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CHAPTERI 
INTRODUCTION 
1.1 HIV -1 as the causative agent of AIDS 
In the early 1980s a mysterious immune disorder epidemic emerged, initially 
within the homosexual population, intravenous drug us ers and immigrants from Haiti, 
which gradually spread into the general population. The starting point of the epidemic is 
dated June 5th 1981, when the Centers for Disease Control and Prevention (CDC) 
reported several outbreaks of opportunistic diseases in previously healthy patients. 
(CDC, 1981). At that time, the disorder was referred to as gay-related immunodeficiency 
due to reported incidence of the disease among this group. In 1982, it was renamed 
acquired immunodeficiency syndrome (AIDS)(CDC, 1982). Its causative agent was 
discovered by two independent groups in 1983-4 and the virus was called human 
immunodeficiency virus (HIV). (Barre-Sinoussi et al, 1983; Gallo et al, 1984; Popovic 
et al, 1984). Shortly after the identification ofHIV, later referred to as HIV-l, a second 
virus causing AIDS was discovered, named HIV-2 (Clavel et al, 1986). The two viruses 
differ substantially, resulting in differences in serological detection (Clavel et al, 1987). 
Although HIV-l and HIV-2 cause the same disease, individuals infected with HIV-2 
usually have a longer life span than those infected with HIV -1, as it takes more time to 
develop into full-blown AIDS (Reeves & Doms, 2002). 
Both HIV-l and HIV-2 originate from closely related simian immunodeficiency 
virus (SIV) found in many African primate species. The genetic sequence of HIV-l 
resembles SIV from chimpanzees (Pan troglodytes), while HIV-2 is similar to SIV 
infecting sooty mangabeys (Cercocebus atys) (Sharp et al, 2001; Sharp et al, 2005). The 
transfers of SIV from primates to humans happened multiple times. Interestingly, the 
oldest documented case of HIV-l infection dates to 1959; the virus was detected in a 
specimen collected in Kinshasa, the capital of Congo (Zhu et al, 1998). Although the 
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virus was present in the human population likely as early the 1920s, it did not reach an 
epidemic threshold until 1980s, as a result of colonialism-related trade in Cameroon 
(Sharp & Hahn, 20 Il). 
HIV-l can be divided into four genetically diverse groups M, N, 0 and P that 
reflect separate transfers of SIV from chimpanzees to humans (Sharp et al, 2005). The 
most widespread is HIV -1 from the M group, while the N, 0 and P groups, as weIl as 
HN-2, are limited to Africa (De Cock et al, 1993; Sharp & Hahn, 2011). The M group 
can be further divided into at least nine genetically distinct subtypes (or clades); 
subtypes A, B, C, D, F, G, H, J and K. This thesis focuses on the aspects of infection 
caused by HIV -1 belonging to M group, as this virus is the major cause of the present 
AIDS epidemic. 
1.1.1 The AIDS epidemic 
In 2012, the United Nations program on HIV/AIDS (UNAIDS) reported that 
35.3 million people were estimated to be living with HIV-1 or HIV-2 (UNAIDS, 2013). 
That year, the number of newly infected individuals reached 2.3 million people and 
approximately 2 million deaths resulting from AIDS-related diseases were reported 
(UNAIDS, 2013). Thanks to pharmacological treatments, education and interventions of 
various organizations, these numbers reached stable levels, however there is still no 
perspective to eradicate the disease. The most dramatic situation is in sub-Saharan 
Africa, where in some countries more than 25% of population is infected (Fig. 1.1). 
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Figure 1.1 Global prevalence of HIV-1. 
Image source: (UNAIDS, 2010). 
Following IDV-1 contraction a patient may experience an acute phase of infection 
with flu-like symptoms which gradually transfonns into an asymptomatic chronic 
infection. The latter usually lasts several years during which T lymphocytes bearing 
clusters of differentiation 4 receptor (CD4+ T -cells) are slowly eradicated (Organization., 
2007). The CD4+ T -cell count in healthy individuals ranges from 500 cells/J!l to 
1,500 cells/J!1. AIDS is defmed by low CD4+ T ..:cell count (less than 200 cells/J!l) and/or 
occurrence of opportunistic diseases, such as pneumonia caused by Pneumocystis carinii 
(Gottlieb, 2006) or Kaposi's sarcoma (Friedman-Kien, 1981; Rymes et al, 1981). People 
with AIDS usually die as a result of opportunistic diseases. 
1.1.2 Treatment and prevention HIV-l infection 
To this date, neither a cure nor a vaccine effective against RIV -1 have been 
developed. There are multiple obstacles in developing safe, effective and durable 
vaccines, including the fast mutation rate of the virus and high glycosylation of its spike 
proteins, which unables immune system detection of viral epitopes. Oruy one trial, 
RV144, consisting of two vaccines that individually shown no efficacy, resulted in a 
moderate, ~30%, protection (Rerks-Ngann et al, 2009). This study suggests that 
developing an effective vaccine could be feasible in the future. 
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The frrst drug effective against HIV-l azidothymidine (AZT) was introduced in 
1987. (Yarchoan & Broder, 1987). This drug is now classified as nucleoside/nucleotide 
reverse transcriptase inhibitor (NRTI). NRTIs are nucleoside analogues. that resemble 
naturally occurring nucleosides and are incorporated into nascent DNA by viral 
reverse transcriptase but not human polymerases. AZT, which was initially used as 
monotherapy, quickly resulted in the emergence of drug-resistant virus es and subsequent 
failure of the treatment. Between 1991 and 1995, four additional NRTIs were developed. 
A breakthrough came in 1995 when a new protease inhibitor (PI, saquinavir) was 
introduced, which led to the CUITent approach of combining multiple antiretroviral 
drugs targeting various steps of the viral replication cycle, known as highly active 
antiretroviral therapy (HAART) (Flepp et al, 2001). In 1996 nevirapine, a drug 
belonging to a new class of pharmaceuticals, was introduced, along with two additional 
PIs. Nevirapine is a non-nucleoside reverse transcriptase inhibitors (NNRTI) and acts 
directly on the reverse transcriptase. In 2003, the frrst fusion inhibitor was introduced 
(enfuvirtide), and in 2007 inhibitors of entry (maraviroc) and integrase (raIte gravir) were 
approved (palmisano & Vella, 20 Il), increasing therapy options for infected patients. 
Currently, there are over twenty pharmaceuticals available. Despite increased life 
expectancy and overall health improvement of patients, HAAR T has serious drawbacks, 
e.g. it has to be taken for the whole of the patient's life and administered daily; viral 
targets might acquire drug resistance; fmally, side effects such as anemia, 
hepatotoxicity, hyperglycemia, hyperlipidemia and lipodystrophy are common (Flepp et 
al, 2001). 
A very important aspect of fighting HIV -1 epidemics IS education about 
its transmissibility and the prevention of new infections. In general, three 
approved protocols employing antiretroviral pharmaceuticals to prevent HIV-l 
infection/transmission are commonly used. Treatment as prevention (TasP) is an 
approach, in which infected patients receive antiretroviral drugs in order to lower the 
chances of infecting others, and can be as effective as in 96% of cases; this approach is 
commonly used in HIV-discordant couples and to prevent mother-to-child transmission 
(De Cock et al, 2000). Also, healthy individuals can decrease the odds of becoming 
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infected by taking prophylactic antiretroviral drugs. This approach is known as 
pre-exposure prophylaxis (prEP) and is commonly practiced in HIV -discordant couples 
and sex workers; it has been shown to be effective in 70% of cases (Anglemyer et al, 
2011; Liu & Chibwesha, 2013; Vaid et al, 2013). In the case of a healthy individual that 
has been exposed to HIV -1 a post-exposure prophylaxis (PEP) can be employed to 
reduce the chances of becoming infected. This is approach is commonly used in health 
workers after accidentaI exposure to the virus, for example a needlestick injury (Cardo et 
al, 1997; Smith et al, 2005). Interestingly, male circurncision has been found to decrease 
HIV -1 transmission by at least 60% in males that have been circumcised (Auvert et al, 
2005). Additionally, it is estimated that male circumcision might prevent male-to-female 
transmission by 46% (Hallett et al, 20 Il). 
In conclusion, while the past years have seen a tremendous development in 
antiretroviral therapy, mitigating adverse effects and simplifying treatments, finding 
either a cure or a vaccine has proven elusive. 
1.1.3 Perspectives for a cure 
The ultimate aim of HIV -1 research is a complete eradication of the virus from the 
infected organism, which is known as a 'sterilizing cure '. Up to this date, only one case 
ofthis kind of cure has been described, known as the 'Berlin patient'. Timothy Brown as 
a therapy for acute myeloid leukemia underwent myeloablative treatment and then 
received a bone marrow transplant from a donor whose cells were resistant to HIV-1 
infection; this intervention resulted in a complete elimination of the virus (Hutter et al, 
2009; Hutter & Thiel, 2011). The donor had a homozygotic deletion in the HIV-1co-
receptor C-C chemokine receptor 5 (CCR5) gene (Alkhatib et al, 1996; Deng et al, 
1996; Dragic et al, 1996); lack of which prevents infection with this virus (Liu et al, 
1996). Until this date this remains the only case of a 'sterilizing cure ' . The other famous 
cases turned out to be prematurely optimistic. For example, the famous 'Mississippi ' 
infant was an infant reported to be cured as a result of an aggressive antiretroviral 
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treatment prior to, it was thought, the virus being able to establish its reservoir (Cohen, 
2013). Unfortunately, in July 2014 the virus re-emerged in the baby's blood. 
While the sterilizing cure is still beyond our reach a more feasible goal may be 
obtained, known as a ' functional cure'. The functional cure is defmed as spontaneous 
drug-free control of the viral replication. For example, the members of the ANRS 
VISCONTI study in which up to ~ 15% of early treated individuals wereshown to 
display spontaneous control of viremia (Saez-Cirion et al, 2013). The reasons for this 
viral control are still not fully understood, but it could be that early treatment, while 
limiting the viralload, enables the immune system to produce a specific response against 
the virus. 
1.1.4 The HIV-l genome and its structure 
Taxonomically HIV -1 belongs to the viral Group VI, family Retroviridae, 
subfamily Lentivirus. The genome of retroviruses exists in the form of a single-stranded 
RNA (ssRNA) which upon infection is reverse transcribed into a double-stranded 
complementary DNA (cDNA) by the viral enzyme reverse transcriptase. This DNA is 
later inserted into the host' s genome by the viral enzyme integrase. The hallmark of 
lentiviruses is their ability to actively import their cDNA into the nucleus through the 
nuclear pore complex (NPC), which allows for infection of non-dividing cells. 
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Figure 1.2 Organization of HIV -1 genome and the structure of the virus. 
(A) A schematic representation of the organization of HIV -1 genome. 
LTR - long terminai repeat. (B) A schematic representation of cleavage 
products of HIV-1 polyproteins. Gag is cleaved to MA (matrix, p17), 
CA (capsid, p24), NC (nucleocapsid, p7) and p6; Pol to PR (protease), 
RT (reverse transcriptase) and IN (integrase); Env to SU (surface 
protein, gp120) and TM (transmembrane protein, gp41). (C) A schematic 
representation of HIV -1 virion. vRNA - viral RNA. 
Image source: (Krogan, 2011). 
The HIV-1 genome consists of two positive-sense ssRNAs, ~10 kb in length 
(Ratner et al, 1985; Wain-Hobson et al, 1985) that contain nine genes (Fig. 1.2A). Three 
encode the polyproteins Gag, Pol and Env, while the others encode regulatory and 
accessory proteins, sorne of which are the result of post-transcriptional splicing. The 
regulatory proteins regulator of expression of virion proteins (Rev) , trans-activator of 
transcription (Tat) and negative factor (Nef) are expressed during the viral replication. 
The accessory proteins viral infectivity factor (Vif), viral protein R (Vpr) and viral 
protein unique (Vpu) are usually packed into the virion and play roles during the early 
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steps of infection. Interestingly. the related HIV -2 does not encode Vpu, but in its place 
encodes viral prote in X (Vpx) (Coffin et al, 1997). 
HIV-1 is an enveloped virus whose size is estimated to be approximately 120 nm 
(Kuznetsov et al, 2003). The structural proteins matrix (MA, p17), capsid (CA, p24), 
nucleocapsid (NC, p7) and p6 are the result of cleavages of the Gag precursor (P55) 
(Fig. 1.2). The CA protein forms a conical-shaped core that encases the viral RNA 
(vRNA) associated with Ne. The CA core also contains three viral enzymes, products of 
the Pol precursor: reverse transcriptase (RT, p66), integrase (IN, p32) and protease (PR, 
plO). The virions also enclose accessory proteins Vif, Vpr, Vpu (or Vpx). MA forms an 
inner shell below the lipid envelope originating from a producer cell. The envelope, 
shielding the CA core, mediates viral entry. This lipid membrane is spanned with 
transmembrane (TM, gp41) viral prote in, one of the products of the Env precursor. 
Associated with gp41 is the surface protein (SU, gp120), which is responsible for 
receptor recognition and its binding (Coffin et al, 1997). 
1.1.5 HIV-l replication cycle 
The replication cycle of lentiviruses can be clearly divided into two phases, early 
and late, whereby the first consists of the steps leading to the integration of the viral 
genome into the host's genome. The late phase consists of all subsequent events. 
1.1.5.1 Early phase 
The primary targets for HIV -1 are cells of the immune system bearing the CD4 
receptor, mainly macrophages, dendritic cells and helper T-cells (Dalgleish et al, 1984; 
Klatzmann et al, 1984a; Klatzmann et al, 1984b). Initially, the gp120 (SU) triplet, 
protruding from the viral envelope, attaches to the CD4 receptor and one of the two 
co-receptors; either CCR5 (Alkhatib et al, 1996; Deng et al, 1996; Dragic et al, 1996) or 
C-X-C chemokine receptor type 4 (CXCR4) (Deng et al, 1996; Feng et al, 1996) 
(Fig. 1.3). Receptor binding results in a conformational change of gp120, allowing for 
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penetration of the cellular membrane by gp4l (TM). This event brings the two 
membranes together which causes their fusion (Melikyan, 2014). Next, the HIV-l CA 
core is released into the cytoplasm and this is followed by two processes: reverse 
transcription and core disassembly (uncoating), which are likely inter-dependent (Rulme 
et al, 2011; Roa et al, 2012). Interestingly, RT has no proofreading properties and its 
fidelity is considerably low (1.4 x 10-5 errors per base pair (Abram et al, 2010)), thus the 
reverse transcription process is extremely error-prone. This results in an enormous 
RIV -1 mutation rate which allows the virus to quickly adapt to a changing environment, 
such as the presence of an antiretroviral drug. Transcribed double-stranded cDNA 
together with IN and other remaining viral proteins form the pre-integration complex 
(PIC) which associates with the NPC. The distinctive feature of lentiviruses is their 
ability to actively pass through the NPC and infect non-dividing cells (Lewis & 
Emerman, 1994; ~oe et al, 1993). This process is not fully understood, but it is likely 
supported by the viral protein Vpr (Kogan & Rappaport, 20 Il). Once in the nucleus, the 
viral cDNA is inserted into the host's genome, with a preference towards actively 
transcribed regions (Schroder et al, 2002). 
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Figure 1.3 mv -1 repli cation cycle. 
(1) Recognition of the cellular receptors. (2) Fusion of the viral and 
cellular membranes. (3) Core uncoating and reverse transcription. 
(4) Formation of the pre-integration complex (PIC). (5) Import and 
integration of vDNA (cDNA) into the host genome. (6) Synthesis of 
vRNAs and viral proteins. (7) Viral budding from the cellular membrane. 
(8) Maturation of released virions. . 
Image source: (NIH, 2012). 
1.1.5.2 Late phase 
Once integrated, the viral genetic material is called a provirus and is actively 
transcribed by cellular RNA polymerase II. The transcription is mediated by a single 
promoter in the 5' LTR of the provirus and requires cellular transcription factors, of 
which the most crucial is NF-KB (Nabel & Baltimore, 1987). Notably, long-living cells 
carrying proviruses can be deactivated, during which the virus can remain 
transcriptionally dormant for many years while retaining the ability to be reactivated 
with full pathogenic capacity upon the cell ' s activation (Chun et al, 1998). This state is 
called latency and is the reason why HIV -1 infection remains incurable. 
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Post integration, the frrst transcripts are spliced and regulatory proteins Tat, Rev 
and Nef are expressed (Greene & Peterlin, 2002; Jordan et al, 2003). Tat and Rev 
proteins shuttle back to the nucleus. Tat activates the production of fulliength transcripts 
and in trans stimulates the expression of all HIV -1 genes (Kao et al, 1987). Rev binds to 
newly transcribed unspliced vRNA and allows it to leave the nucleus (Pollard & Malim, 
1998). In the cytoplasm, unspliced vRNA either serves as a template for the production 
of the polyproteins Gag, Pol and Env, or is to be incorporated in newly produced virions. 
Nef is a virulence factor that significantly increases viral titers and is crucial for the 
development of AIDS (Kimpton & Emerman, 1992). Nefhas many functions, ofwhich 
the best described is its down-regulation of CD4 receptors (Aiken et al, 1994). When 
Env precursor (gp 160) is synthesized it remains attached to endoplasmic reticulum and 
then transported to Golgi where it is cleaved by cellular enzymes furin or other, related 
subtilisin-like proteases to gp120 and gp41(Decroly et al, 1994; Decroly et al, 1996). 
gp41 is embedded in the membrane and anchors gp 120, which protrudes into the Golgi 
lumen. Then the vesicles are transported to the cellular membrane at which in case of 
T -cells the viral assembly takes place (Finzi et al, 2007). Altematively, in the case of 
macrophages, newly synthesized virions bud inside so-called viral containing 
compartments (VCCs) (Nguyen et al, 2003; Pelchen-Matthews et al, 2003), which then 
frequently connect with the plasma membrane to release the virions into extracellular 
environment (Tan & Sattentau, 2013). gp41 associates with Gag and Gag-Pol precursors 
(Wyma et al, 2000), while the NC region of Gag interacts with vRNA (Sandefur et al, 
1998). Gag has been reported to interact with the KIF4 kinesin motor (Martinez et al, 
2008; Tang et al, 1999), Staufen 1 (Milev et al, 2010) and with components of 
intracellular vesicle trafficking pathways (Batonick et al, 2005; Camus et al, 2007; Dong 
et al, 2005). Viral budding is mediated by cellular endosomal sorting complexes 
required for transport (ESCRT) machinery, whose members are recruited by the p6 
region of Gag (Martin-Serrano et al, 2003). Once virions detach, PR is activated and 
undergoes auto-cleavage releasing the other viral enzymes IN and RT, and then cleaves 
Gag precursor into MA, CA, NC and p6 (Freed, 1998; Fu & Rein, 1993). Subsequently, 
these proteins assemble into the CA core, which encapsulates NC together with vRNA. 
This process is called maturation and is necessary for HIV-l infectivity. Mature virions 
12 
also enclose accessory proteins and cellular molecules, such as tRNA Lys3 that serves as a 
primer for reverse transcription (Ott, 2008; Sundquist & Krausslich, 2012). 
1.1.6 The capsid core and its uncoating 
The mature HIV-l CA core is a ~60 nm x 120 nm (Briggs et al, 2003) 
cone-shaped, protein lattice and is composed of 1,500 CA monomers arranged in 
~250 hexamers and 12 pentamers (Briggs et al, 2004; Pomillos et al, 2009) through 
interactions involving their N-terminal domains (NTD) (Pomillos et al, 2009), while CA 
C-terminal domains (CTD) are important for homodimerization and connecting the rings 
into a lattice (GambIe et al, 1997) (Fig. 1.4). 
Figure 1.4 Model of HIV -1 capsid core. 
Fullerene cone model composed of 1,056 CA subunits. NTD driven CA 
hexamers are coloured in orange, pentamers in yellow, while CTD driven 
homodimers in blue. NTD - N-terminal domain, CTD - C-terminal 
domain. 
Image source: (Pomillos et al, 20 Il). 
For many years it was thought that the HIV-l CA core disassembled immediately 
after its entry to the cytoplasm, which would then be followed by reverse transcription. 
This reasoning stemmed from the difficulties of isolating particulate cores from infected 
cells, as this structure is very fragile (Bukrinsky et al, 1993; Famet & Haseltine, 1991 ; 
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Karageorgos et al, 1993). However, more recently we have gained critical insight into 
the importance of the HIV -1 CA core and its proper disassembly, referred to as 
uncoating. 
1.1.6.1 Evidence supporting regulated HIV-1 uncoating 
The fIfst line of evidence suggesting that uncoating is an important step in HIV-l 
replication was provided by mutagenesis. CA mutants resulting in either hypostable or 
hyperstable cores are not infectious (Forshey et al, 2002; Tipper & Sodroski, 2013). 
The retroviral restriction factors TRIM5a and TRIMCyp inhibit viral infection 
(Sayah et al, 2004; Stremlau et al, 2004) through binding to incoming CA cores and 
destabilizing them (Bérubé et al, 2007; Stremlau et al, 2006). TRIM5 proteins will be 
discussed in the next section. Nevertheless, their action provides functional evidence of 
the signiticance of the 'intact' HIV-l capsid core during the tirst few hours post 
infection (p.i.). Additionally, the HIV-l small-molecule inhibitor PF-3450074 (PF74) is 
known to inhibit HIV -1 infectivity specitically by destabilizing the CA core (Shi et al, 
2011). 
Interesting evidence on the importance of uncoating was provided by linking 
uncoating with reverse transcription, since an inhibition of the latter led to a slower CA 
core disassembly (Hulme et al, 2011; Roa et al, 2012; Yang et al, 2013). The initiation 
of reverse transcription likely depends on an initial destabilization or increased 
permeability of the CA core after entry into the cytoplasm (Hulme et al, 20 Il; Zhang et 
al, 2000; Zhang et al, 1998). However, it has been suggested that the completion of 
reverse transcription takes place inside the CA core (Arhel et al, 2007; Schaller et al, 
20 Il) which at that time would likely be at the NPC. It is most likely that uncoating 
takes place in several well-orchestrated steps instead of being a rapid single-step 
process; one report suggested it might happen in at least two phases (Xu et al, 2013). 
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Additionally, a recent study reported that cellular factors are recruited to the 
incoming CA core thus shielding actively transcribing viral genetic material from 
detection by pattern-recognition receptors (PRRs) (Rasaiyaah et al, 2013). The same 
study showed that HIV -1 viruses bearing mutations in the CA protein, which unable CA 
interaction with certain cellular partners, fail to replicate in macrophages due to 
activation of innate immune response. 
Finally, CA mutagenesis also suggested that this protein has a role in nuclear entry 
(Dismuke & Aileen, 2006) and in the ability to transduce non-dividing cells (Yamashita 
& Emerman, 2004; Yamashita et al, 2007). It was also suggested that CA is linked with 
specificity to integration sites of proviral DNA (Schaller et al, 2011). Altogether, these 
reports demonstrate that the full uncoating does not happen immediately after the release 
of the CA core into the cytoplasm. 
1.1.6.2 HIV-l uncoating 
The knowledge regarding HIV -1 uncoating is very limited. This process is thought 
to be initiated soon after the exposure to the cellular environment, within the frrst hours 
from infection (Hulme et al, 2011). Large amounts of CA cores can still be observed in 
infected cells 6 hours post infection and longer (Li et al, 2009; Pawlica et al, 2014; 
Stremlau et al, 2006). Where uncoating takes place is still under debate: sorne reports 
proposed that it occurs in the cytoplasm (Hulme et al, 20 Il ; McDonald et al, 2002), 
while others suggested that uncoating takes place at the NPC (Arhel et al, 2007; 
Rasaiyaah et al, 2013; Schaller et al, 2011). The latter is supported by microscopic 
observations in which HIV-1 CA cores reach the proximity of the nucleus 1-2 h p.i. 
(Arhel, 2010; Arhel et al, 2007; McDonald et al, 2002). Additionally, CA was also 
observed at the NPC and was proposed to be responsible for the docking of the virus at 
the nuclear membrane (Arhel et al, 2007; Di Nunzio et al, 2012). Interestingly, the NPC 
members Nup358 and Nup153 were shown to directly bind to CA protein, as 
demonstrated by immunoprecipitation (Matreyek et al, 2013; Schaller et al, 2011). 
Additionally, both CA-binding domains of Nup153 and Nup538 when fused to the 
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effector domain of the rhesus TRIM5a restricted IllV -1 , providing an intracellular 
readout for the direct interaction during retroviral infection. One study reported that a 
small fraction of CA proteins might be transported inside the nucleus (Zhou et al, 2011). 
1.1.6.3 Cellular proteins regulating uncoating 
Following its entry, the IllV-1 CA core interacts with various cellular factors 
(Ambrose & Aiken, 2014). So far a handfu1 of cellular partners have been shown to 
directly bind CA core after its entry to the cytoplasm: Cyclophilin A (CypA) (Fricke et 
al, 2013; Li et al, 2009; Shah et al, 2013), cleavage and polyadenylation specific factor 6 
(CPSF6) (De laco et al, 2013; Shah et al, 2013), peptidyl-prolyl isomerase Pin1(Misumi 
et al, 2010) and PDZ domain-containing prote in 8 (PDZD8) (Guth & Sodroski, 2014). 
It was proposed that CypA and CPFS6 are recruited to the CA core to conceal the viral 
genetic material from detection by innate immunity sensors (Lahaye et al, 2013; 
Rasaiyaah et al, 2013). 
Another prote in playing a defmite yet unclear role in IllV -1 replication is 
transportin TNP03 (Ambrose & Aiken, 2014), and its importance for IllV-1 was 
genetically mapped to CA prote in (Krishnan et al, 2010). It has been suggested that the 
function of TNP03 is indirect and that it acts positively on RIV -1 replication by 
sequestering CPSF6 (De laco et al, 2013; Shah et al, 2013). At the later early stage of 
RIV-1 infection the CA core associates with nucleoporins Nup358 and Nup153 
(Schaller et al, 2011; Shah et al, 2013), which mediate nuclear import of viral PIC. 
These two NPC members also directly bind to CA proteins (Matreyek et al, 2013 ; 
Schaller et al, 20 Il). 
Interestingly, two recent studies have validated the existence of cellular proteins 
responsible for modulation of CA core stability, as evidenced by incubation with cellular 
lysates which increased the stability of CA cores (Fricke et al, 2013; Guth & Sodroski, 
2014). These also support the hypothesis that following entry the CA core is initially 
shielded from the cellular environment and uncoats later in a well-orchestrated manner. 
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However, the knowledge about the uncoating process and its cellular partners remains 
very poor and additional studies are needed for its better understanding. 
Sorne steps of the viral replication, such as intracellular transport, rely on the 
host's cytoskeleton. The eukaryotic cytoskeleton is a good target to be intercepted by 
viruses, as it is essential for cellular life and is involved in many cellular processes. 
1.2 The cytoskeleton 
The eukaryotic cytoskeleton is an abundant, complex and dynamic network of 
various filaments and regulatory proteins associated with them. They are divided into 
three groups: actin filaments (also known as microfilaments), intermediate filaments and 
microtubules. These filaments have distinct roles, structure and organization (Fig. 1.5). 
Actin filaments Intermediate filaments Microtubules 
Figure 1.5 Schematic representation of cytoskeletal filaments. 
MTOC - microtubule-organizing centre. 
Image source: (Alberts, 2002). 
Actin filaments are the smallest, 5-9 nm in diameter, and are dispersed throughout 
the cytosol with the greatest concentration below the plasma membrane, known as the 
actin cortex. Microfilaments play major functions in cytokinesis, maintaining cellular 
shape and cell migration; they are the main components of lamellipodia and filopodia. 
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Intermediate filaments belong to a large heterogeneous family of rod-like 
filaments ~ 10 nm in diameter. Most of them, such as vimentins, cytokeratins, desmins 
neurofilaments, are found in the cytosol, while others, such as lamins, are in the nucleus. 
They are stress-resistant, conferring great mechanical strength, and are responsible for 
maintaining the cell's integrity, organelle positioning and contributing to cellular 
adhesion e.g. as a component of desmosomes (Alberts, 2002; Lodish, 2004). 
1.2.1 The microtubule network 
Measuring 25 nm in diameter, microtubules are the longest, most rigid and thickest 
components of the cytoskeleton. These filaments are important in many cellular 
processes. They are responsible for organelle positioning, intracellular transport, cell 
division and migration. Additionally, they serve as an internaI scaffolding of cilia and 
flagella. 
The basic components of microtubules are heterodimers of (l- and P-tubulin which 
are tightly associated with each other by a noncovalent bond. Tubulin heterodimers 
assemble head-to-tail, forming polar protofilaments. Usually 13 protofilaments interact 
laterally to form a hollow tube known as a microtubule. These fibres assemble towards 
their plus-end, usually orientated towards the cell periphery, while the minus-end 
is usually focused in microtubule-organizing centres (MTOC) (Fig. 1.5). The MTOC, 
which is often localized in the perinuclear region (except during the cell division), 
consists of a pair of centrioles, built of nine microtubule triplets surrounded by a number 
of proteins, including y-tubulin. Microtubule growth is initiated on the y-tubulin 
complex (Alberts, 2002; Lodish, 2004). 
Microtubules are highly dynamic structures constantly switching between being 
assembled and disassembled. This property is called 'dynamic instability' (Mitchison & 
Kirschner, 1984). It allows the plus-end of microtubules to explore the cellular 
environment in the process called 'search and capture' and adapt rapidly to changing 
conditions, e.g. during cell division (Kirschner & Mitchison, 1986). Once in the right 
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place, the filaments are bound by a specialized farni1y of proteins and undergo post-
translational modifications modulating their stability (Alberts, 2002; Kueh & Mitchison, 
2009; Lodish, 2004). 
L2.l.l Regulation ofmicrotubule dynamics 
Dynarnic instability provides the basis for rnicrotubule plasticity, which is highly 
regulated by cellular factors such as rnicrotubu1e-associated proteins (MAPs), molecular 
motors and others proteins, such as kinases (Mandelkow & Mandelkow, 1995). MAPs 
specifically bind to rnicrotubules and either stabilize (e.g . Tau, MAP2 or MAP4) or 
destabilize them (e.g. katanin, stathrnin). An important group ofMAPs are the plus-end 
tracking proteins (+TIPs) that usually prevent depolymeization of rnicrotubules. 
Additionally, +TIPs serve in connecting rnicrotubules to actin filaments and organelles 
(Gouveia & Akhmanova, 2010). The most well-known members of this group are 
end-binding (EB) proteins that promote growth of rnicrotubules (Komarova et al, 2009). 
Other important regulators of rnicrotubule dynarnics are kinesin motors, especially the 
kinesin-8 farnily, members of which are known to destabilize rnicrotubules (Su et al, 
2012). Interestingly, the cortex-associated dynein motor complex was also proposed to 
play a role in binding the plus-end of rnicrotubules and stabilizing them (Hendricks et al, 
2012). 
Additional mechanisms regulating rnicrotubule dynarnics are post-translational 
modifications, usually carried out on polymerized rnicrotubules. It was proposed that 
these modifications generate a specific 'code' readable by MAPs and molecular motors 
that allows carrying divergent functions on rnicrotubules (Verhey & Gaertig, 2007). For 
example, acetylation increases binding of molecular motors (Friedman et al, 2010) while 
detyrosination decreases binding affmity of destabilizing MAPs and promotes formation 
of a stable sub-population of rnicrotubules (de Forges et al, 2012). Additionally, tubulin 
subunits have different isoforms, which contribute to the extreme diversity of 
rnicrotubules (Luduena, 1998). In conclusion, microtubule dynarnics is highly regulated 
by many cellular factors. 
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1.2.1.2 Treafments targeting microtubules 
Drugs targeting microtubules can be divided into two groups: those preventing 
microtubule assembly and others preventing their disassembly. Sorne of the drugs 
preventing assembly bind to aJ~-tubulin heterodimers, such as colchicine (Ravelli et al, 
2004) and nocodazole (Xu et al, 2002), while others bind between the dimers, e.g. 
vinblastine (Gigant et al, 2005). The second group of drugs (such as paclitaxel, 
originally named taxol (Schiff & Horwitz, 1981)), binds to and stabilizes tubulin 
polymers, also resulting in a loss of their dynamics (Derry et al, 1995). An alternative 
way to study micro tubule dynamics is to target various MAPs that regulate it: for 
instance a depletion of EB 1 results in a dramatic loss of microtubule dynamics (Rogers 
et al, 2002). 
1.2.2 Molecular motors and their role in cellular transport 
The cytoplasm is a crowded and viscous environment where only small molecules 
and proteins can freely diffuse. Movement of larger components, 20 nm of size and 
more, requires active transport (Ellis, 2001; Luby-Phelps, 2000). This transport, usually 
ATP-driven, is mediated by three classes of molecular motors: actin-based myosins and 
microtubule-based kinesins and dyneins. The myosin motor superfamily consists of 
22 groups of proteins (Foth et al, 2006). Myosins are involved in various cellular 
processes, such as cytokinesis, actin-dependent transport, membrane trafficking and 
signal transduction. Interestingly, different types of myosin motors are responsible for 
movements in opposite directions; most of the myosins move towards the plus-end of 
microfilaments, while the members of group VI move towards the minus-end (Buss & 
Kendrick-Jones, 2008). 
There are 45 known members of the kinesin motors superfamily, grouped into 
14 families. Kinesin motors are responsible for microtubule-dependent anterograde 
transport, towards the plus-end of microtubules (Hirokawa et al, 2009; Verhey & 
Hammond, 2009), with an exception of the kinesin-14 family that moves towards the 
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minus-end (Ambrose et al, 2005). In addition to the transport, kinesin motors play roles 
in cell division, exocytosis and organelle positioning. 
Dynein motors are the least diverse; there are only two members that are 
responsible for retro grade transport towards the minus-end of microtubules: the 
cytoplasmic dynein motor complex (known as dynein 1) and the intraflagellar transport 
dynein motor (known as dynein lB or dynein 2). In most cells, àll retrograde transport is 
carried out by dynein 1, thereafter referred to as the dynein motor complex. There are, 
additionally, 13 axonemal dyneins that are a part ofaxoneme and are responsible for 
cilia beating and are not involved in molecular transport. The dynein motor complex has 
multiple functions in the cell: transporting cargos towards the minus-end of 
microtubules; positioning organelles, such as Golgi, nucleus and lysosomes, and, during 
cell division, forming the mitotic spindle, attaching kinetochores and pulling astral 
microtubules (Gennerich & Yale, 2009; Roberts et al, 2013; Yale, 2003). 
DLlCs_._.~ .. 
Integral membrane protein 
(e.q. rhodopsin 
Figure 1.6 The dynein motor complex. 
Membrane Cargo 
DHC - dynein heavy chain, DLIC - dynein light-intermediate chains, 
DLC - dynein light chain, RP3 - dynein light chain Tctex-type 3, 
Arp 1 - actin-related protein 1. 
Image source: (Sung, 2006). 
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1.2.2.1 The dynein motor comp/ex 
The dynein motor complex, belongs to the AAA+ superfamily (ATPases 
associated with diverse activities) (Neuwald et al, 1999). This motor is a large protein 
complex consisting of two heavy chains (DHC, for dynein heavy chain) and several 
pairs of lighter chains (Fig. 1.6). DHC is a large protein (~520 kDa) and consists of a 
head - made of six AAA+ domains arranged into a ring -, a stalk with a microtubule-
binding site, and a tail. The tail of DHC associates with five pairs of homodimers of 
intermediate, light-intermediate and three light chains. There are three classes of light 
chains: LC8 and Roadblock (also known as LC7) and T-complex testis-specific 
protein 1 (Tctex-l) (Pfister et al, 2005). 'Lighter' subunits of the dynein motor complex 
are responsible for determining cargo specificity and thus the function of the whole 
complex (Pfister et al, 2005). Additionally, ~he dynein motor complex interacts with 
regulatory and adaptor prote in complexes, including the dynactin complex, 
lissencephaly (LIS 1), nuclear distribution protein E (NUDE) and others. The dynactin 
complex is coniposed of eleven different subunits, such as pl50Glued, p50 (also known as 
dynamitin) and actin-related protein 1 (Arp 1), and seems to be essential for most of 
the functions performed by the dynein motor complex (Fig. 1.6). The dynactin complex 
enables inter aUa an association of dynein motor complexes with cargos via Aprl and 
pl50Glued• Additionally, this complex seems to be required for the processivity of the 
dynein motor complex (McKenney et al, 2014). Regulators, such as LISI and NUDE, 
mediate targeting the dynein motor complex to the plus-end of microtubules and thus are 
essential for mitotic spindle formation and in kinetochore activity, as well as in 
intracellular transport (Kardon & Yale, 2009). 
The ATP-driven movement is carried out by DHCs that most likely associate and 
disassociate with microtubules in an altemating manner, which could be said to resemble 
'walking'. The binding of ATP to the head of dynein DHC results in the disassociation 
of the stalk from microtubules (lmamula et al, 2007). Then DHC undergoes ATP-driven 
remodelling and the ' free' stalk can reach in search for a new binding site on 
microtubules. Initially, the binding is weak, but gets very strong as a result of the 
phosphate released through ATP hydrolysis (Roberts et al, 2013). 
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1.2.2.2 Inhibitors of the dynein motor complex function 
Until recently, dynein-specific pharmacological agents were not available. The 
drug erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA) , used in this study, is a potent 
adenosine deaminase inhibitor and was also shown to inhibit ATPase activity associated 
with the DHC ofaxonemal dyneins (Bouchard et al, 1981; Penningroth et al, 1982). 
EHNA was sometimes used to study cytoplasmic dyne in (pawlica et al, 2014; Zhang et 
al, 2012), however this drug might result in other changes in the cytoskeleton, such as 
the disruption ofF-actin (Schliwa et al, 1984). 
More specific approaches to inhibit dynein-mediated transport consist of 
disrupting adaptor complexes. The best example is over-expression of p50/dynamitin, 
which causes disassociation of the dynactin complex and thus inhibition of dyne in-
dependent transport (Burkhardt et al, 1997). Rab7-interacting lysosomal protein (RlLP), 
which is a Rab7 effector found in late endosomes, is another interesting example. RlLP 
interacts with p 150Glued -C and this interaction promotes the localization of the dyncatin 
complex (and thus the dyne in motor complex) to Rab7-containing late endosomes. As a 
result of RlLP over-expression, the dyne in motor complex is employed in transporting 
the late endosomes to MTOC and thus dynein-mediated transport towards the cell 
periphery is impaired (Cantalupo et al, 2001). 
A common approach to inhibiting dynein function is the use of small interfering 
RNA (siRNA) to target one of the chains of the dynein motor complex; siRNA is often 
utilized against the DHC of dynein (He et al, 2005; Lehmann et al, 2009; Pawlica et al, 
2014). 
1.2.2.3 Coordination of bidirectional transport 
In vivo observations revealed that transported on microtubules cargos exhibit 
saltatory bidirectional movements reversing the direction every few seconds CW elte, 
2004). This led to understanding that most likely multiple kinesin and dynein motors are 
simultaneously attached to the transported cargo (Gross, 2004). Each of the motors has 
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different cargo-binding adaptors, but sorne adaptors, like the dynactin complex, can 
be important for the attachment of both the kinesin and dynein motor complexes 
(Deacon et al, 2003). Row the bidirectional transP'?rt is coordinated remains to be 
elucidated. 'Tug-of-war' is the leading theory (Hendricks et al, 2010; Muller et al, 2008) 
and suggests that both motors are active at the same time and undergo competition. 
When the force coming from one type of motors prevails, it pulls the cargo in its 
direction causing transient detachment of the opposite motors (Hendricks et al, 2010; 
Muller et al, 2008). 
1.2.3 Hijacking of the host cytoskeleton by viruses 
Many, ifnot all, viruses evolved to hijack cellular transport machinery during their 
replication cycle (Cohen et al, 2011; Dodding & Way, 2011; Radtke et al, 2006). 
Multiple viruses subvert the microtubule network and microtubule-associated molecular 
motors; examples of such viruses are adenoviruses (Leopold et al, 2000; Suomalainen et 
al, 1999), parvoviruses (Xiao & Samulski, 2012), herpes simplex virus (Radtke et al, 
2010; Wolfstein et al, 2006) and, fmally, retroviruses (Arhel et al, 2006; McDonald et 
al, 2002; Petit et al, 2003). AIso, the actin filaments are broadly subverted for viral 
trafficking, as evidenced by herpes simplex virus (van Leeuwen et al, 2002), influenza 
virus (Sun & Whittaker, 2007) and retroviruses (Arhel et al, 2006; Lehmann et al, 
2005). The knowledge on this subject is quickly expanding, providing more and more 
insight on the importance of the cytoskeleton in viral replication. 
1.2.3.1 HW-1 trafficking towards the nucleus 
The frrst step in which lllV-1 seems to require the cytoskeleton is receptor-
mediated entry to the cytoplasm; actin filaments were proposed to be necessary for 
clustering of the receptors used by lllV -1 (lyengar et al, 1998; Viard et al, 2002). Post 
fusion of viral and cellular membranes RIV -1 might temporarily associate with actin 
filaments (Fig. 1.7) (McDonald et al, 2002). This is supported by studies reporting that 
actin inhibitors inhibit lllV -1 infectivity (Bukrinskaya et al, 1998; Yoder et al, 20 Il). 
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Additionally, as observed by immunofluorescence (IF) microscopy, a treatment with an 
actin inhibitor prior to RIV -1 infection caused an accumulation of viral CA foci in the 
cell periphery (Arhel et al, 2006). Such CA foei detected in infected cells are thought to 
be individual viruses (Arhel et al, 2006; Arhel et al, 2007; Campbell et al, 2007b; 
McDonald et al, 2002). These observations confirmed that actin cytoskeleton is 
important in the early steps of viral movement towards the nucleus. 
After this initial phase, HIV -1 most likely uses the microtubule network for its 
transport towards the nucleus, specifically towards the MT OC (Fig. 1.7) (McDonald et 
al, 2002). The transfer between micro filaments and microtubules could be mediated by 
cellular microtubule-associated proteins or motors having the ability to bind both 
microtubule and actin filaments (Rodriguez et al, 2003). As observed by IF, HIV-l 
particles associated with microtubules and exhibited saltatory movements with a 
velocity of approximately ~ 1 I ..unfs (Arhel et al, 2006; MeDonald et al, 2002). Next, 
RIV-l RTCs were found to accumulate in the proximity of the MTOC (Arhel et al, 
2006; McDonald et al, 2002; Zamborlini et al, 2007). Additionally, upon treatment with 
nocodazole an accumulation of viral complexes in the vicinity of the nucleus was 
observed (Arhel et al, 2006; Arhel et al, 2007). Recently, one team reported that HIV-l 
induces the formation of a stable sub-population of microtubules and uses them for its 
transport to the nucleus (Sabo et al, 2013). Preventing the formation of these stable 
microtubules abolished HIV-l infectivity (Sabo et al, 2013). 
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Figure 1.7 Schematic representation ofHIV-l trafficking inside the celle 
Following entry, HIV-l briefly associates with the actin cortex, after 
which it is transferred to microtubules, along which it is transported 
towards the nucleus. This transport is carried out by the dynein motor 
complex. In the proximity of the nucleus HIV -1 is likely transferred to 
microfilaments, which would enable association with the nuclear pore 
complex. Newly produced viral proteins are transported towards the 
plasma membrane either in endosomes or directly on microtubules, likely 
employing kinesin-mediated transport. In the case of macrophages, 
virions bud inside virus-containing compartments (VCC). 
Image source: (Gaudin et al, 2013). 
To complete the picture, this transport is likely mediated by the dynein motor 
complex, as evidenced by an accumulation of HIV -1 virions in the cell periphery 
following microinjection of anti-dynein antibodies (McDonald et al, 2002). It remains 
uncertain which of the HIV-l proteins would interact with the dynein motor complex, 
and with which of its chains. 
Once in the vicinity of the nucleus, HIV -1 is likely transferred to perinuclear actin 
filaments, as evidenced by an observation of a slow velocity actin-like movement before 
docking at the NPC (Arhel et al, 2006). Furthermore, an actin inhibitor added 1 h p.i. 
resulted in an accumulation of HIV -1 foci in the proximity of the nucleus, but not at the 
nuclear membrane (Arhel et al, 2006). 
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Post the entry into the cell, viruses encounter not only proteins that enable their 
replication, but also specific mechanisms that have evolved to counteract the infection. 
These cellular protective systems are part ofthe host's immune system and are discussed 
in the next section. 
1.3 Innate immunity and TRIM5a 
Most organisms have developed protective systems against pathogens known as 
immune systems. Starting with a relatively simple cIustered regularly interspaced short 
palindrornic repeat (CRISPR)/CRISPR-associated protein 9 (Cas9) system in Archaea 
and Bacteria (Marraffmi & Sontheimer, 2010), continuing with an innate immune 
system in aIl Eukaryota; incIuding plants, with various effector mechanisms (Jones & 
Dangl, 2006), and finishing with a composed immune system in vertebrates. Vertebrates, 
in addition to the innate immune system, evolved an adaptive immune system (Janeway, 
2001). The adaptive immune system provides target-specific, long-lasting response, and 
its hallmark is the production of antigen-specific antibodies. Patients infected with 
RN -1 also produce specific antibodies, but the virus quickly mutates recognized 
epitopes and escapes antibody-mediated neutralization. 
While it takes a few days for the adaptive immune system to be protective, the 
innate immune system is active within minutes of infection. It is the first line of defence; 
fast, but nonspecific. When a pathogen enters the cell, specific sensors called pattern-
recognition receptors (PRRs) can detect conserved pathogen-specific motifs called 
pathogen-associated molecular patterns (P AMPs). Various PRRs can detect different 
PAMPs in distinct cellular compartments, e.g. double-stranded RNA (dsRNA) in 
endosomes is detected by Toll-like receptor 3 (TLR3), and in the cytoplasm by retinoic-
acid-inducible gene 1 (RlG-I) (Fig. 1.8). Detection of P AMPs triggers innate immune 
responses through the activation of various transcription factors e.g. nucIear factor-KB 
(NF-KB) and IFN-regulatory factor 3 (IRF-3) (Trinchieri & Sher, 2007). Detection of 
viral components results in the production of cytokines, chemokines, and interferons, 
this is known as antiviral state. Produced type 1 IFNs, which acts both in autocrine and 
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paracrine manners, activate the Janus kinase (JAK)-signal transducer and activator of 
transcription (ST A T) signalling pathway that leads to the transcription of antiviral 
IFN-stimulated genes (ISGs) (Schoggins & Rice, 2011). Many viruses evolved various 
ways to evade PRR detection and activation of the antiviral state (Rajsbaum & Garcia-
Sastre, 2013). Aiso HIV-l evades innate immunity sensors in its natural targets T-cells 
and macrophages (Rasaiyaah et al, 2013; Yan et al, 2010). 
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Figure 1.8 Mechanisms of Viral Detection in dendritic cells. 
Viral P AMPs (pathogen-associated molecular patterns), such as dsRNA, 
are detected by various PRR (pattern recognition receptors) either in the 
cytosol (RIG-I) or in endosomes (TLR3), which induces proinflammatory 
cytokines and type 1 IFNs. TLR3 - Toll-like receptor 3; TRIF - TIR-
domain-containing adapter-inducing interferon-p; TRAF6 - TNF receptor 
associated factor 6; RIPI - Receptor-interacting protein 1; NF-KB -
nuclear factor kappa-light-chain-enhancer of activated B cells; IKK i -
IKB kinase i ; TBKl - TANK-binding kinase 1; !RF - Interferon 
regulatory factor; RIG-I - retinoic acid-inducible gene 1; MDA-5 
Melanoma Differentiation-Associated protein 5; CARDs - Caspase 
activation and recruitment domains; IPS 1 - interferon-beta promoter 
stimulator 1. 
Image source: (Akira et al, 2006). 
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1.3.1 Restriction factors 
Restriction factors are proteins belonging to ISGs that dominantly act to 
specifically inhibit pathogens (Harris et al, 2012). So far, several restriction factors 
targeting IllV-1 have been described: TRIM5a (Hatziioannou et al, 2004; Stremlau et 
al, 2004), bone marrow stromal cell antigen 2 (BST -2ffetherin) (Neil et al, 2008), 
apolipoprotein B rnRNA-editing, enzyme-catalytic, polypeptide-like 3 (APOBEC3) 
(Lecossier et al, 2003; Mangeat et al, 2003), SAM domain and HD domain-containing 
protein 1 (SAMHD 1) (Hrecka et al, 20 Il ; Laguette et al, 20 Il) and myxovirus 
resistance 2 (Mx2!MxB) (Goujon et al, 2013; Kane et al, 2013; Liu et al, 2013). Most of 
these factors are counteracted by IllV -1 proteins. The restriction factor Tetherin, which 
acts by preventing viral budding, is counteracted by Vpu (Neil et al, 2008; Varthakavi et 
al, 2003). The function of APOBEC3 proteins is counteracted by the viral protein Vif 
(Sheehy et al, 2002). In the absence of Vif APOBEC3 gets incorporated into budding 
RIV -1 virions and upon the second round of infection causes hypermutations during 
viral reverse transcription (Lecossier et al, 2003; Mangeat et al, 2003). IllV-2 does not 
encode Vpu protein, but instead carries Vpx, whose role was described as counteracting 
the restriction factor SAMHD1 (Hrecka et al, 2011; Laguette et al, 2011). SAMHD1 
decreases IllV -1 infectivity in myeloid cells, such as macrophages and dendritic cells, 
by decreasing dNTP levels, which prevents viral reverse transcription (Goldstone et al, 
2011; Powell et al, 2011). Notably, the restriction factor TRIM5a, which will be 
discussed later on, is not known to be antagonized by any viral protein. Little is known 
about the mechanism of MxB-mediated inhibition, except that its block is prior to viral 
integration. Interestingly, MxB function was mapped to the CA prote in (Busnadiego et 
al, 2014; Goujon et al, 2013; Liu et al, 2013) and it was recently proposed that MxB 
might prevent IllV-1 uncoating (Fricke et al, 2014). 
1.3.2 The TRIM family of proteins 
The tripartite motif (TRIM) family of proteins encompasses multiple members 
involved in many cellular processes, such as proliferation, differentiation, signalling and 
innate immune response. The human genome contains around 100 genes coding for 
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TRIM proteins and many of them are synthesized as multiple isoforms. AH TRIM 
proteins have a common N-terminal tripartite motif comprising three domains: RING 
('reaHy interesting new gene'), one or two B-boxes and ~oiled-~oil, and therefore are 
often referred to as RBCC proteins. The C terminus of the proteins vary among the 
members and consist of one or two domains, such as SPRY (also known as PRYSPRY 
or B30.2) or Fibronectin III (FN3) (Fig. 1.9). UsuaHy, the C-terminal domain determines 
the function of the whole protein, while RBCC works as an executive module (Han et al, 
2011; Nisole et al, 2005; Reymond et al, 2001). 
Many of the TRIM proteins are involved in the antiviral defence, such as TRIM5a 
(Hatziioannou et al, 2004; Keckesova et al, 2004; Stremlau et al, 2004; Yap et al, 2004), 
TRIMII (Uchil et al, 2008), TRIM19 (promyelocytic leukemia protein, PML) (Chelbi-
Alix et al, 1998; Regad et al, 2001), TRIM21 (Hauler et al, 2012), TRIM22 (Kajaste-
Rudnitski et al, 2011), TRIM25 (Gack et al, 2007) and TRIM28 (KRAB-associated 
protein 1, Kap-l) (Wolf & Goff, 2007). The majority, if not aH, TRIM proteins are 
involved in modulation of immune responses, however they can act in diverse ways, e.g. 
TRIM5a directly interacts with a restriction-sensitive virus (Sebastian & Luban, 2005; 
Stremlau et al, 2006), TRIMII inhibits viral entry (Uchil et al, 2008) and TRIM25 is 
essential for the ability of RIG-I to trigger the innate immune response foHowing 
detection of cytosolic viral RNA (Gack et al, 2007). 
1.3.3 TRIM5a 
One of the most studied members of the TRIM family is TRIM5a that belongs to 
ISGs (Asaoka et al, 2005). It was initiaHy discovered as a cytoplasmic factor from Old 
World monkeys that inhibits IllV-I replication (Hatziioannou et al, 2004; Stremlau et 
al, 2004). Further studies revealed that TRIM5a works in a virus-specifie, species-
specifie manner. For example, rhesus macaque TRIM5a inhibits IllV-l, but not 
macaque SN, whereas human TRIM5a inhibits N-tropic murine leukemia virus 
(N-MLV) and equine infectious anemia virus (EIA V), but neither B-tropic murine 
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leukemia virus (B-MLV) nor HIV-I (Hatziioannou et al, 2004; Keckesova et al, 2004; 
Perron et al, 2004; Stremlau et al, 2004; Yap et al, 2004). 
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Figure 1.9 Structure of TRIM5a and the current model of its action. 
(A) Linear diagram representing domain organization of TRIM5a. 
(B) Schematic model of the full-Iength TRIM5a dimer. The domain 
colors are the same as in (A). (C) Schematic model ofthe TRIM5a 
hexagonal lattice, showing the deduced positions of the different domains 
and overlaid with the cryoEM projection map (gray contours). 
(D) A model in which TRIM5.a proteins form a hexagonallattice around 
the capsid core that triggers auto-ubiquitylation of TRIM5a and its 
prote as omal de gradation, which leads to tearing apart the capsid core. 
E2 - ubiquitin-conjugating enzyme. 
Image sources: (Diaz-Griffero, 2011 ; Sanchez et al, 2014). 
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TRlM5 as a member of the tripartite family contains the three domains: RING, one 
B-box and coiled-coil, while its splice a additionally encodes a SPRY domain at the 
C terminus (Fig. 1.9A) (Reymond et al, 2001). Two additional linker sequences are 
found in the protein, between RING and B-box and between coiled-coil and SPRY. 
1.3.3.1 Mechanism of action 
Following entry of a restriction-sensitive virus into the cytoplasm, TRlM5a binds 
the incoming viral core via its SPRY domain (Nakayama et al, 2005; Sawyer et al, 2005; 
Stremlau et al, 2005; Yap et al, 2005). This interaction is host-specific, virus-specific 
and is determined by both SPRY domain and viral CA (Ohkura et al, 2006; Song et al, 
2005b). A few consequences of this interaction can be observed as early as a few 
minutes post viral entry (perez-Caballero et al, 2005). The CA core is ' quickly 
disassembled, which is linked with the decreased amounts of reverse transcription 
products (perron et al, 2007; Roa et al, 2012; Stremlau et al, 2006). This is likely due to 
E3 ubiquitin ligase activity of the RING domain that results in TRlM5a auto-
ubiquitylation and its proteasomal degradation, which is thought to tear the viral CA 
core apart (Fig. 1.9D) (Diaz-Griffero et al, 2006; Langelier et al, 2008; Lukic et al, 
2011 ; Pertel et al, 2011 ; Rold & Aiken, 2008). Auto-ubiquitylation is important, but not 
essential, for TRIM5a restriction potency (Javanbakht et al, 2005; Lienlaf et al, 2011). 
Indeed, although a pharmacological inhibition of the proteasome rescues reverse 
transcription and seemingly normal stability of the CA core infectivity is still 
greatly inhibited (Anderson et al, 2006; Diaz-Griffero et al, 2006; Wu et al, 2006). 
Additionally, mutations in the RING domain that abrogate the ability of TRlM5a to 
inhibit reverse transcription and destabilize the CA core still allow potent retroviral 
restriction (Roa et al, 2012). This could be due to a sequestration of the incoming virus 
in cytop1asmic bodies (CBs; discussed below) formed by TRlM5a (Campbell et al, 
2008; Danielson et al, 2012). 
TRlM5a forms a hexagonal lattice around the CA core (Ganser-Pomillos et al, 
20 Il) and binds to a conical core, rather than to a monomeric CA protein (Sebastian & 
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Luban, 2005; Zhao et al, 2011) (Fig. 1.9C-D). Interestingly, TRIM5a is thought to 
recognize multiple epitopes on the core interface and its action resembles antigen 
recognition by IgM antibodies (Biris et al, 2012). While monomeric TRIM5a weakly 
interacts with the CA structure, assembled TRIM5a proteins have very high 
avidity (Biris et al, 2013; Biris et al, 2012). Coiled-coil domain is required for 
homodimerization of TRIM5a proteins, which is necessary for the avidity of TRIM5a 
(Ganser-Pornillos et al, 2011; Kar et al, 2008; Langelier et al, 2008; Zhao et al, 2011). 
Interestingly, Linker2 was also linked to the ability of TRIM5a to self-associate (Sastri 
et al, 2010). Initial reports hypothesized that the dimers associate with each other 
laterally, whereas recent emerging reports suggest that this interaction is anti-parallel 
(Goldstone et al, 2014; Pomillos, 2014; Sanchez et al, 2014) (Fig. 1.9B). In the new 
model, the TRIM5a dimer would homo-associate anti-parallely via strong interactions 
between coiled-coil domains and helixes H3, which is contained in linker2. The B-box 
domain is responsible for higher-order multimerization, which is essential for fuU 
retroviral restriction (Diaz-Griffero et al, 2007b; Diaz-Griffero et al, 2009; Ganser-
Pornillos et al, 2011; Javanbakht et al, 2005; Nepveu-Traversy et al, 2009). 
1.3.3.2 Cell bi%gy ofTRIM5a 
ln the cytoplasm, over-expressed TRIM5a proteins form so-called cytoplasmic 
bodies (CBs) (Strernlau et al, 2004). It is uncertain if these structures reflect the real 
intracellular state of TRIM5a proteins, and their role in the retroviral restriction remains 
unclear, sorne studies deny their relevance (perez-Caballero et al, 2005; Song et al, 
2005a). Indeed, as endogenous levels of TRIM5a proteins are often too low to allow IF 
detection, most of the observations came from imaging of over-expressed proteins. The 
probable reason that CBs are observed is due to their ability to multimerize. However, 
these CBs were described as highly dynamic structures constantly associating and 
disassociating with each other (Campbell et al, 2007a). TRIM5a CBs co-Iocalize with 
microtubules and undergo curvilinear movements along them. Additionally, live-ceU 
imaging demonstrated that TRIM5a proteins self-associate around incoming restriction-
sensitive viruses (Campbell et al, 2008). In the cytoplasm, TRIM5a CBs were shown to 
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co-Iocalize with several proteins involved in proteasomal degradation pathway 
(Campbell et al, 2008; Danielson et al, 2012; Lukic et al, 2011). Additionally, in the 
presence of a restriction-sensitive virus this co-Iocalization increases (Danielson et al, 
2012). Moreover, TRIM5a proteins were shown to shuttle between the cytoplasm and 
the nucleus, although their predominant localization is cytoplasmic (Diaz-Griffero et al, 
2011). When present in the nucleus, TRIM5a co-Iocalize with PMLrrRIM19 nuclear 
bodies (Diaz-Griffero et al, 20 Il). Therefore, although the possibility cannot be 
excluded that CBs formed by TRIM5a are artifacts stemming from protein over-
expression (Song et al, 2005a), it is unlikely that these kind of dead artifacts would be as 
highly dynamic as those described by Campbell et al. (Campbell et al, 2007a). 
TRIM5a has an additional role in mediating innate immune response, as it has 
been proposed to be a PRR (Pertel et al, 20 Il). TRIM5a promotes the innate immune 
signalling via activator protein 1 (AP-l) and NF-KB (Nepveu-Traversy & Berthoux, 
2014; Pertel et al, 2011 ; Tareen & Emerman, 2011). 
1.3.4 TRIMCyp 
TRIMCyp is a protein related to TRIM5a that independently emerged in sorne 
monkeys by retrotransposition of the cyclophilin A (CypA) pseudogene sequence into the 
TRlM5 locus, replacing the SPRY sequence (Nisole et al, 2004; Sayah et al, 2004; 
Wilson et al, 2008). This protein binds the CA core through its CypA domain and 
potently inhibits retroviruses in a virus-specific, species-specific manner, e.g. TRIMCyp 
from owl monkeys inhibits HIV-l (Sayah et al, 2004), African green monkey SIV and 
feline immunodeficiency virus (FlV) (Lin & Emerman, 2006), while TRIMCyp arising 
in sorne rhesus macaques inhibits HIV-2 and FIV, but not HIV-l (Wilson et al, 2008). 
TRIMCyp-mediated restriction can be inhibited by the specific CypA inhibitor 
cyclosporin A (CsA). 
The next section briefly introduces the importance and rationale for conducting the 
following research. Also outlined are the hypotheses and specific objectives for the 
studies, as well as a summary of obtained results. 
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1.4 Importance, hypotheses and objectives 
. Despite the great progress in IllV -1 research, infection with this AIDS-causing 
virus remains incurable. Current antiretroviral therapies have many side effects and 
inconveniences, such as daily, life-Iong administration (Flepp et al, 2001). Additionally, 
the ability ofHN-1 to mutate and acquire multidrug resistance is tremendous (Abram et 
al, 2010). Whereas no sterilizing cure is accessible, new drugs have to be developed to 
keep up with this host-pathogen race. In particular, a new class of pharmaceuticals 
would be advantageous, targeting a different step of viral replication than currently used 
drugs. Promising new target for IllV -1 treatment seems to be the viral CA core, as 
evidence demonstrated that disrupting the incoming CA core inhibits infectivity 
(Forshey et al, 2002; Shi et al, 2011; Stremlau et al, 2004; Stremlau et al, 2006). Very 
little is known about the process of HIV -1 uncoating and how it employs cellular 
partners. It is crucial to gain more insight in this unexplored area in order to enable the 
development of novel drugs to target it. 
While new drugs have to be developed, it is unlikely that they could ever become 
curative; taking into account that IllV-l establishes reservoirs in long-living cells. The 
restriction factor TRlM5a could point to new approaches towards frnding a sterilizing 
cure. Importantly, it has been suggested that TRlM5a could be employed in gene 
therapy approach targeting HN-I (Anderson, 2013). Gaining detailed knowledge about 
this prote in is important as it could contribute to frnding a cure to HIV -1 infection. 
1.4.1 Objective 1: To study the involvement of microtubules and dynein motor 
complexes in TRIM5a-mediated restriction 
Both IllV-l and TRlM5a CBs associate with and move along microtubules 
(Campbell et al, 2007a; McDonald et al, 2002). Additionally, HN-I uses the dynein 
motor complex for its route the nucleus (McDonald et al, 2002). Here, we hypothesized 
that the microtubule network could be a platform enabling TRlM5a to meet restriction-
sensitive viruses. In this study, we investigated the role of microtubules and dynein 
motor complexes in the restriction of retroviruses mediated by TRlM5a. Interventions 
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disrupting microtubule dynamics and the function of the dynein motor complex partially 
rescued retroviral restriction, without affecting TRIM5a stability or causing excessive 
cytotoxicity. These interventions affected the dynamics of TRIM5a cytoplasmic bodies 
and decreased TRIM5a ability to destabilize incoming retro viral core. In conclusion, we 
found that both the microtubule network and the dynein motor complex are involved in 
the TRIM5a-mediated restriction of retroviruses. 
1.4.2 Objective II: To study the involvement of microtubules and dynein motor 
complexes in HIV-l uncoating 
Following its entry to the cytoplasm, replication of lllV-l is dependent on the 
cellular machinery. The incoming CA core is thought to be transported towards the 
nucleus via microtubules and dyne in motor complexes (McDonald et al, 2002). During 
that time the CA core likely recruits cellular proteins to shield its genomic material from 
the hostile cellular environment (Lahaye et al, 2013; Rasaiyaah et al, 2013). Initially, 
cellular factors likely stabilize the lllV -1 CA core until it reaches the NPC, through 
which lllV-l enters the nucleus (Fricke et al, 2013; Guth & Sodroski, 2014). A handful 
of cellular partners for HIV-l uncoating have been described (De Iaco et al, 2013; 
Fricke et al, 2013; Guth & Sodroski, 2014; Li et al, 2009; Misumi et al, 2010; Shah et 
al, 2013). Rere, based on the observations in the manuscript presented in Chapter II, we 
hypothesized that dynein-dependent transport along microtubules might be involved in 
RIV -1 uncoating. Indeed, pharmacological abrogation of microtubule dynamics and 
depletion ofDRC led to an accumulation oflllV-l CAfoei in infected cells observed by 
IF. We also employed the fate-of-capsid as say, which allows for the isolation of 
particulate viral cores from infected cells (perron et al, 2004). Perturbation of either 
microtubule dynamics or dynein-dependent transport resulted in a transient increase in 
the amount of pelletable (particulate) HIV-l CA cores. In conclusion, we found that 
dynein-dependent transport along microtubules of lllV -1 might be linked with its 
uncoating. 
Chapter II contains a study that demonstrates that microtubules and dynein motor 
complexes are involved in the retroviral restriction mediated by TRIM5a. 
CHAPTERII 
FUNCTIONAL EVIDENCE FOR THE INVOL VEMENT OF MICROTUBULES 
AND DYNE IN MOTOR COMPLEXES IN TRIM5a-MEDIATED 
RESTRICTION OF RETROVIRUSES 
PAULINA PA WLICA, VALERIE LE SAGE' , NOL WENN POCCARDI, 
MICHEL J. TREMBLAy2, ANDREW 1. MOULAND' , LIONEL BERTHOUX 
Published on 5th of March 2014 in Journal of virology 
2.1 Contributions 
L.B. designed the study. L.B., P.P. and AJ.M interpreted the results and prepared the 
manuscript. M.J.T shared materials. P.P. performed 95% of the experiments. V.L.S and 
N.P. performed 5% of the experiments. 
2.2 Abstract 
The tripartite motif (TRIM) family of proteins includes the TRIM5a antiretroviral 
restriction factor. TRIM5a from many Dld World and sorne New World monkeys can 
restrict the human immunodeficiency virus type 1 (HIV -1), while human TRIM5a 
restricts N-tropic Murine Leukemia Virus (N-ML V). TRIM5a forms highly dynamic 
cytoplasmic bodies (CBs) that associate with and translocate on microtubules. However, 
the functional involvement of microtubules or other cytoskeleton-associated factors in 
the viral restriction process had not been shown. Here, we demonstrate the dependency 
of TRIM5a-mediated restriction on microtubule-mediated transport. Pharmacological 
1 HIV-I RNA Trafficking Laboratory, Lady Davis Institute at the Jewish General Hospital and 
Department of Medicine, McGill University. 
2 Centre de Recherche en Infectiologie, Centre de Recherche du CHU de l'Université Laval. 
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disruption of the microtubule network using nocodazole or disabling it using paclitaxel 
decreased restriction of N-MLV and HIV-l by human or simian alleles of TRIM5a, 
respectively. In addition, pharmacological inhibition of dynein motor complexes using 
erythro-9-(2-hydroxy-3-nonyl)adenine (ERNA) and siRNA-mediated depletion of the 
dynein heavy chain (DHC) similarly decreased TRIM5a-mediated restriction. The 10ss 
in restriction resulting from either the disassembly of microtubules or the disruption of 
dynein motor activity was se en for both endogenous and over-expressed TRIM5a and 
was not due to differences in protein stability or cell viability. Both nocodazole 
treatrnent and DHC depletion interfered with the dynamics of TRIM5a CBs, increasing 
their size and altering their intracellular localization. In addition, nocodazole, paclitaxel 
and DHC depletion were all found to increase the stability of HIV -1 cores in infected 
cells, providing an alternative explanation for the decreased restriction. In conclusion, 
association with microtubules and the translocation activity of dynein motor complexes 
are required to achieve efficient restriction by TRIM5a. 
2.3 Importance 
The primate innate cellular defenses against infection by retroviruses include a 
protein named TRIM5a, belonging to the family of restriction factors . TRIM5a is 
present in the cytoplasm where it can intercept incoming retroviruses shortly after their 
entry. How TRIM5a manages to be present at the appropriate subcytoplasmic location to 
interact with its target is unknown. We hypothesized that TRIM5a, either as a soluble 
protein or a high-molecular-weight complex (the cytoplasmic body) is transported 
within the cytoplasm by a molecular motor called the dynein complex, itself known to 
interact with and move along microtubules. Our results show that destructuring 
microtubules or crippling their function decreased the capacity of human or simian 
TRIM5a to restrict their retroviral targets. Inhibiting dynein motor activity, or reducing 
the expression of a key component of this complex, similarly affected TRIM5a-
mediated restriction. Thus, we have identified speçific cytoskeleton structures involved 
in innate antiretroviral defenses. 
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2.4 Introduction 
Members of the tripartite motif (TRIM) family of proteins have been described to 
exhibit antiviral properties (lIauler et al, 2012; Kajaste-Rudnitski et al, 2011; Uchil et 
al, 2008; Wolf & Goff, 2007). The best-known member is TRIM5a, first characterized 
as a factor from Rhesus macaque (rhTRIM5a) that potently inhibits human 
immunodeficiency virus 1 (HIV-1) (Stremlau et al, 2004). Other TRIM5a orthologs 
from sorne New World and Old World monkeys also provide protection against IllV-1 
infection (Ratziioannou et al, 2004; Keckesova et al, 2004; Song et al, 2005b). Ruman 
TRIM5a (huTRIM5a), while not having the ability to restrict IllV-1, protects against 
N-tropic murine leukemia virus (N-ML V) and equine infectious anaemia virus (ElA V) 
(Hatziioannou et al, 2004; Keckesova et al, 2004; Perron et al, 2004; Rahm et al, 2011; 
Yap et al, 2004). Expression of TRIM5a is induced by type 1 interferons, supporting 
their role as innate immunity effectors (Asaoka et al, 2005; Carthagena et al, 2008). In 
addition, TRIM5a acts as an innate sensor of retroviral infections, triggering an antiviral 
signalling pathway that can lead to interferon production (pertel et al, 20 Il; Tareen & 
Emerman, 2011). 
Retroviral restriction is initiated by specific recognition of the N-terminal domain 
ofincoming retroviral capsid (CA) proteins by the B30.2IPRYSPRY domain ofTRIM5a 
(Sebastian & Luban, 2005; Stremlau et al, 2006a). TRIM5a binds to intact CA cores 
rather than monomeric CA proteins (Ganser-Pomillos et al, 2011) and as a result ofthis 
interaction, replication is irnpaired by several effector mechanisms [rewieved in: (Luban, 
2007; Nisole et al, 2005; Towers, 2007)]. So far two major TRIM5a-mediated blocks 
have been described. The first one is accelerated disassembly of the retroviral CA core 
accompanied by a decrease in amounts of reverse transcription products (Bérubé et al, 
2007; Perron et al, 2007; Roa et al, 2012; Stremlau et al, 2006a). As a consequence of 
the disassembly induced by TRIM5a, core components such as the viral RNA and 
integrase are solubilized or degraded (Kutluay et al, 2013). This restriction effector 
mechanism also involves the degradation of TRIM5a by the proteasome in presence of 
the restricted virus (Rold & Aiken, 2008). Accordingly, treatment with proteasome 
inhibitors restores seemingly normal disassembly of the viral core and rescues the 
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production of viral cDNA (Anderson et al, 2006; Diaz-Griffero et al, 2007; Kutluay et 
al, 2013). However, prote as orne inhibition does not fully rescue infectivity in restrictive 
conditions, pointing to the existence of a second, proteasome-independent restriction 
mechanism. The precise mechanism of this second block is still unclear but access of the 
viral DNA to the nucleus is inhibited (Anderson et al, 2006; Wu et al, 2006). This could 
be related to the 'sequestration' of incoming retroviruses in CBs formed by TRIM5a 
proteins (Campbell et al, 2008; Danielson et al, 2012). 
TRIM5a contains a coiled-coil domain responsible for prote in dimerization and a 
B-box domain important for the higher order organized states that probably promote the 
formation of CBs (Kar et al, 2008; Li & Sodroski, 2008). CBs were described as 
dynamic structures constantly associating and disassociating with each other, 
exchanging TRIM5a proteins with a pool of proteins diffused in the cytoplasm 
(Campbell et al, 2007), and their size depends on the level of TRIM5a expression 
(Perez-Caballero et .al, 2005). The role of CBs in retroviraI restriction is still unclear and 
sorne reports refute their relevance in this process (perez-Caballero et al, 2005; Song et 
al, 2005a). Indeed, no CBs have been detected at endogenous TRIM5a expression 
levels, and it is possible that sorne observed CBs are artifacts stemming from prote in 
over-expression (Song et al, 2005a). On the other hand, TRIM5a CBs were found to 
co-Iocalize with ubiquitin (Campbell et al, 2008), prote as omal subunits (Danielson et al, 
2012; Lukic et al, 2011) and p62/Sequestosome-1 (O'Connor et al, 2010). p62 is an 
important adaptor protein with a roIe in cell signalling and protein degradation 
[reviewed in (Moscat et al, 2007; Seibenhener et al, 2007)]. Additionally, TRIM5a 
proteins form bodies that enclose incoming restriction-sensitive viruses and closely 
resemble pre-existing CBs (Campbell et al, 2008). Collectively, these observations 
suggest that TRIM5a CBs are relevant to restriction mechanisms. 
The microtubule network, a component of the cellular cytoskeleton, is made of 
highly dynamic filaments built of tubulin a/~ heterodimers and plays multiple roles in 
the cell, including intra-cellular transport, organelle positioning and cell division (de 
Forges et al, 2012). Microtubules provide platforms for molecular motors, which enable 
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active transport through the dense cytoplasm of the cell. The dynein motor complex 
[reviewed in (Hook & Vallee, 2006)] is a microtubule-associated molecular motor that 
transports various cellular cargos towards the microtubule-organizing center (MTOC) at 
the minus-end of microtubules. The MTOC is found in the vicinity of the nucleus except 
during cell division. Several viroses, including HIV -1 , were described to recruit dynein 
motor complexes for their transport during the early stages of their replication [reviewed 
in (Dodding & Way, 2011 ; Hsieh et al, 2010; Mouland & Milev, 2012)]. TRIM5a CBs 
also associate with microtubules and their movements along these filaments have been 
observed (Campbell et al, 2007). However, a functional role for this association has not 
been demonstrated, nor have the molecular motors responsible for TRIM5a movement 
been identified. Here we asked whether the integrity of microtubules was functionally 
important for restriction to OCCUf. In addition, we investigated the role of the dynein 
motor in this process. Using pharmacological and genetic approaches coupled with 
imaging analyses, we provide evidence that both microtubules and dynein motor activity 
are important for the restriction process mediated by TRIM5a. 
2.5 Materials and methods 
Cells, pharmaceuticals and antibodies. Human embryonic kidney 293T ceIls, 
human epithelial carcinoma HeLa ceIls, human U373-derived MAGI cells, Rhesus 
macaque kidney FRhK-4 cells and feline renal CRFK cells were maintained in 
Dulbecco's modified Eagle's medium (DMEM) with high glucose, supplemented with 
10% fetal bovine serum (FBS) and antibiotics at 37°C, 5% CO2. AIl cell culture reagents 
were from HyClone (Thermo Scientific, Logan, UT). HeLa cells stably expressing 
FLAG-tagged TRIM5 proteins were generated by retroviral transduction as described 
previously (Bérubé et al, 2007; Pham et al, 2010). Nocodazole, paclitaxel 
(taxol), erythro-9-(2-hydroxy-3-nonyl)adenine (ERNA), 2,3-Bis-(2-Methoxy-4-Nitro-5-
Sulfophenyl)-2H-Tetrazolium-5-Carboxanilide (XTT) , phenazine methosulfate (PMS), 
heparin sodium salt and cycloheximide were provided by Sigma (St Louis, MI). Anti-
DHC rabbit polyclonal antibodies were from Santa Cruz (Dallas, TX). The HRP-
conjugated mouse anti-actin antibody was from Sigma. Capsid (CA, p24) was detected 
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using a mouse monoclonal antibody (clone 183) from the AIDS Research and Reference 
Reagent Program. The FLAG epitope was detected using the M2 mouse monoclonal 
antibody (Sigma) or the M2 rabbit polyclonal antibody from CeU Signaling (Danvers, 
MA). HRP-conjugated goat anti-rabbit and goat anti-mouse antibodies used as 
secondary antibodies in western blots were aU from Santa Cruz. 
Plasmid DNAs and retroviral vectors production. The plasmid encoding a 
GFP-tagged version of a-tubulin (Rusan et al, 2001) was a gift from Ali Saib. To 
produce viral vectors, 10-cm culture dishes of sub-confluent HEK293T ceUs were 
co-transfected using polyethylenimine (25,000 kDa, Polyscience) with the appropriate 
plasmids as foUows. For wild-type (WT) or the G89V CA mutant ofHIV-1CMV-oFP, we 
used 10 llg of pTRIPCMV-OFP, 10 llg of WT or G89V p~R8.9 and 5 llg of pMD-G; for 
N -ML V OFP and B-ML V OFP, we used 10 llg of pCNCG, 5 llg of pMD-G and 10 llg of 
pCIG3N (N-MLVoFP) or pCIG3B (B-MLVoFP); for HIV-lNIA3-oFP, we used 10 llg of 
pNL-GFP and 5 llg of pMD-G; for SIV mac-OFP, 10 llg of pSIV mac-OFP and 5 llg of pMD-G 
(Berthoux et al, 2005a; Berthoux et al, 2004; Berthoux et al, 2005b; Berthoux et al, 
2003; Bérubé et al, 2007; Naviaux et al, 1996; Pham et al, 2010; Sebastian et al, 2006; 
Zufferey et al, 1997). pNL4.3IRES-OFP (Imbeault et al, 2009) encodes a version of the 
HIV-1 NL4-3 strain (Adachi et al, 1986) expressing GFP in addition to the viral 
proteins, and was a gift from David N. Levy. Production of the corresponding virus 
(HIV-lNIA3-IREs-oFP) was done by transfecting 10 llg of the plasmid in sub-confluent 
HEK293T ceUs in a 75-cm flask. Media were changed 16 h post transfection and virus-
containing supernatants were coUected after an additional 32 h of culture. AU viral 
stocks were clarified by centrifugation for 5 min at 400 x g. AU viral vectors were 
titrated in permissive CRFK ceU using GFP expression as a marker of successful 
transduction. In sorne experiments, reverse transcriptase activity was measured on virus 
stocks using the EnzCheck kit (Molecular Probes) according to the manufacturer's 
instructions. 
Viral challenges, pharmacological treatments and RNA interference. Cells 
were seeded in 24-well plates at 1 x 105 cells/well (HeLa, CRFK, MAGI) or 
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5 X 104 cells/well (FRhK-4) , and were challenged the next day with vanous 
retroviral vectors (IllV-1cMV-GFP, HIV-1G89v, HIV-1NIA3-GFP, SIVmac-GFP, N-MLVGFP or 
B-MLVGFP) or a replication-competent retrovirus (HIV-1NIA3-IREs-GFP). When applicable, 
cells were pre-treated for 15 min with nocodazole, pac1itaxel or ERNA, and infections 
were then performed in presence of these drugs. Media were changed after 16 h, and 
48 h post-infection cells were trypsinized and fIxed in 2% formaldehyde (Fisher 
ScientifIc) in phosphate buffer saline (PBS). The % of GFP-positive cens were then 
determined by analyzing 1 x 104 to 3 x 104 cells on a FC500 MPL cytometer (Beckman 
Coulter) using the CXP software. For the siRNA treatments, 2 x 105 cens were plated 
in each 3.5-cm of a 6-well plate and transfected with 40 nM of siRNA using 
DharmaFECT 1 (Dharmacon). The siRNA against heavy chain of dynein (DHC) was 
previously described (Lehmann et al, 2009) and targets the following sequence: 
5'GATCAAACATGACGGAATT. The control siRNA (purchased from Dharmacon) 
was designed to target a luciferase sequence (5'CGTACGCGGAATACTTCGATT) 
absent in the human genome. 48 h post transfection, cells were seeded in 24-well plates 
and were challenged the next day with retroviral vectors as described above. 
Stability assay. 1 x 106 HeLa cens stably expressing FLAG-rhTRIM5a were 
seeded in 6-well plates one day prior to the experiment. For the siRNA treatments, cells 
were transfected 48 h before seeding, as described above. cens were pre-treated for 1 h 
with 1 00 ~g/m1 of cyc1oheximide, then treated with the indicated drugs without 
removing cyc10heximide and harvested at the indicated time points. Drug concentrations 
were as follows: nocodazole, 0.1 ~M; pac1itaxel, 0.1 ~M, ERNA, 600 ~M. Cells were 
lysed in co Id stability buffer (100 mM Tris-HCl pH 8.0, 100 mM NaCI, 0.5% NP-40) 
supplemented with Complete protease inhibitor cocktail (Roche, BaIe, Switzerland) and 
processed for western blotting. rhTRIM5a was detected using the anti-FLAG rabbit 
polyc1onal antibody. 
Viability assay. 1 x î 04 HeLa or 5 x 103 FRhK -4 cells were seeded per weIl in 
96-well plates. The next day, cells were washed with PBS and wells were replenished 
with 1 00 ~l of DMEM without phenol red supplemented with serum and seriaI dilutions 
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of the tested drugs. After 16 h of incubation, 100 J.lI of the PBS solution containing 
50 J.lg of XTT and 6 J.lg of PMS were added. Cells were incubated 2- 4 hours at 37°C, 
then the absorbance was read at 490 nm on a Synergy HT (BioTek) plate reader and 
corrected for background value determined on blank samples. 
Fate-of-capsid assay. To analyze post-entry capsid disassembly, a protocol 
adapted from Stremlau et al (Perron et al, 2004) was used as described earlier 
(Keckesova et al, 2004). Briefly, 3 x 106 HeLa cells seeded in 10-cm dishes were 
infected with HIV-1cMV-GFP at a multiplicity of infection (MOI) of ~2 as calculated on 
the permissive control cells. 2 h later, virus-containing supernatants were removed and 
cells were rinsed once in PBS followed by a gentle trypsinization treatment 
(1:1 trypsin:PBS mixture for 10 sec at room temperature). Fresh medium containing the 
appropriate drugs was then added, and cells were incubated at 37°C, 5% C02 for an 
additional 4 hours. Cells were then trypsinized and resuspended in ice-cold lysis buffer 
(100 J.lM Tris-HCl pH 8.0, 0.4 mM KCI, 2 J.lM EDTA, Roche' s Complete protease 
inhibitor) and disrupted with a dounce homogenizer. Whole cell Lysate (WCL) samples 
were collected at tms point. In order to remove cell debris and nuclei, lysates were 
centrifuged for 5 min at 1,000 x g, 4°C, and then layered on top of a 50% sucrose 
cusmon prepared in STE buffer (100 mM NaCI, 10 mM Tris-HCl pH 8.0, 1 mM EDTA). 
Particulate viral cores were sedimented by ultracentrifugation in a Sorval WX Ultra 
100 ultracentrifuge at 175,000 x g for 2 h at 4°C. Pellets were resuspended in denaturing 
gel loading buffer and processed for CA western blotting together with whole cell 
lysates. Post-centrifugation supernatants were collected from the fraction above the 
sucrose cusmon, excluding the sucrose:supernatant interface. 
Immunofluorescence (IF) microscopy. For the analysis of the localization 
patterns of LAMP-1 and microtubules, 2 x 105 cells (HeLa) or 1 x 105 cells (FRhK-4) 
were seeded on glass coverslips placed in 3.5-cm wells. For siRNA treatments, cells 
were transfected 48 h prior to seeding as described above. For the cells expressing 
GFP-tubulin, 2 J.lg of the plasmid were transfected per well 24 h prior to seeding. The 
day after seeding, cell were fIxed (siRNA treatment) or incubated for 2 h with drugs 
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(nocodazole, paclitaxel, ERNA) and then fixed. Fixation was done for 10 mm ln 
pre-warmed 4% formaldehyde-DMEM at 37°C, then cells were washed once in PBS, 
blocked in IX blocking solution (Roche, BaIe, Switzerland) and stained or not for 
LAMP-l for 1 h at room temperature. Primary rabbit LAMP-l antibodies were 
described previously (Lehmann et al, 2009) and diluted 1: 1000. LAMP-l was revealed 
using the AlexaFluor594-conjugated donkey anti-rabbit secondary antibody (Molecular 
Probes, Eugene, OR). Cell nuclei were stained with DAPI (Invitrogen), then washed 
with PBS and mounted on glass slides using ImmunoMount (Thermo-Fisher Scientific). 
Microscopy was performed using a microscope (DMI6000B; Leica) equipped with a 
spinning disk confocal head (WaveFX; Quorum Technologies, Guelph, Ontario), a 63X 
(1.4 numerical aperture oil immersion) plan apochromat objective lens, and an EM 
charge-coupled device camera (ImageEM; Hamamatsu Photonics, Boston, MA). The 
Volocity Imaging software (v4.3.2; PerkinElmer, Waltham, MA) was used as 
acquisition software. Image analyses were perfonned using the Imaris software v7.4 
(Bitplane Inc., South Windsor, .CT). We estimated the effect of ERNA treatment or 
DHC depletion by counting the % of cells (n = 100-300 in two experiments) exhibiting 
predominant LAMP juxtanuclear staining versus cells exhibiting mostly peripheral 
staining, as described earlier (Lehmann et al, 2009). 
For the analysis of TRIM5a CBs and of microtubules, HeLa cells in 3.5-cm wells 
were transfected or not with siRNAs directed against DHC or Luciferase as described 
above. The next day, cells were additionally transfected or not with 2 Ilg of pGFP-
tubulin per well, using polyethyleneimine. The next day, 2 x 105 of these cells were 
seeded on glass coverslips placed in 3.5-cm wells. 24 h later, the cells were treated or 
not with nocodazole for 4 h and then flXed and processed for IF staining. Fixation was 
done for 10 min in 4% formaldehyde-DMEM in 37°C, followed by three washes with 
ice-cold PBS. Cells were then permeabilized by treatment with 0.1% Triton X-IOO, 
0.1 mM sodium citrate for 1-2 min on ice. Cells were then washed again three times 
with PBS and treated with 10% normal goat serum (Sigma) containing 0.3 M glycine 
(Sigma) for 30 min at RT. This was followed by a 4-hours incubation with a murine 
antibody against the FLAG epitope diluted 1 :400 in PBS containing 10% normal goat 
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serum. Cells were washed five times and fluorescently stained with the Alexa594-
conjugated goat anti-mouse antibody (Molecular Probes) at a 1 :200 dilution. Cells were 
washed five times in PBS before mounting in Vectashield CV ector Laboratories, 
Burlington, Ontario). Hoechst33342 (0.8 flglml ; Molecular Probes) was added along 
with the penultimate PBS wash to reveal DNA. Z-stacks were acquired on the 
AxioObserver Microscope (Carl Zeiss, Jena, Germany) equipped with the Apotome 
module and median Z-stacks were retained for analysis. For the analysis of TRIM5a CB 
sizes, FLAG foci in a given cell were manually outlined in the Axio Vision software for 
calculation of the surface. A minimum of 100 and up to 214 CBs from 10 randomly 
chosen cells were included in the analysis. For the analysis of TRIM5a CB localization, 
the cell's edge was outlined and for each FLAG foci in a given ceIl, we measured the 
closest distance to the nuclear membrane and the closest distance to the plasma 
membrane, using Axiovision. A minimum of 85 and up to 440 CBs from a minimum of 
5 randomly chosen ceIls were included in the analysis. To avoid human bias, CBs size 
and localization analyses were performed blindly by students not otherwise involved in 
this project, using image files that had coded names. For the analysis of TRIM5a-
microtubules co-Iocalization, images were acquired using the Apotome in Raw Data 
mode to aIlow for subsequent deconvolution, which was done using the Axio Vision 
software (Carl-Zeiss). 
2.6 Results 
Nocodazole and paclitaxel treatments rescue infectivity of retroviruses 
restricted by endogenous TRIM5a. In order to determine whether the microtubule 
network has a functional role in retroviral restrictions mediated by TRIM5a, we used 
nocodazole and paclitaxel, pharmacological agents that prevent the polymerization of 
microtubules (Luduena & Roach, 1991) or block their dynamics by preventing 
disassembly (Jordan & Wilson, 2004), respective1y. First we tested the effect of 
nocodazole and paclitaxel on restriction of HIV-l or N-MLV at multiple drug 
concentrations (Fig. 2.1). In this set of experiments, we infected human HeLa ceIls with 
N-MLVGFP, a huTRIM5a-sensitive N-tropic MLV vector expressing GFP and, as a 
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control, its restriction-insensitive B-tropic counterpart (B-ML V). Similarly, we infected 
Rhesus macaque FRhK-4 cens with a rhTRlM5a-sensitive HIV-I vector expressing 
GFP or, as a control, with SIV mac-GFP, a rhTRIM5a-insensitive simian immunodeficiency 
virus (SIV) strain mac239-based vector also expressing GFP. These infections were 
done using virus doses that had been previously determined to result in 0.1 % to 1% 
infected (GFP-positive) cens in the absence of drug. In these experimental conditions, 
we found that both nocodazole and paclitaxel increased GFP transduction by the 
restricted virus while having little effect on infection by the unrestricted control virus 
(Fig. 2.1). Specificany, nocodazole treatment of cens increased N-MLV infection of 
HeLa cens by up to 45.2-fold, and was active at a large range of concentrations peaking 
at about 0.1 IlM (Fig. 2.IA). Nocodazole also increased the permissiveness ofFRhK-4 
cens to infection by HIV-INIA3-GFP by up to 8.5-fold (Fig.2.IB). In these cens, 
nocodazole was active at higher concentrations (> 0.5 IlM). Nocodazole slightly 
increased infection by the unrestricted retro viral vector (B-ML V GFP or SIV mac-GFP) in 
both ceIllines, but the magnitude of this effect reached :::; 4-fold and:::; 2-fold in HeLa 
and FRhK-4 cells, respectively (Fig. 2.1). This subtle enhancement in infection might be 
the result of cell cycle arrest mediated by nocodazole (Groschel & Bushman, 2005). 
Similar to nocodazole, paclitaxel increased N-MLV infection of HeLa cells by up to 
33.1-fold (Fig. 2.IA). This enhancement was seen for aIl drug concentrations tested in 
HeLa cells, peaking at ~O.I IlM. Paclitaxel increased HIV-I infection ofFRhK-4 cells 
by up to 7.9-fold (Fig. 2.IB), and similar to nocodazole, higher concentrations of the 
drug (~ IIlM) needed to be used in this cell line in order to observe an effect on 
restriction. Paclitaxel slightly increased the infection of FRhK-4 cells by SIV mac-GFP 
(Fig. 2.IB) but, conversely, decreased B-ML V infectivity in HeLa cells at 
concentrations> 6 IlM (Fig. 2.IA). 
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Figure 2.1 Drug concentration-dependent enhancement of permlsslveness to 
infection by TRIM5a-restricted retroviral vectors in hum an and 
simian cells. 
HeLa cells (A) and FRhK-4 cells (B) were infected with single doses of 
the indicated viral vectors in the absence or presence of increasing 
amounts of nocodazole or paclitaxel (taxol) for 16 h. The amounts of 
viroses used were adjusted to obtain in the vicinity of 0.1 to 1 % of 
infected cells in the absence of the drug and yielded 0.09% (N-ML V GFP), 
0.38% (B-MLVGFP), 0.85% (HIV-1 NIA3-GFP) and 1.23% (SIVmac-GFP) 
infected cells. The % ofinfected (GFP-positive) cells were determined by 
flow cytometry 2 d post infection and results are presented as -fold 
changes in infectivity relative to the relevant untreated controls. 
Partial inhibition of TRIM5a-mediated restriction by disruption of the 
microtubule network. The experiments shown in Fig. 2.1 indicated that disruption of 
microtubules by nocodazole or paclitaxel treatments could increase infection by 
TRlM5a-sensitive viroses but not TRIM5a-insensitive ones. However, these results did 
not allow us to quantify the extent of inhibition conferred by nocodazole or paclitaxel 
treatments, relative to the magnitude of restriction itself. They also did not allow us to 
analyze whether the effect seen was dependent on the MOI used. Therefore, we 
performed virus dose-dependent experiments using ftxed drug concentrations. We used 
nocodazole and paclitaxel concentrations that corresponded to their peak of anti-
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restriction activity as determined in Fig. 2.1. When the VlfUS amounts used were 
norma1ized according to infectivity in non-restrictive CRFK cells (CRFK Infectious 
Units [IU]), we found N-MLVGFP to be to ~500-times less infectious than B-MLVGFP 
in · HeLa cells (Fig. 2.2A), reflecting the expected level of N-ML V restriction by 
endogenous huTRIM5a in these cells (Keckesova et al, 2004). Permissiveness to the 
huTRIM5a-insensitive B-ML V vector was not significantly affected by either 
nocodazo1e or paclitaxel treatments, regardless of the virus amounts used (Fig. 2.2A). In 
contrast, N-MLV infectivity was increased by up to 65-fold following nocodazole 
treatment and 71-fold following paclitaxel treatment (Fig.2.2A). In other words, 
nocodazo1e and paclitaxe1 reduced restriction of N-MLV to on1y about 20-fold in HeLa 
cells. In these cells, the effects of nocodazole and paclitaxel on N-ML V were the 
greatest when a re1atively small amount of virus was used (5 CRFK IU), while there was 
oilly a ~7-fo1d increase in N-MLV infection at MOIs 10-times higher (Fig. 2.2A). These 
observations probably reflect the fact that saturation of endogenous huTRlM5a by large 
amounts of N-MLV capsids partly suppresses restriction in the absence of 
pharmacological treatment. 
As expected, HIV -1 NIA3-GFP was strongly restricted (~ 1000-fold) relative to 
SIV mac-GFP in macaque FRhK -4 cells, when the two viruses were normalized according 
to their infectious titers in CRFK cells (Fig. 2.2B) (Berthoux et al, 2005b; Besnier et al, 
2002). Nocodazole and paclitaxel had no effect on infection by SIV mac-GFP, regardless 
of the amount of virus used (Fig. 2.2B). In contrast, both nocodazole and paclitaxel 
increased infection by HIV-1 NIA3-GFP in these cells by 16- to 17-fold at low MOIs. When 
the virus dose used was > 100 CRFK lU, the enhancing effect of nocodazole and 
paclitaxel was smaller, which again was probably due to saturation of TRIM5a by 
incorning capsids. The cyclophilin A (CypA) binding loop of CA is a major deterrninant 
of HIV -1 sensitivity to restriction by TRIM5a (Lin & Emerman, 2008), and the 
CA-G89V mutant, which abrogates CypA binding (Yoo et al, 1997), is known to be less 
susceptible to restriction by rhTRIM5a (Berthoux et al, 2005b; Strernlau et al, 2006b). 
Thus, we hypothesized that nocodazole and paclitaxel treatments wou1d have a smaller 
enhancing effect on CA-G89V HIV-1 compared to its WT counterpart. Indeed, we 
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found that in subsaturating conditions «200 CRFK IU), nocodazole and paclitaxel 
increased WT HIV-l cMV-GFP by ~lO-fold (5 .6- to 16-fold) and ~7.5-fold (4.7- to 
10.5-fold), respectively (Fig.2.2C). In contrast, nocodazole and paclitaxel increased 
infectivity of the mutant virus by only ~3 .7-fold (2.3- to 5.0-fold) and ~3.4-fold (2.0- to 
5.7-fold), respectively (Fig. 2.2C). 
In order to verify that nocodazole and paclitaxel had the expected effect on the 
microtubule network in the cell lines used, we transfected a construct expressing a 
GFP-a-tubulin fusion in HeLa and FRhK.-4 cells and then treated the cells with the same 
concentrations of nocodazole and paclitaxel as used in Fig. 2.2A-C. The cells were 
then processed for IF analysis (Fig. 2.2D). Nocodazole prevents polymerization of 
microtubules (Luduena & Roach, 1991) and consequently, microtubules appeared 
shortened and/or disassociated; most of the signal was diffuse and distributed throughout 
the cytoplasm (Fig. 2.2D). Paclitaxel, on the other hand, binds to microtubule polymers 
to prevent their disassembly (Jordan & Wilson, 2004), resulting in the formation of 
abnormal microtubules bundles (Homick et al, 2008), a phenotype that was observed in 
both HeLa and FRhK.-4 cell lines (Fig. 2.2D). Collectively, the data in Figures 2.1 and 
2.2 show that disrupting the dynamics (either assembly or disassembly) of microtubules 
results in a decrease of restriction by endogenous TRIM5a without inhibiting it 
completely. Interestingly, when drug concentrations were optimized, we observed that 
nocodazole and paclitaxel had very similar effects on N-MLV or HIV-l (Fig.2.2A-C), 
suggesting that disruption of the microtubule network inhibited TRIM5a regardless of 
the drug's mechanism of action. 
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Figure 2.2 Pharmacological disruption of microtubules decreases endogenous 
TRIM5a-mediated retroviral restriction. 
(A to C) Effect of nocodazole (noc) and pac1itaxel (txl) on restriction. 
Human HeLa cens (A) or macaque FRhK-4 cens (B, C) were infected 
with multiples doses of N-MLVGFP, B-MLVGFP, HIV-INL43-GFP or 
SIV mac-GFP as indicated. In (C), FRhK-4 cens were infected with 
WT HIV-l cMV-GFP or with the CA-G89V mutant ofthis vector. Infections 
were performed for 16 h and in the absence of drug or in the presence of 
either nocodazole or pac1itaxel. Nocodazole was used at 0.1 !lM in HeLa 
cens and 6 !lM in FRhK-4 cells, and pac1itaxel was used at 0.1 !lM in 
HeLa cens and 2 !lM at FRhK-4 cens. The x-axis in each graph represents 
the amounts of virus used expressed in infectious units (lU) based on 
infectious titers calculated for each virus in permissive feline CRFK cens. 
Infected (GFP-expressing) cens were detected by flow cytometry 2 d 
post-infection. (D) IF microscopy analysis of microtubules in treated 
cens. HeLa and FRhK-4 cells were transfected with GFP-a-tubulin, and 
2 d later subjected to two-hour drug treatments using the same 
concentrations as above, and then fixed. GFP fluorescence was observed 
by IF microscopy, along with DNA which was stained using DAPI (blue 
staining). The bar on the images represents 10 !lm. A representative 
image from each condition is presented. Taxol - pac1itaxel. 
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Pharmacological inhibition of dynein function rescues the infectivity of 
TRIM5a-restricted retroviruses. TRIM5a CBs are associated with microtubules and 
their movements within the cytoplasm seem to be at least partly dependent upon them 
(Campbell et al, 2007). However, the molecular motors driving TRIM5a CBs 
movements along microtubules are not known. We hypothesized that dyne in played a 
role in TRIM5a localization and contributed to its antiretroviral activity. We first 
infected HeLa cells with N- or B-MLV GFP viral vectors in the presence of increasing 
concentrations of ERNA (Fig. 2.3A), a drug that inhibits the ATPase activity associated 
with the heavy chain ofaxonemal and cytoplasmic dyneins (penningroth et al, 1982; 
Zhang et al, 2012). In the presence of ERNA, N-MLVGFP infectivity increased by up to 
22-fold compared to the vehic1e control, while the ERNA treatment caused a drug 
concentration-dependent decrease in permissiveness to B-ML V (Fig. 2.3A). In macaque 
FRhK-4 cells, ERNA increased permissiveness to HIV-INL43-GFP by up to 18.5-fold in a 
drug concentration-dependent fashion (Fig. 2.3B). By contrast, ERNA slightly decreased 
(less than 2-fold) infection by the restriction-insensitive SIVmac-GFP. We then performed 
the reverse experiments, infecting the cells at a fixed ERNA concentration but using 
multiple MOIs. Viruses were equalized as before, based on their titers in the non-
restrictive CRFK cells. In HeLa cells, treatment with 600 IlM of ERNA had no effect on 
B-MLV GFP infectivity, but it increased permissiveness to N-ML V GFP infection by up 
to 22-fold, depending on the MOI (Fig. 2.3C). In FRhK-4 cells (Fig. 2.3D), ERNA 
(1.2 mM) enhanced HIV-INL43-GFP infection at subsaturating MOIs (:::;100 CRFK lUs) by 
7.5-fold on average (3.2- to 13.5-fold). In contrast, ERNA caused a reduction in SIVmac-
GFP infectivity to ~O.4-fold the untreated control (Fig. 2.3D). Thus, the magnitude of 
HIV-l enhancement by ERNA in FRhK-4 cells is probably underestimated in this 
experiment due to the negative effect of the drug on infectivity, as seen with SIV mac-GFP. 
In order to verify that the ERNA treatments indeed affected dyne in function, we 
analyzed the subcellular distribution of LAMP-l, a marker for late endosomes (Fukuda, 
1991). Impairment of dynein function causes a shift of late endosomes towards the cell 
periphery, as previously described by us (Lehmann et al, 2009) and others (Burkhardt et 
al, 1997). Cells were stained for LAMP-l following treatment or not with 600 IlM 
(HeLa) or 1.2 mM (FRhK-4) of ERNA. We then counted the number ofcells exhibiting 
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a juxtanuclear localization of LAMP-l versus the ones with peripheral localization 
(Fig. 2.3E). In the DMSO-treated control cells, the localization of LAMP-l was 
predominantly juxtanuclear. Specifically, 92% ± 2.1 (standard deviation) HeLa cells and 
87% ± 1.5 FRhK-4 cells hadjuxtanuclear LAMP-1. As exemplified in Fig. 2.3E, EHNA 
treatment caused a significant decrease in juxtanuclear LAMP-l , to Il % ± 4.6 in HeLa 
cells and 8.6% ± 1.7 in FRhK-4 cells. In conclusion, EHNA can rescue both N-MLV 
and HIV-l from restriction by different orthologs of endogenously expressed TRIM5a, 
but does not totally block restriction. 
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Figure 2.3 Pharmacological disruption of dynein motor function decreases 
endogenous TRIM5a-mediated retroviral restriction. 
(A, B) Dose-dependent effect ofEHNA on restriction. Human HeLa cens 
(A) and macaque FRhK-4 cens (B) were infected for 16 h with a single 
dose of the indicated viroses in the presence of increasing concentrations 
of EHNA. The amounts of viroses used were the same as in Fig. 2.1. 
Infected (GFP-expressing) cens were detected by flow cytometry 2 d post 
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infection. (C, D) Virus dose-dependent effect of ERNA on restriction. 
Human HeLa cens (C) and macaque FRhK-4 cens (D) were infected for 
16 h with multiples doses of the indicated viruses in the presence or 
absence of ERNA at 600 ~ (HeLa) or 1.2 mM (FRhK-4). The x-axis 
represents the amounts of virus used expressed in infectious units (lU) 
based on infectious titers calculated for each virus in permissive feline 
CRFK cells. Infected (GFP-expressing) cens were detected by flow 
cytometry 2 d later. (E) IF microscopy analysis of LAMP-l distribution. 
HeLa and FRhK-4 cens were treated for 2 h with ERNA or left untreated, 
then flXed and stained for the lysosomal marker LAMP-l (red) and DNA 
(blue). cen edges are outlined and examples of localization shift caused 
by impaired dynein function are indicated by white arrows. A 
representative image from each condition is presented. The bar on the 
image panels represents 10 !lm. 
Depletion of dynein heavy chain counteracts TRIM5a-mediated retroviral 
restriction. In order to directly test the hypothesis that dynein function is important for 
TRIM5a-mediated restriction, we depleted DHC by transfection of a siRNA, as 
described previously (Lehmann et al, 2009). Knocking down DHC is known to disrupt 
an dynein-mediated transport activities, and it can also affect the assembly of 
microtubules by inhibiting the anterograde transport of microtubule complexes (He et al, 
2005). HeLa cells were transfected with a siRNA targeting DHC or with an irrelevant 
siRNA targeting luciferase (Luc). Knockdown of DHC was efficient (Fig. 2.4A), 
resulting in an 85.4% (± 6.7%) reduction in protein levels as estimated by western 
blotting in 4 independent experiments. In addition, DHC depletion caused a 
redistribution ofLAMP-l fromjuxtanuclear to peripheral (Fig. 2.4B), similar to what we 
had previously published (Lehmann et al, 2009). Specificany, 86.6% of HeLa cens 
transfected with the control siRNA had juxtanuclear staining, compared with 35.5% for 
the cens transfected with the siRNA targeting DHC. As shown Fig. 2.4C, DHC 
knockdown caused a significant increase in HeLa permissiveness to N-ML V GFP 
infection at an MOIs examined (4.6-fold on average; range, 4.0- to 6.0-fold), while 
having no effect on infection by B-ML V GFP. Thus, dynein motor complexes are involved 
in the restriction of N-MLV by endogenous huTRIM5a. Since dynein's transport 
function is dependent on microtubules, we predicted that combining pharmacological 
disruption of microtubules and DHC depletion would have non-additive effects. 
Therefore, we analyzed the permissiveness to infection by N-ML V GFP and B-ML V GFP of 
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cells depleted or not for DHC, in the presence of nocodazole or paclitaxel. As shown 
in Fig. 2.4D, nocodazole alone increased N-MLV infection by an average of 23-fold 
(range, 11- to 34-fold) while dual treatment with nocodazole and DHC siRNAs resulted 
in a slightly smaller increase in N-ML V GFP infectivity (13-fold on average; range, 8- to 
19-fold). Treatment with paclitaxel resulted in an average increase of 16.7-fold (range: 
13- to 24-fold) in permissiveness to N-MLVGFP, and the enhancement effect was only 
slightly bigger (23-fold; range, 18- to 28-fold) when DHC depletion was combined with 
paclitaxel treatment (Fig.2.4E). Altogether, the results in Fig.2.4D and 2.4E show 
that disruption of the microtubule network and DHC depletion had non-additive effects 
on the restriction of N-ML V by endogenous huTRIM5cx. None of the treatments or 
combinations of treatments had a significant effect on the infectivity of the non-
restricted B-ML V GFP control (Fig. 2.4C-E). 
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Figure 2.4 DHC depletion decreases TRIM5a-mediated retroviral restriction 
and bas no effect on cells treated witb nocodazole or paclitaxel. 
(A) Western blot analysis of DHC expression in HeLa cens 48 h after 
transfection of the indicated siRNAs. Actin was analyzed as a loading 
control. (B) IF microscopy analysis of LAMP-l . LAMP-l was stained 
72 h post siRNAs transfection (red) and DNA was stained using DAPI 
(blue). cen edges are outlined and a LAMP-l distribution shift caused by 
impaired dynein function is indicated by a white arrow. A representative 
image is shown for each condition. The bar on the image panels 
represents 10 ~m. (C) Effect of DHC knockdown on restriction. Human 
HeLa cens were transfected with siRNAs against dynein heavy chain 
(siDHC), or against luciferase (siLuc) as a control. 72 h later, cens were 
infected for 16 h with multiple doses ofN- or B-MLVGFP. Infected cens 
were detected by flow cytometry 2 d after infection. The x-axis shows the 
amounts of virus used expressed in CRFK infectious units. (D, E) Effect 
of combining siRNA transfections with 0.25 ~M of nocodazole (D) or 
0.1 ~M of pac1itaxel (taxol) (E). Infections were performed and analyzed 
as in panel C, and panels C-E an share the same legend. 
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Inhibition of HIV-l restriction by over-expressed rhTRIM5a in human cells 
is counteracted by depletion of dynein heavy chain or microtubules disruption. The 
experiments shown in Fig. 2.1 to 2.4 indicate that restriction of mV-1 or N-MLV by 
endogenous huTRIM5a or rhTRIM5a cells is partly suppressed by DHC knockdown or 
by phannacological disruption of microtubules using nocodazole or paclitaxel. We 
therefore decided to determine whether these interventions would also inhibit IDV-1 
restriction in cells in which exogenous FLAG-tagged rhTRIM5a was over-expressed. 
rhTRIM5a was expressed in HeLa cells through retroviral transfer, and non-transduced 
cells were eliminated by puromycin treatment. We infected the transduced cells with 
the restriction-sensitive HIV-1 vectors IDV-1cMV-GFP and HIV-1NL43-GFP as well as 
the rhTRIM5a-insensitive SIV mac-GFP (Fig. 2.5A). The two vectors used differ in that 
HIV-1cMV-GFP does not carry the viral products Vpr, Nef, Vif and Vpu, and no viral 
proteins are expressed following integration (Naldini et al, 1996). In contrast, 
HIV-1NL43-GFP encodes all IDV-1 proteins with the exception of Env and Nef, and viral 
proteins are expressed in infected cells (He et al, 1997). Restriction was observed for 
both viruses in HeLa-rhTRIM5a cells, compared with SIV mac-GFP and after nonnalization 
of viral stocks according to their titers on CRFK cells (Fig. 2.5A). Specifically, 
HIV-1cMV-GFP and IDV-1NL43-GFP were restricted ~40-fold and between ~48- and 78-fold, 
respectively. Nocodazole and paclitaxel increased permissiveness to HIV-1CMV-GFP by 
1O.1-fold and 9.8-fold, on average, and they increased permissiveness to IDV-1NL43-GFP 
by an average of 17.8-fold and 15.6-fold, respectively (Fig. 2.5A). None of the drug 
treatments had a significant effect on infection by SIV mac-GFP, although paclitaxel 
seemed to increase IDV-1 infectivity at relatively low MOIs and decrease it at relatively 
high MOIs (Fig. 2.5A). Next, we used FLAG-rhTRIM5a transduced HeLa cells 
transfected with the control (luciferase-targeting) siRNA or with the siRNA targeting 
DHC (Fig.2.5B). In this experiment, restriction of IDV-1NL43-GFP by rhTRIM5a was 
particularly high (>l,OOO-fold). We found that cells depleted of DHC were more 
permissive to infection by IDV-1 NL43-GFP than cells transfected with the control siRNA 
(an 11.1-fold increase on average). In contrast, DHC knockdown slightly decreased 
infection by the control SIV mac-GFP vector (Fig. 2.5B). 
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In the next set of experiments (Fig.2.5C-F), we compared the effect of 
nocodazole, paclitaxel and DHC depletion on the permissiveness to HIV -lof cens 
transduced with FLAG-rhTRIM5a or with a non-restrictive control (huTRIM5a). The 
expression levels of huTRIM5a and rhTRIM5a were found to be comparable 
(Fig. 2.5F). cens were infected at an MOI leading to approximately 1 % infected 
cens in the absence of treatment, as in Fig. 2.1. Addition of nocodazole increased 
permissiveness of HeLa-rhTRIM5a to HIV-lcMV-GFP by 5.3-fold ± 0.21 (Fig.2.5C), 
while it had a much smaller effect on HeLa transduced with the 'empty' vector (1.5-fold 
± 0.04) or HeLa transduced with huTRIM5a (1.46-fold ± 0.10). Likewise, treating the 
cens with paclitaxel increased permissiveness to HIV-lcMV-GFP by 3.9-fold ± 0.33 
(Fig. 2.5D), while it slightly decreased infection of HeLa-vector and HeLa-huTRIM5a 
cens (0.6 fold ± 0.13 and 0.63-fold ± 0.12, respectively). Depleting DHC similarly 
increased permissiveness to HIV-lcMV-GFP in cens expressing rhTRIM5a (4.2-fold ± 
0.38) while having no effect in cells expressing the human ortholog (Fig. 2.5E). In 
conclusion, microtubule disruption with nocodazole and paclitaxel treatment and DHC 
depletion specifically inhibited the restriction of HIV -1 by exogenously expressed 
rhTRIM5a in human cells. 
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Figure 2.5 Inhibition of HIV-l restriction by rhTRIM5a exogenously expressed 
in HeLa cells. 
(A) Effect of nocodazole (noc) and paclitaxel (txl) on the restriction of 
HIV -1 vectors at multiple virus doses. HeLa cens stably expressing 
FLAG-tagged rhTRIM5a (rhT5a) were infected for 16 h with multiple 
amounts of the indicated vectors in the presence or absence of 0.1 ~ of 
nocodazole or paclitaxel. Virus doses were normalized according to titers 
in CRFK cens. % of infected cens were analyzed 2 d post infection. 
(B) Effect of DHC depletion on the restriction of HIV-1NIA3-GFP. HeLa 
cens stably expressing rhTRIM5a (rhT5a) were transfected with siRNAs 
targeting DHC (siDHC) or, as a control, luciferase (siLuc). The efficiency 
of DHC knockdown was similar to that in Fig. 2.4A (not shown). cens 
were then infected for 16 h with HIV-1NIA3-GFP or SIV mac-GFP, and the % of 
infected cens were determined 2 d later. (C, D) Effect of nocodazole or 
paclitaxel treatment on the infectivity ofHIV-lcMV-GFP in cens expressing 
HIV -1 restrictive or non-restrictive TRIM5a alleles. HeLa cens 
transduced as indicated with FLAG-tagged huTRIM5a (huT5a), 
rhTRIM5a (rhT5a) or with the empty vector were treated or not with 
0.1 !lM of nocodazole (C) or paclitaxel (D). cens were simultaneously 
infected in triplicates with single doses ofHIV-lcMV-GFP adjusted to yield 
~ 1-1 0% of infected cens in the absence of the drug. Infectivities obtained 
in the absence of drugs were as follows: for (C), HeLa [vector], 1.23 ± 
0.09%; HeLa [huT5a], 2.14 ± 0.81%; HeLa [rhT5a], 0.82 ± 0.06%; for 
(D), HeLa [vector], 6.84 ± 0.14%; HeLa [huT5a], 6.58 ± 0.27%; HeLa 
[rhT5a], 2.79 ± 0.19%. Infected cens were detected by flow cytometry 
2 d post infection and results are presented as -fold changes relative to the 
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relevant untreated controls (relative change in infectivity). (E) Effect of 
DHC depletion on restriction. HeLa cells stably expressing huTRIM5a or 
rhTRIM5a were transfected with siRNAs against DHC (siDHC) or 
against luciferase (siLuc) as a control and infected 72 h later in triplicates 
with single doses of the viral vector HIV-lcMV-oFP for 16 h. Virus doses 
were adjusted to obtain ~ 1 % of infected cells for the siLuc control and 
yielded 1.61% ± 0.29 infected HeLa [huT5a] cells and 0.30 ± 0.08% 
infected HeLa [rhT5a] cells. Infected cells were detected by flow 
cytometry 2 d post infection and results are presented as -fold changes 
relative to the relevant untreated controls (relative change in infectivity). 
*** indicates P < 0.0001 in a Student t test. (F) Western blotting analysis 
of cells stably transduced with FLAG-tagged huTRIM5a and rhTRIM5a, 
with actin as a loading control. 
Nocodazole and paclitaxel inhibit TRIM5a-mediated restriction of an IDV-l 
vector bearing autologous envelope proteins. The experiments shown in Fig. 2.1 to 
2.5 were all performed using VSV G-pseudotyped vectors. TRIM5a-mediated restriction 
is not known to be affected by the mode of virus entry, nonetheless we decided to verify 
that nocodazole and paclitaxel would inhibit the TRIM5a-mediated restriction of a virus 
bearing its autologous envelope. For that, we used a fully infectious HIV-l clone 
(HIV-INL43"IREs-oFP) encoding GFP in addition to all the other viral proteins. Human 
MAGI cells (Vodicka et al, 1997), which are U373 (glioblastoma) cells stably 
expressing the HIV -1 receptors and thus are permissive for HIV -1 infection, were 
retrovirally transduced to express huTRIM5a or rhTRIM5a. rhTRIM5a was expressed 
at higher levels as compared to huTRIM5a (Fig. 2.6B), which may reflect intrinsic 
differences in expression levels of the two proteins, since similar observations were 
made in other cellular contexts (Bérubé et al, 2007; Pham et al, 2010). HIV-l was 
restricted ~41-fold in the cells transduced with rhTRIM5a compared to control ('empty' 
vector-transduced) cells, while as expected, it was not restricted in cells transduced with 
huTRIM5a (not shown). Cells transduced with either of the two TRIM5a orthologs or 
transduced with the empty vector were then infected with HIV -1 NL43-IRES-OFP using 
amounts of the virus leading to approximately 0.1 % infected cells and in the presence or 
absence of drug treatment. As shown Fig. 2.6A, nocodazole and paclitaxel increased the 
capacity of HIV-l to infect cells transduced with rhTRIM5a by 6.1-fold ± 1.7 and 
12.1-fold ± 4.5, respectively. The drugs had no significant effect on HIV-l infectivity in 
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the non-restrictive control cells. Thus, integrity of the microtubule network is important 
for efficient restriction by TRIM5a regardless ofthe mechanism of virus entry. 
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Figure 2.6 Nocodazole and paclitaxel inhibit TRIM5a-mediated restriction of 
non-pseudotyped HIV-1. 
(A) MAGI cells transduced with FLAG-tagged huTRIM5a (huT5a), 
rhTRIM5a (rhT5a) or with the empty vector were treated or not with 
0.25 )lM nocodazole (noc) or 0.1 )lM paclitaxel (txl). As a control, cells 
were also infected in presence of the fusion inhibitor heparin (20 )lglml). 
Cells were infected in triplicates with single doses of HIV -lNIA3-IREs-GFP. 
The amounts of virus used were adjusted to obtain ~0.1 % of infected cells 
in the absence of the drug and yielded 0.22% ± 0.025 infected MAGI 
[vector] cells, 0.16% ± 0.03 infected MAGI [huT5a] cells and 0.043% ± 
0.006 infected MAGI [rhT5a] cells. Supernatants were replaced with 
fresh medium containing heparin 16 h post infection in order to prevent 
re-infections. Infected (GFP-positive) cells were detected by flow 
cytometry 2 d post infection and results are presented as -fold changes in 
the % of infected cells relative to the relevant untreated controls (relative 
change in infectivity). * and ** indicate P = 0.0134 and P= 0.0068 in 
a Student t test, respectively. (B) Western blot analysis of FLAG-
huTRlM5a and FLAG-rhTRIM5a expression in stably transduced MAGI 
cells. Actin was analyzed as a loading control. 
Loss of restriction is not caused by decreased TRIM5a stability nor by 
decreased cellular viability. Next, we investigated a possible impact of the treatments 
on the turnover/stability of TRIM5a. HeLa cells stably expressing FLAG-rhTRIM5a 
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were either subjected to treatment with vehicle, nocodazole, paclitaxel or ERNA, or 
transfected with DHC or control siRNAs, using the same conditions as before. De novo 
rnRNA translation was inhibited using cycloheximide, and we monitored the decrease in 
prote in levels for TRIM5a and for actin as a control (Fig. 2.7A-B). We found that the 
turnover of TRIM5a was not affected by the various treatments used. ERNA slightly 
decreased TRIM5a levels at a single -time-point (1 h of cycloheximide treatment) while 
DHC depletion also slightly decreased TRIM5a levels at 3 and 4.5 h of cycloheximide 
treatment (Fig. 2.7A). However, the results derived from several experiments revealed 
that these effects were not statistically significant (Fig. 2.7B). 
Nocodazole, paclitaxel and ERNA disrupt essential cellular functions and it was 
thus important to insure that the loss of restriction observed in our experimental 
conditions was not an artifact caused by gross cytotoxic effects. In all our infectivity 
assays, drugs are added for only 16 h and then removed, since only the frrst hours of 
infection are relevant to mechanisms of TRIM5a-mediated restriction. Thus, we 
examined cellular viability following 16-hour treatments of HeLa and FRhK-4 cells with 
increasing concentrations of nocodazole, paclitaxel and ERNA (Fig.2.7C). Viability 
was monitored using the XTT assay, a colorimetric method to measure cellular 
metabolic activity, specifically the activity of dehydrogenase enzymes (Scudiero et al, 
1988). Both nocodazole and paclitaxel caused a progressive but relatively modest loss in 
viability, obviously reflecting a concentration-dependent inhibition of cell division 
(Jordan et al, 1992; Sorger et al, 1997). At the relatively low concentrations used for 
infectivity assays, nocodazole caused a ~19% decrease in the viability of HeLa cells and 
a ~32% decrease in the viability of FRhK-4 cells (Fig.2.7C). Similarly, paclitaxel 
caused a ~23% decrease in the viability of HeLa cells and a ~20% decrease in the 
viability ofFRhK-4 cells at the concentrations used in our restriction assays (Fig. 2.7C). 
In both cases, the concentrations used were well below the threshold at which the 
decrease in viability becomes sharper, probably reflecting the occurrence of cytotoxic 
mechanisms in addition to the inhibition of cell division. Based on our XTT data, we 
would estimate these cytopathic effects to take place at above ~30 f.lM for nocodazole, 
~20 f.lM for paclitaxel. We obtained a different pattern for ERNA: in both HeLa and 
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FRhK-4 cells, viability decreased slowly to reach 85-90% of the controllevels at 1 mM 
of the drug, but the drop in viability was much sharper at higher concentrations, and 
.viability was fully lost at -5 mM (Fig.2.7C). At the concentrations used in our 
infectivity assays (600 !lM in HeLa cells, 1.2 mM in FRhK-4 cells), ERNA caused a 
-12% decrease in viability in HeLa cells, 8% in FRhK-4 cells (Fig. 2.7C). Thus, even 
though these concentrations are close to the concentrations at which viability starts 
declining sharply, cellular viability is still at the level ofuntreated cells, and it is unlikely 
that the effects of ERNA on restriction result from its cytotoxicity. 
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Figure 2.7 Effect oftreatments on TRIM5a stability and cell viability. 
(A) Effect on rhTRIM5a protein levels. HeLa cells stably expressing 
FLAG-tagged rhTRIM5a were treated with nocodazole (0.1 flM), 
paclitaxel (taxol) (0.1 flM), ERNA (600 !lM) and concomitantly treated 
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with cycloheximide. Alternatively, cells were transfected with luciferase-
or DHC-targeting siRNAs like before and treated with cycloheximide 
72 h later. The efficiency of DHC knockdown was similar to that in 
Fig. 2.4A (not shown). Protein lysates were prepared at the indicated 
time points following the beginning of drug treatments. Lysates were 
subjected to Western blotting to detect FLAG-rhTRIM5a and actin. One 
representative experiment out of 3 independent experiments is shown. 
(B) Analysis of FLAG-rhTRIM5a prote in turnover. FLAG-rhTRIM5a 
bands detected by Western blotting were quantified by densitometry and 
normalized to actin levels and then to the value obtained at the '0' time 
point; ctl, control; noc, nocodazole; txl, paclitaxel. Average data from 
3 independent experiments with standard deviations are shown. The 
P-values indicated on the graphs were calculated using a Student t test for 
the three conditions at which an effect could be observed: ERNA 
treatment (1 h) and DHC siRNA transfection (3 h and 4.5 h). (C) Cell 
viability assay. HeLa and FRhK-4 cells were treated with multiple 
concentrations of the indicated drugs for 16 h and cell viability was then 
detertnined using the XTT assay and normalized using the value obtained 
in absence of drug as a reference. Vertical lines indicate the drug 
concentrations used in this study, for each combination of drug and cell 
line. 
DHC depletion, nocodazole treatment and paclitaxel treatment stabilize post-
entry HIV -1 cores. A characteristic effect of TRIM5a-mediated post-entry retroviral 
restriction is the increase in the CA core disassembly of restriction-sensitive 
retroviruses, i.e. a decrease in core stability. We used the well-established fate-of-capsid 
assay (Bérubé et al, 2007; Ohkura et al, 2011; Stremlau et al, 2006a) to analyze the 
impact of nocodazole treatment, paclitaxel treatment and DHC depletion on TRIM5a-
mediated core disassembly. HeLa cells expressing rhTRIM5a or mock-transduced with 
the empty vector were exposed to HIV-INIA3-GFP in the presence or the absence of 
nocodazole, paclitaxel or DHC siRNA. The efficiency of DHC knockdown was the 
same as in Fig. 2.4A (not shown). Cells were lysed and core-associated (pelletable) CA 
was isolated by ultracentrifugation through a sucrose cushion. The relative amounts of 
core-associated, soluble (post-centrifugation supernatant-associated) and total (whole 
cell lysate, WCL) CAp24 were assessed by densitometry of western blots from three 
independent experiments (Fig. 2.8). The amounts of pelletable CA recovered were 
estimated relative to total CA or relative to soluble CA. As a control, cells were infected 
with a vector devoid of envelope proteins and thus incompetent for entry. Both virus 
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preparations were normalized using a reverse transcription assay to insure equal virus 
input. In the absence of the VSV G envelope, no or little CA signal was detectable in the 
infected cells, confmning that the CA detected was not associated with unfused viral 
partic1es (Fig. 2.8A-C). As expected and in the absence of treatment, the relative 
amounts of pelletable CA cores were reduced in cells expressing rhTRIM5a, compared 
to the control cells transduced with the empty vector (Fig. 2.8A-C). Specifically, the 
pellet/WCL CA ratio was reduced by 85.9% (± 9.0), 70.4% (± 14.0) and 75.7% (± 23.0) 
in the experiments shown Fig. 2.8A, 2.8B and 2.8C, respectively. Similarly, the 
pelletlsupematant CA ratio was reduced by 85.0% (± 12.7), 72.2% (± 11.5) and 88.4% 
(± 9.1) in cells expressing rhTRIM5a (Fig. 2.8A-C, right panels). 
We observed that all the treatments used had a stabilizing effect on post-entry CA 
cores, both in permissive (control) cells and in restrictive (TRIM5a-expressing) cells 
(Fig.2.8A-C). However, the increase in stability mediated by DHC depletion and 
pac1itaxel treatment was greater in rhTRIM5a-expressing cells than in control cells, 
consistent with the ability of these treatments to rescue infection. Specifically, DHC 
depletion increased the pellet/WCL CA ratio by 1.28-fold in control cells while this 
increase was of 3.1O-fold in rhTRIM5a-expressing cells (Fig. 2.8A). Similarly, DHC 
depletion increased thepelletlsupematant CA ratio by 2.11-fold in control cells and by 
5.78-fold in rhTRIM5a-expressing cells (Fig. 2.8A). Pac1itaxel treatment increased the 
pellet/WCL CA ratio by 1.61-fold in control cells while the corresponding increase 
in rhTRIM5a-expressing cells was 2.52-fold. Similarly, pac1itaxel increased the 
pelletlsupematant CA ratio by 1.46-fold in control cells and 3.87-fold in rhTRIM5a-
expressing cells (Fig. 2.8B). We obtained different effects for nocodazole, since 
treatment with this drug sharply increased CA core stability both in permissive and 
restrictive conditions (Fig. 2.8C). Specifically, nocodazole increased the pellet/WCL CA 
ratio by 3.94-fold in control cells and by 2.83-fold in rhTRIM5a-expressing cells. 
Similarly, the pelletlsupematant CA ratio was increased by 3.77-fold in control cells and 
by about the same amount (4.05-fold) in rhTRIM5a-expressing cells treated with this 
drug (Fig. 2.8C). Therefore, disrupting the microtubule network or the dynein heavy 
chain motor has a stabilizing effect on post-entry HIV -1 cores, which may decrease their 
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susceptibility to TRIM5a-mediated restriction. In addition, the magnitude of this 
stabilizing effect was greater in cells expressing rhTRIM5a under treatment by 
pac1itaxel or DHC siRNAs, which is consistent with these interventions specifically 
increasing HIV-1 infectivity in restrictive conditions. Nocodazole treatment increased 
post-entry HIV -1 cores stability equally in permissive and restrictive conditions, but its 
effects in permissive conditions was also much stronger (3.94-fold) compared to DHC 
depletion (1.28-fold) or pac1itaxel treatment (1.61-fold), perhaps masking the specifie 
effect on restriction (see Discussion). 
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Figure 2.8 DHC depletion, paclitaxel treatment and nocodazole treatment 
increase the stability of HIV-l cores in permissive or restrictive 
conditions. 
(A) HeLa cells stably expressing rhTRIM5a (rhT5a) or transduced with 
the empty vector were transfected with the indicated siRNAs and 72 h 
later infected with HIV -1NL43-GFP or an entry-incompetent version of this 
vector lacking the VSV G envelope protein. Supematants were replaced 
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by fresh medium 2 h post infection and cells were lysed after an 
. additional 4 h of incubation. Pre-cleared lysates were layered on sucrose 
cushions and particulate viral CA cores were pelleted by 
ultracentrifugation. Proteins in post-centrifugation pellets (PEL), 
supernatants (SUP) and whole cell lysates (WCL) were analyzed by 
Western blotting to detect CA (P24). Bands corresponding to p24 were 
quantified by densitometry and plotted as pellet/WCL and 
pelletlsupernatant ratios, relative to the non-restrictive untreated control. 
Average data from 3 independent experiments with standard deviations 
are shown. -fold changes and P-values (calculated using a Student t test) 
are shown for specific pairs of data. (B) Same as (A), but cells were 
treated or not with 0.1 f..lM paclitaxel (txl) during the 2 h of infection and 
during the 4 h of incubation. (C) Same as (B), but cells were treated or 
not with 0.1 f..lM nocodazole (noc). 
Effect of nocodazole treatment and DHC depletion on the size and 
localization of TRIM5 CBs. The capacity of nocodazole treatment and DHC depletion 
to reduce TRIM5a-mediated restriction could stem from effects on the dynamics of 
TRIM5a, which would affect the size and/or localization of CBs. HeLa cells stably 
expressing FLAG-tagged rhTRIM5a were treated with nocodazole or depleted for DHC 
and then stained for FLAG (Fig. 2.9A-B). The settings were adjusted to reveal CBs 
but not the diffuse FLAG signal. The size (area) of CBs (Fig. 2.9C) and their relative 
distances to the nucleus and to the 'edge-of-cell' (Fig. 2.9D) were calculated as detailed 
in 'Materials and Methods'. Nocodazole treatment and DHC knockdown increased 
the average size of rhTRIM5a CBs by 33.9 ± 7.8% and 52.6 ± 8 .. 9%, respectively 
(Fig.2.9C). In addition, rhTRIM5a CBs were found to be 31.5 ± 3.7% closer to the 
nucleus following nocodazole treatment (Fig. 2.9D). In contrast, DHC depletion caused 
a significant rhTRIM5a CBs localization shift (14.2 ± 2.8%) towards the plasma 
membrane (Fig. 2.9D). The results presented in Fig. 2.9 show that the microtubule 
network is important for the dynamics of TRIM5a CBs. Depletion of DHC and 
disruption of microtubules can have distinct effects on TRIM5a CBs, but the increased 
peripheral localization of CBs seen upon DHC depletion suggests that dyne in motor 
complexes are responsible for their retrograde transport. To test more directly whether 
dynein is involved in the association of TRIM5a CBs with microtubules, we co-
transfected HeLa cells stably expressing FLAG-rhTRIM5a with siRNAs targeting either 
DHC or an irrelevant control and with a plasmid expressing GFP-a-tubulin, then stained 
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for FLAO (Fig.2.9E-F). Images were acquired with · the Apotome system and 
deconvolved to facilitate analysis, and co-localization was quantified from multiple 
randomly chosen cells. The depletion of DHC resulted in a modest (23% ± 0.3) yet 
statistically significant decrease in the co-Iocalization of rhTRlM5a. CBs and 
microtubules (Fig. 2.90). Altogether, these results suggest that dynein motor complexes 
are involved in the association of TRlM5a. CBs with microtubules and in the retrograde 
transport of either TRlM5a. CBs. 
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Influence of DHC depletion and nocodazole treatment on the 
localization and dynamics of rhTRIM5a cytoplasmic bodies (CBs). 
(A, B) IF microscopy. HeLa cells transduced with FLAO-tagged rhT5a. 
and control cells transduced with the empty vector were (A) seeded on 
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glass coverslips and 24 h later treated or not with 2 ~ of nocodazole for 
6 h, or (B) transfected with 40 nM of siRNAs targeting DHC or Luc and 
48 h later seeded on glass coverslips and incubated for an additional 24 h. 
cens were fixed and immunostained for FLAG (red). DNA was stained 
with Hoechst33342 (blue). Representative images are shown. (C) Sizes of 
CBs. AlI CBs were outlined in cens from a minimum of 5 randomly 
chosen fields and their area was calculated using an image analysis 
software (AxioVision). Red bars show the standard error of the mean 
(SEM). *** indicates P :S 0.0001 in a Student t test analysis. (D) The 
relative localization of an TRIM5a CBs from a minimum of 5 randomly 
chosen cens was calculated using the formula x/(x+y), where x is the 
shortest distance to the nucleus and y is the shortest distance to the cen ' s 
edge. SEM are shown as red bars, and *** indicates P :S 0.0001. 
(E-G) Co-Iocalization of rhT5a CBs and microtubules. (E) HeLa cells 
transduced with FLAG-tagged rhTRIM5a were transfected with siRNAs 
targeting Luc or DHC and 24 h later cells were additionally transfected 
with a plasmid expressing GFP-a-tubulin. The next day, ceUs were 
seeded on glass coverslips and grown for 24 h. Cells were fixed and 
immunostained for FLAG (red) and DNA (blue). (F) Same as (E), except 
that cells were transduced with the empty vector and were transfected 
with the luciferase-targeting siRNA. Representative images are shown. 
Boxes in the top right corner show enlarged regions outlined on the 
images, and white arrows show examples of GFP-tubulinIFLAG-TRIM5a 
co-Iocalizations. (G) Events of co-Iocalization were quantified as a % of 
total CBs in 10 randomly chosen fields. Bars represent the mean values 
from analyzed cells with SEM (** indicates P < 0.005). 
2.7 Discussion 
In this work, we examined the importance of microtubules and of the micro tubule-
associated dyne in motor complexes in the restriction ofHIV-l and N-MLV by TRIM5a. 
Pharmacological and siRNA-mediated depletion studies clearly show that the capacity 
of TRIM5a to efficiently restrict incoming retroviruses is dependent on intact 
microtubules and a functioning dynein motor complex (Fig. 2.1 to 2.6). This was true 
regardless of (i) the retro virus and TRIM5a ortholog studied, (ii) whether TRIM5a was 
expressed at endogenous levels or over-expressed through stable transduction, and 
(iii) the mechanism of virus entry. Nocodazole and paclitaxel, two drugs that disrupt the 
structure of the microtubule network through different mechanisms, had very similar, 
sometimes identical effects on retroviral restriction levels (Fig. 2.2, 2.4). DHC depletion 
generally had a smaller effect on restriction than treatment with nocodazole or pa?litaxel 
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(Fig. 2.4), whichmay be due to the observed incomplete knockdown (Fig.2.4A). 
However, DHC depletion did not synergistically inhibit TRIM5a in the presence of 
either nocodazole (Fig. 2.4D) or paclitaxe1 (Fig. 2.4E), implying that these treatments all 
affected the same pathway. Finally, the observed impact of microtubules or dynein 
disruption on virus restriction was not caused by gross differences in expression levels 
or TRIM5a stability (Fig. 2.7A-B) and was not a putative artifact stemming from 
cytotoxicity (Fig. 2.7C). 
Destabilization of the viral CA core upon interaction with TRIM5a is a hallmark 
of restriction and occurs in the hours following virus entry. We observed that DHC 
depletion, nocodazole treatment and paclitaxel treatment all increased the relative 
amounts of pelletable CA, both in permissive and. restrictive conditions. This indicates 
that these treatments increase the stability of post-entry HIV-1 CA cores. To our 
knowledge, this effect of interventions altering the cytoskeleton on HIV -1 disassembly 
had never been investigated before. Although the mechanism behind HIV -1 post-entry 
CA core stabilization is unclear, it could contribute to making HIV -1 partly resistant to 
TRIM5a, by counteracting the destabilizing effect of TRIM5a (Black & Aiken, 2010). 
The increase in the relative amounts of core-associated CA induced by DHC depletion 
or paclitaxel treatment was greater in cells expressing rhTRIM5a compared to control 
cells (Fig. 2.8A, 2.8B). This is consistent with these treatments specifically increasing 
HIV -1 infectivity in restrictive conditions. The results with nocodazole were more 
ambiguous, as this drug strongly increased the relative levels of core-associated CA 
(a 3- to 4-fold increase) both in permissive and restrictive conditions (Fig. 2.8C). This 
apparent lack of specificity of nocodazole in this assay might be due to compounding 
effects of the drug. For instance, nocodazole could increase the apparent stability in 
permissive conditions through an additional mechanism that does not take place in 
restrictive conditions, hence masking the restriction-specific effect that is seen with 
DHC siRNAs or paclitaxel. Consistent with this, nocodazole increased the relative 
amounts of core-associated CA in permissive cells about twice as much as DHC 
depletion or paclitaxel treatment did. 
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Nocodazole treatment increased the size of TRIM5a. CBs and caused them to 
be positioned closer to the nucleus (Fig. 2.9), which is consistent with previous 
observations by Diaz-Griffero et al. (Diaz-Griffero et al, 2006). These data suggest that 
nocodazole interferes with the dynamics of TRIM5a. CBs, perhaps by preventing 
the exchange of TRIM5a. proteins between diffuse cytoplasmic population and CBs-
associated population (Campbell et al, 2007). DHC depletion increased the average size 
of rhTRIM5a. CBs (Fig.2.9C), but also caused CBs to accumulate towards the cell 
periphery (Fig. 2.9D). In addition, there was a modest but significant decrease in the 
association between microtubules and rhTRIM5a. (Fig. 2.9G). Altogether, these results 
suggest that the dynein motor translocates rhTRIM5a. CBs on microtubules and is at 
least partly responsible for their retrograde transport. When DHC is depleted, rhTRIM5a. 
CBs may shift towards the periphery of cells due to interactions with other molecular 
motors, such as the reverse polarity motor kinesin, which performs anterograde transport 
and can transport the samecargos as dynein does (Muller et al, 2008). Altematively, 
DHC depletion could enhance the association ofrhTRIM5a. with late endosomes, as was 
observed previously for components of the HIV -1 ribonucleoprotein such as Gag and the 
genomic RNA (Lehmann etaI, 2009). Nocodazole treatment and DHC depletion showed 
distinct phenotypes with regard to TRIM5a.-mediated CA core disassembly (Fig. 2.8) 
and TRIM5a. CBs localization (Fig. 2.9D), yet their effects on restriction are clearly not 
additive (Fig. 2.4). Thus, it is likely that these phenotypic differences simply reflect 
different mechanisms of action by which the two treatments inhibit a single pathway. 
Perhaps surprisingly, the various interventions used in this study generally had 
little effect on the transduction of HIV -1 , SIVmac and ML V vectors in permissive 
conditions. Nocodazole was originally reported to modestly inhibit the early stages of 
HIV-1 infectivity in MAGI cells (Bukrinskaya et al, 1998). However, other studies 
demonstrated a lack of HIV-1 sensitivity to this drug in human embryo kidney 293T 
cells (Daniel et al, 2005) and in CEM T cells (Yoder et al, 20 Il). At first glance, such a 
lack of inhibition by nocodazole contradicts a role for microtubules in HIV -1 post-entry 
intracellular transport (McDonald et al, 2002). However, the existence of a population of 
nocodazole-resistant microtubules, which are less dynamic, has been described (Schulze 
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& Kirschner, 1987), raising the possibility that HIV-l uses these specifie microtubules 
for its transport. Likewise, depleting DHC had a small effect on the infection of human 
permissive HeLa cells by an SIVmac vector (Fig. 2.5B) and no effect was seen on 
infection of HeLa cells by B-MLV (Fig. 2.4C) or HIV-l (Fig. 2.5E) vectors. To the best 
of our knowledge, the only published evidence of a functional role for dynein motor 
complexes in HIV -1 post-entry transport consisted in the injection of an antibody 
interfering with dynein motor function, leading to a -50% decrease in HIV-l 
movements toward the nucleus (McDonald et al, 2002); however, this observation was 
not supported by infectivity data. Clearly, the precise mechanism of retroviral capsids 
transport toward the nucleus is yet to be determined (Mouland & Milev, 2012). 
Regardless, our results show that disruption of the microtubule network and DHC 
depletion affect TRlM5a-mediated restriction without strongly impairing infectivity in 
permissive cells, firmly establishing specificity. The effects seen on restriction probably 
stem from effects on TRlM5a localization (Fig. 2.9), on CA stability (Fig. 2.8), or a 
combination ofboth. 
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INIDBITION OF MICROTUBULE- AND DYNE IN-DEPENDENT 
TRANSPORT COUNTERACTS HIV-l UNCOATING 
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3.1 Contributions 
P.P. and L.B. designed the study, interpreted the results and prepared the manuscript. 
P.P. performed the experiments. 
3.2 Abstract 
Retroviral caps id cores undergo uncoating during th~ir transport toward the 
nucleus and/or after reaching the nuclear membrane. Here we investigate the role of the 
microtubule network and dynein-dependent transport in HIV -1 uncoating. We used the 
pharmacological agents nocodazole and paclitaxel (formerly named taxol) to inhibit 
microtubule dynamics, while dynein-mediated transport was perturbed either by 
depletion of dynein heavy chain (DHC) or by p50/dynamitin over-expression. In 
immunofluorescence microscopy experiments, we detected an accumulation of CA foci 
in HIV-1 infected cells following DHC depletion or microtubule perturbation. Using a 
fate-of-capsid assay to monitor HIV -1 CA core disassembly in infected cells, we 
observed an increase in the amounts of pelletable CA cores following treatments with 
nocodazole or paclitaxel, DHC depletion and p50/dynamitin over-expression. Our 
results show that inhibiting microtubules dynamics or dynein-mediated transport 
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interferes with uncoating in the cytoplasm of infected cells, suggesting a functional link 
between HIV -1 transport and uncoating. 
Keywords: HIV -1 ; uncoating; capsid; microtubules; dyne in 
3.3 Introduction 
The mature CA core of human immunodeficiency virus 1 (HIV -1) is a ~60 nm x 
120 nm (Briggs et al, 2003) cone-shaped prote in lattice, encasing viral genomic RNA, 
enzymes (integrase and reverse transcriptase) and other viral proteins [reviewed in 
(Briggs & Krausslich, 2011)]. It is composed of ~1000 CA monomers (pomillos et al, 
20 Il) arranged in ~ 170 hexamers and 12 pentamers through interactions involving their 
N-terminal domains (pornillos et al, 2009), whereas C-terminal domains are important 
for homodimerization that connects the rings into a lattice (GambIe et al, 1997). In 
addition to viral proteins, the CA core also encloses many cellular components 
originating from the producer cells, such as APOBEC3G [reviewed in (Ott, 2008)] . 
Following receptor-mediated entry into the cytoplasm, HIV-l undergoes tightly 
regulated processes that prepare the virus for nuclear import and integration of its 
genetic material into host DNA. The nucleoprotein complex formed before completing 
reverse transcription (RT) is usually referred to as the reverse transcription complex 
(RTC), which is later transformed into the pre-integration cornplex (PIC). RT is thought 
to be initiated within 30 min post virus entry (Goff, 2001) by a still unknown 
mechanism. Before, during or after RT, the CA core must be disassembled in a process 
called 'uncoating'. The precise timing and location of uncoating remain unclear; sorne 
reports propose that it occurs in the cytoplasrn (Hulme et al, 20 Il ; McDonald et al, 
2002), while others suggest that uncoating takes place at the nuclear pore (Arhel et al, 
2007; Rasaiyaah et al, 2013; Schaller et al, 2011). It is possible that a small fraction of 
CA proteins remain associated with PICs and are transported to the nucleus (Zhou et al, 
20 Il), and CA has been identified as a determinant for HIV -1 integration site specificity 
(Schaller et al, 2011). These hypotheses are not mutually exclusive considering that 
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uncoating could take place in several well-orchestrated steps instead of being a rapid 
single-step process (Ambrose & Aiken, 2014). Additionally, recent lines of evidence 
indicate that uncoating is linked with RT (Hulme et al, 2011; Roa et al, 2012; Yang et 
al, 2013) and suggest that RT triggers uncoating (Hulme et al, 2011; Zhang et al, 2000). 
However, it cannot be excluded that RT initiation itself depends on prior destabilization 
or increased permeability of the CA core after entry into the cytoplasm (Zhang et al, 
1998). Altematively, uncoating could be triggered by an as yet unknown cellular factor 
(Auewarakul et al, 2005). 
Numerous studies indicate that CA is the main viral determinant for uncoating. 
Mutations resulting in either hypostable or hyperstable CA cores almost completely 
abolish viral infectivity despite normal virion protein content (Forshey et al, 2002). 
Additionally, the retroviral restriction factors TRIM5a. and TRIMCyp inhibit viral 
infection (Sayah et al, 2004; Stremlau et al, 2004) through binding to and destabilization 
of incoming CA cores, in essence causing 'premature uncoating' (Stremlau et al, 2006). 
Furthermore, the HIV-l small-molecule inhibitor PF-3450074 (PF74) inhibits HIV-l 
infectivity specifically by destabilizing the CA core (Shi et al, 2011). Uncoating is also 
likely dependent on cellular factors, but these remain mostly elusive (Ambrose & Aiken, 
2014). A few cellular partners that interact with the HIV-l CA core were characterized 
and sorne were proposed to modulate uncoating, such as cyclophilin A (CypA) (Li et al, 
2009; Shah et al, 2013), nucleoprotein RanBP2/Nup358 (Schaller et al, 2011), 
transportin 3 (TNP03) (Shah et al, 2013), cleavage and polyadenylation specific factor 6 
(CPSF6) (De laco et al, 2013) and PDZ Domain-containing 8 (Guth & Sodroski, 2014). 
Similarly to other viruses [reviewed in (Slonska et al, 2012)], HIV-l hijacks the 
cell's cytoskeleton and associated molecular motors for its trafficking towards the 
nucleus [reviewed in (Gaudin et al, 2013)]. The microtubule network and microtubule-
associated dyne in motor complexes were proposed to transport HIV-l RTCs towards the 
nucleus (McDonald et al, 2002). Specifically, HIV-l translocation on microtubules was 
evidenced by live microscopy, and was inhibited by micro-injection of anti-dynein 
antibodies (McDonald et al, 2002). Recently, one team reported that HIV-l induces the 
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formation of and co-Iocalizes with a stable sub-population of microtubules whose 
disruption abolishes infectivity (Sabo et al, 2013). Thus, the microtubule network seems 
to be important for HIV-l trafficking and infectivity. 
In this study, we hypothesized that uncoating of the HIV-l CA core and its 
trafficking towards the nucleus were linked mechanisms. Our results suggest a role for 
the microtubule network and dynein motor complexes in HIV -1 uncoating. 
3.4 Results 
Disruption of the dynein motor complex and the microtubule network causes 
an accumulation of CA foci in infected cells. We used immunofluorescence (IF) 
microscopy with a monoclonal antibody to analyze the presence of CA foci in human 
HeLa cells infected with VSV G-pseudotyped HIV-l cMV-GFP or in human MAGI cells 
infected with HIV-1NIA3, and in the presence of treatments disrupting the microtubule 
network or dynein motor function. Such CA foci detected in acute infection conditions 
are thought to be individual viroses that are not or only partially uncoated (Arhel et al, 
2007; Campbell et al, 2007; Hulme et al, 2011; McDonald et al, 2002). HeLa cells 
transfected with siRNAs targeting either the dynein heavy chain (DHC) rnRNA 
(Lehmann et al, 2009; Pawlica et al, 2014) or the non-relevant luciferase (Luc) rnRNA 
(Pawlica et al, 2014) were infected with the VSV G-pseudotyped lentiviral vector 
HIV -1 CMV -GFP for 4 h, at which point the virus was removed and cells were incubated for 
an additional 2 h. DHC depletion was efficient as assessed by Western blotting, since 
transfection ofDHC siRNA led to a reduction of ~ 85.4% ± 6.7 (n = 10) in protein levels 
(Fig. 3.1A). Upon staining infected cells using an antibody against CA, we detected 
distinct foci as expected, that were absent from mock-infected cells (Fig. 3.1B). DHC 
depletion caused an increase in the amounts of these foci. Specifically, the average 
number of CA foci per cell increased ~2.5-fold following DHC depletion, from 6.98 ± 
0.818 to 17.4 ± 2.88 (P = 0.0038) (Fig. 3.1C). Moreover, CA foci tended to accumulate 
in the cell periphery, as evidenced by measuring relative distances to the nucleus 
(calculated using the formula x/(x+y) where x is the shortest distance to the nucleus and 
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y the shortest distance to the cell's edge). The median relative distance to the nucleus 
changed significantly (P < 0.0001) from 0.44 (95% CI, 0.39-0.52) for the Luc siRNA-
transfected control cells to 0.83 (95% CI, 0.79-0.84) for cells transfected with DHC 
siRNA (Fig. 3.1D). A similar accumulation of viral RTCs in the cell periphery was 
observed upon transfection of anti-dynein antibodies prior to infection (McDonald et al, 
2002). 
HIV -1 virions pseudotyped with VSV Gare delivered through clathrin-mediated 
endocytosis (Sun et al, 2005) and are further released into the cytoplasm following 
acidification of endosomes (Blumenthal et al, 1987). Clathrin-mediated entry relies 
mainly on actin filaments (Cureton et al, 2009), while maturation of endosomes involves 
microtubules (Lakadamyali et al, 2006) and possibly the dynein motor complex 
(Lehmann et al, 2009). Therefore, in order to confirm that the effects observed in 
Fig. 3.1B-D were not stemming from pseudotyping, we repeated the experiment using a 
virus harboring an autologous HIV-l envelope. U373-derived MAGI cells (Vodicka et 
al, 1997) were infected with the replication-competent HIV-INL43 • Since dyne in-
mediated movements are microtubule-dependent [reviewed in (Kikkawa, 2013)], we 
also disrupted microtubule dynamics using nocodazole and paclitaxel, which inhibit 
microtubule polymerization (Luduena & Roach, 1991) or their disassembly (Schiff et al, 
1979), respectively. We previously established low-toxicity effective concentrations of 
the se drugs (Pawlica et al, 2014). MAGI cells were infected for 2 h with HIV-INL43 and 
in the presence of the various treatrnents or left uninfected (Fig. 3.1E). We observed a 
significant increase in the amount of CA foci per cell following DHC depletion 
(Fig 3.1F). Specifically, the average number of CA foci per cell was 16.07 ± 2.27 in 
cells transfected with DHC siRNA compared to 5.4 ± 0.41 in control cells (P = 0.0001). 
Pharmacological disruption of microtubules also resulted in a significant increase in the 
number of CA foci per cell, as we observed 14.47 ± 2.05 (P = 0.0001) and 10.08 ± 1.30 
(P = 0.0007) cores per cell in the presence of paclitaxel and nocodazole, respectively 
(Fig.3.1F). Accordingly, another study also reported an accumulation of CA foci 
following nocodazole treatrnent (Arhel et al, 2007). CA foci were predominantly found 
in proximity to the nucleus of control cells (Luc siRNA), with a median relative distance 
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to the nucleus of 0.30 (95% CI, 0.26-0.37) (Fig. 3.10). Like before, DHC depletion 
caused a significant (P < 0.0001) shift in the distribution of CA cores towards the cell 
periphery; CA foci were found at a median relative distance of 0.70 (95% CI, 0.63-0.75). 
These observations confinn that the effects reported in Fig. 3.1B-D did not result from 
pseudotyping, and suggest that the dynein motor complex might be involved in HIV-1 
core disassembly. As shown Fig. 3.10, nocodazole and paclitaxel treatments also 
resulted in a shift of CA foci localization towards the periphery of the cytoplasm, 
although this effect was more pronounced with paclitaxel. The different effects of 
nocodazole and paclitaxel can be explained by differences in the mechanism of action of 
these two phannacological agents, with nocodazole causing microtubule disassembly 
while paclitaxel prevents their depolymerisation (Schiff et al, 1979) and inhibits dynein-
mediated translocation (Nilsson & Wallin, 1998). Collectively, the results shown in 
Fig. 3.1 suggest that dynein motor complexes and the microtubule network influence 
both HIV -1 retro grade transport and CA core stability in infected cells, irrespective of 
the mode of viral entry. 
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Figure 3.1 Dynein heavy chain (DHC) depletion and microtubule perturbation 
cause the accumulation of HIV-l CA cores in infected cells and alter 
their subcellular distribution. 
(A) HeLa cells were transfected with siRNAs targeting either dynein 
heavy chain (siDHC) or luciferase (siLuc) as a control, and DHC 
expression was analyzed 2 days later by Western blotting. (B) IF 
microscopy observations of CA foci following infection with VSV G-
pseudotyped HIV -1. HeLa cells were transfected with the indicated 
siRNAs and 72 h later were infected or not with VSV G-pseudotyped 
HIV-1cMV-GFP in the presence of MG132. At 4 h p.i., supernatants were 
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replaced with virus-free medium supplemented with MG132. Cells were 
fixed 6 h p.i. and stained to detect CA (green) or DNA (blue). The outline 
of cells was revealed by low-exposure bright-field microscopy. 
Representative images are shown. The white bar represents 10 /llll. 
(C) Box plots showing total amounts of CA foci per cell. The total 
numbers of CA foci and nuclei in 10 randomly chosen fields were 
counted and the CA foci/nuclei ratios were calculated. 375 and 1047 CA 
foci were counted for siLuc and siDHC, respectively. Center green lines 
show the medians; box limits indicate the 25th and 75th percentiles as 
determined by R software; whiskers extend 1.5 times the interquartile 
range from the 25th and 75th percentiles; and red crosses represent 
sample means. **, P-::: 0.001 in a Student t-test. (D) Box plots showing 
the relative localization of CA foci in 10 randomly chosen cells, 
calculated using the formula x/(x+y) where x is the shortest distance to 
the nucleus and y is the shortest distance to the cell's edge. Data points 
are plotted as open circles; center green lines show the medians; box 
limits indicate the 25th and 75th percentiles as determined by R software; 
whiskers extend 1.5 times the interquartile range from the 25th and 
75th percentiles; and red crosses represent sample means. *** indicates 
P -::: 0.0001 in a Student t-test analysis. (E) IF microscopy observation of 
CA foci following infection with HIV -1 bearing an autologous envelope. 
MAGI cells were either transfected with siDHC or siLuc 72 h prior to 
infection, or were pretreated for 15 min with 2 ~ ofnocodazole (noc) or 
0.1 ~ of paclitaxel (pxl) , and then infected with HIV-INL43 in the 
presence of MG 132. Cells were fixed 2 h later and stained as in (B). The 
white bars represent 10 /llll. (F) The total amounts of CA foci per cell 
were calculated as in (C). At least 250 and up to 800 CA foci were 
counted for each condition (***, P -::: 0.0001). (G) Relative cellular 
distribution of CA foci, analyzed as in (D) (* and *** indicate P < 0.05 
and P -::: 0.0001, respectively). 
Analyzing uncoating using the fate-of-capsid assay. As an independent 
experimental approach to analyze uncoating, we used the well described fate-of-capsid 
biochemical assay (perron et al, 2004; Stremlau et al, 2006) that allows isolation of 
post-entry CA cores from infected cells, by ultracentrifugation of pre-cleared celllysates 
through a sucrose cushion. This assay has been used mostly to study the destabilization 
of HIV-l cores caused by TRIM5 proteins (Bérubé et al, 2007; Pawlica et al, 2014; 
Stremlau et al, 2006). We performed a preliminary experiment to analyze whether 
nocodazole and paclitaxel would affect uncoating as analyzed by fate-of-capsid. In this 
experiment, we additionally used a VSV G-devoid, entry-defective control virus (De 
Iaco et al, 2013; Stremlau et al, 2006; Tipper & Sodroski, 2013) to confum that the fate-
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of-capsid assay detects primarily post-entry viruses. Such 'bald' particles can interact 
non-specifically with the cellular plasma membrane and can be intemalized by 
endocytosis, but cannot enter the cytosol (Marechal et al, 1998). As expected, envelope-
devoid HIV-1NIA3-GFP virions were not infectious in HeLa cells (Fig. 3.2A), but had 
normal CA content (Fig.3.2B). HeLa cells pretreated or not with nocodazole or 
paclitaxel were infected with either HIV-1NIA3-GFP or its envelope-devoid counterpart for 
1 h, at which time point supematants were replaced with fresh media containing the 
appropriate drugs, and we analyzed the presence of CAp24 in whole celllysates (WCL), 
pellets and supematants after an additional 5 h of incubation (Fig. 3.2C). Pellets contain 
particulate, not-yet uncoated CA cores while supematants contain soluble CA proteins. 
The 6-hours timing was chosen because we had previously observed an increase in 
amounts of pelletable IllV -1 CA cores in cells infected for the same amount of time and 
treated with nocodazole, paclitaxel or DHC siRNA (Pawlica et al, 2014). As expected, 
it was possible to detect CAp24 in aIl fractions of cells infected with the VSV G-
pseudotyped vector (Fig. 3.2C). For the envelope-devoid virus, bands corresponding to 
CAp24 were barely detectable in WCL and this signal likely corresponded to virions 
attached to the cellular membrane or trapped in endosomal compartments. However, 
CAp24 was not detected in particulate or soluble forms following ultracentrifugation, 
suggesting that the fate-of-capsid assay detects primarily CA that has entered the 
cytoplasm, at least in the conditions employed here. Additionally, nocodazole and 
paclitaxel did not cause unspecific virus entry. Interestingly, we observed an increase in 
the amounts of pelletable CA cores upon treatment with these two drugs of cells 
infected with the VSV G-pseudotyped virus, compared to untreated cells. Specifically, 
pellet/supematant and pellet/WCL ratios increased by 2.6-fold and 2.9-fold, 
respectively, following nocodazole treatment (Fig. 3.2D). Likewise, paclitaxel increased 
these ratios by 2.0-fold and 2.5-fold (Fig. 3.2D). These results suggest that both drugs 
alter IllV-l CA core disassembly. 
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Figure 3.2 Analysis ofHIV-l uncoating using the fate-of-capsid assay. 
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(A) Percentages of HeLa cells expressing GFP following infection with 
increasing amounts of HIV -1 NIA3-GFP pseudotyped with VSV G or devoid 
of an envelope as indicated. The virus preparations were equalized by RT 
activity and the amounts of virus used are shown as MOI units, as 
calculated for the VSV G-pseudotyped virus. (B) The viral preparations 
used in (A) and normalized by RT assay were concentrated by 
ultracentrifugation and analyzed by Western blotting to detect CA. 
(C, D) Fate-of-capsid assay. HeLa cells were infected with HIV-1NIA3-GFP 
bearing VSV G or not (MOI ~2 as calculated for the VSV G-pseudotyped 
virus) and in the presence or absence of nocodazole (noc; 0.1 /lM) or 
paclitaxel (pxl; 0.1 !lM). ' Supernatants were replaced with virus-free 
media containing the appropriate drugs 1 h p.i., and cells were incubated 
for an additional 5 h, then lysed and fate-of-capsid was performed. 
Western blot analyses of HIV -1 CAp24 in the ultracentrifugation pellets 
(PEL), supernatants (SVP) and whole-cell lysates (WCL) are shown. 
Levels of actin in WCLs were also analyzed. (D) CAp24 bands shown in 
(C) were quantified by densitometry and plotted as pellet/WCL or 
pellet/supernatant ratios normalized to the no-drug control. 
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DHC depletion and nocodazole treatment both alter HIV-l uncoating. In 
order to gain more insight in the timing of HIV -1 uncoating and how it is affected by 
DHC depletion and nocodazole treatment, a time-course fate-of-capsid assay was 
performed (Fig. 3.3A, B). HeLa cells transfected with siRNAs targeting either DHC 
or Luc, or treated with nocodazole were infected with equal amounts of 
VSV G-pseudotyped HIV -1 NIA3-GFP for 1 h and then lysed immediately or placed in 
virus-free medium and lysed at 3, 6, 12 and 24 h post infection (p.i.). To track relative 
changes in the amounts of particulate (pelletable) CA core, the different time points 
were analyzed side by side by CA Western blotting. To enable comparison between 
different conditions, equal amounts of a CAp24-containing reference sample were 
loaded on the different gels (Fig. 3.3A). Only pelletable fractions were analyzed at all 
time points, but the CAp24 content in WCLs, as analyzed at 3 h p.i. , confmned equal 
input (Fig. 3.3A). The amounts ofparticulate CAp24 determined by densitometry were 
then normalized to the reference sample and plotted (Fig.3.3B). These amounts of 
particulate CA likely reflect a balance between the dynamics of CA core release from 
endosomes and its uncoating. In the control cells transfected with Luc siRNA, the 
relative amounts of particulate CA peaked at 6 h p.i. but were smaller at 12 h p.i. 
(Fig. 3.3A, B), suggesting that as expected (Arhel et al, 2007; Hulme et al, 2011), 
uncoating had taken place for most R TCs by that time. CAp24 content did not decrease 
further between 12 and 24 h p.i. (Fig. 3.3A), a probable result of de nove Gag synthesis 
in the infected cells. For that reason, the 24 h time point was not inc1uded in the analysis 
shown in Fig. 3.3B. Increased levels of pelletable CA were observed at 6 h p.i. in cells 
treated with nocodazole or transfected with DHC siRNA (Fig. 3.3A, B). Specifically, 
nocodazole treatment and DHC depletion increased CAp24 content in the pelletable 
fraction by ~1.7-fold (P = 0.017) and ~1.5-fold (P = 0.059) relative to the control cells, 
respectively (Fig. 3.3B). This is consistent with the results shown in Fig. 3.2C and with 
our previous report showing an increase in relative amounts of CA cores 6 h p.i. 
following DHC depletion or treatment with nocodazole and pac1itaxel (pawlica et al, 
2014). Interestingly, the increase in amounts ofparticulate CA caused by DHC depletion 
appeared to be transient, since it was not observed at 12 h p.i. On the other hand, 
nocodazole treatment also increased the amounts of CA cores at 12 h p.i. Specifically, at 
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this time point the CAp24 content in the pelletable fractions of cells treated with 
nocodazole was ~3 times that observed in the control cells (P = 0.013). Collectively, 
these results confmn that perturbation of microtubule dynamics and disruption of dynein 
motor complexes increase the relative amounts of CA cores in infected cells, suggesting 
impaired or delayed HIV -1 uncoating. 
We performed an additional experiment, focusing on the 6 h and 9 h p.i. time 
points, that also included paclitaxel treatment. Results were plotted as pellet/WCL ratios 
normalized to the no-treatment control (Fig.3.3C). As expected, an increase in 
pelletable/total CA ratios could be observed at 6 h p.i. as a result of nocodazole or 
paclitaxel treatments or DHC depletion (an increase of ~2.4-fold, ~2.8-fold and 
~2.4-fold compared to the control cells, respectively). DHC depletion did not have an 
effect on CA core stability at 9 h p.i., confirming that the effect seen was transient 
(Fig. 3.3A, B). Perturbation ofmicrotubule dynamics with nocodazole and paclitaxelled 
to a more persistent increase in pelletable CA cores. Indeed, at 9 h p.i. pellet/WCL ratios 
in nocodazole- and paclitaxel-treated cells were ~2.5-fold and ~2 .3-fold higher, 
respectively, than for the untreated control. In summary, microtubule perturbation and 
DHC depletion both counteract uncoating, although the effect appears to be more 
prolonged for the former than for the latter. 
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Figure 3.3 DHC depletion and nocodazole treatment affect HIV-l uncoating. 
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(A, B) Time-course fate-of-capsid assay. (A) HeLa cells were transfected 
with siRNAs targeting DHC (siDHC) or luciferase (siLuc), or were 
pretreated with 2 !lM of nocodazole (noc) , and were infected with 
HIV-lNIA3-GFP (MOI ~2 as calculated on the untreated cells). Supernatants 
were removed 1 h p.i. and replaced with fresh media containing 
nocodazole, if applicable, and fate-of-capsid was performed 1, 3, 6, 12 
and 24 h p.i. Shown are Western blot analyses of CAp24 at 3 h p.i. in 
WCL (lower panel) and at various times in ultracentrifugation pellets 
(upper panels). Identical amounts of a control CAp24-containing sample 
were included in each gel as an internaI standard ('Std'). (B) Bands 
corresponding to pelletable CAp24 were quantified by densitometry up to 
95 
12 h p.i. and plotted after normalization to the standard. The error bars 
correspond to standard deviations of duplicates. * indicates P < 0.05 in a 
two-way ANOVA analysis, when compared to the untreated (siLuc) 
control at the same time points. (C) Fate-of-capsid analysis at 6 h and 9 h 
p.i. HeLa cells transfected with DHC siRNA or treated with nocodazole 
(0.1 ~M) or paclitaxel (0.1 ~M) were infected with HIV-1NL43-GFP (MOI 
~2). Supernatants were replaced with fresh media containing the 
appropriate drugs 1 h p.i., and fate-of-capsid was performed at 6 or 9 h 
p.i. Bands corresponding to CAp24 detected by Western blotting in 
pellets and WCLs were quantified by densitometry, and the -fold 
differences in pellet/WCL ratio relative to the untreated control (0) are 
shown for each time-point. 
Disruption of the dynactin complex interferes with HIV -1 uncoating. As an 
additional approach to disrupt dynein-dependent transport, we over-expressed 
p50/dynamitin (P50), a subunit of the dynactin complex responsible for binding cargos 
to the dynein motor. p50 over-expression results in the disassembly of the dynactin 
complex, thereby disrupting cargo binding to the dynein motor and inhibiting dynein-
dependent transport (Burkhardt et al, 1997; Melkonian et al, 2007). The efficiency of 
p50 transfection was confirmed by Western blotting (Fig. 3.4A). We analyzed the effect 
ofp50 over-expression on HIV-1 uncoating at 6 h p.i., since the maximal effect ofDHC 
depletion on CA cores was observed at this time point (Fig. 3.3). As a control, we used 
the small-molecule CA inhibitor PF-3450074 (PF74), known to disrupt HIV-l 
infectivity through destabilization of the CA core (Shi et al, 2011). p50 transfection 
resulted in increased amounts of pelletable CA cores isolated at 6 h p.i. from cells 
infected with HIV-1NL43-GFP (Fig. 3.4B). The pellet/WCL ratio was 2.3-fold (± 0.097, 
n = 2) higher than for control cells transfected with an irrelevant plasmid (Fig. 3.4C). As 
expected, PF-3450074 caused a decrease (3.7-fold) in the amounts of pelletable CA 
(Fig.3.4B-C). p50 transfection had no significant effect on HIV-1 infectivity, while 
PF-3450074 decreased permissiveness to HIV-1 by ~150- to ~550-fold, depending on 
the MOI used (Fig. 3.4D) and as previously reported (Blair et al, 2010). These results 
confmn that disruption of dynein-dependent transport counteracts uncoating, but the 
lack of an effect on infectivity suggests that uncoating is delayed rather than abrogated. 
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Figure 3.4 Over-expression of p50/dynamitin affects HIV -1 uncoating. 
(A) Western blot analysis of p50 and actin expression in HeLa cells 
2 days after transfection with a plasmid encoding p50 or an irrelevant 
plasmid (pMIP; 0). (B, C) ' Fate-of-capsid analysis. (B) HeLacells 
transfected with a p50 expression construct or with pMIP (0), or treated 
with 10 ~ of PF-3450074 (PF74) , were infected with IDV-l NIA3-GFP 
(MOI ~2 as calculated in the untreated cells). Supernatants were replaced 
with virus-free media containing PF-3450074, if applicable, at 1 h p.i. and 
fate-of-capsid was performed at 6 h p.i. Shown are Western blot analyses 
of CAp24 in pellets, supernatants and WCLs. Levels of actin in WCLs 
were also analyzed. (C) CAp24 bands were quantified by densitometry 
from an experiment done in a duplicate, and pelletable/WCL ratios were 
calculated and are shown as -fold changes relative to the untreated 
control, with standard deviations. (D) Infectivity. HeLa cells treated as 
in (B) were infected with increasing amounts of IDV-1NIA3-GFP. 
Supernatants were replaced with virus-free, drug-free medium 16 h p.i. 
The percentages of GFP-expressing cells were analyzed 2 days p.i. by 
flow cytometry. 
Nocodazole does not stabilize the intrinsically hypostable CA mutant K203A. 
Next, we asked what would be the effect of nocodazole-mediated core stabilization on 
CA mutants that confer increased or decreased stability to virion-associated CA cores 
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(Forshey et al, 2002). Thus, we analyzed the effect of nocodazole treatment on cores 
produced with CA mutants E45A and K203A, using the fate-of-capsid assay. HeLa cells 
were infected with equal amounts of WT or CA-mutated HIV-1 R9/lli (as normalized by 
RT assay) and in the presence or absence ofnocodazole, and infection was stopped after 
1 h. Fate-of-capsid was performed immediately on half of the cells, while the remaining 
cells were kept in culture for Il additional hours in the absence or presence of 
nocodazole (Fig. 3.5A). CAp24 bands were quantified by densitometry and results were 
plotted as pellet/WCL ratios (Fig. 3.5B). At 1 h p.i., many virions would still be attached 
on the outside of cells or trapped in endocytic vesic1es, or would have just entered the 
cells without having undergone uncoating yet; thus, we expected that the phenotypes 
observed at that point would mirror those seen when analyzing the stability of virion-
associated cores for these two mutants (Forshey et al, 2002). Indeed, the relative levels 
of pelletable CA at 1 h p.i. were ~1.6-fold higher for E45A HIV-1R9~E and ~3.3-fold 
smaller for the K203A mutant, compared to the WT control. These results are consistent 
with the reported in vitro behavior of these mutants (Forshey et al, 2002). Nocodazole 
had no major effect on pellet/WCL ratios at 1 h p.i. Relative to the WT control, levels of 
pelletable K203A CAp24 were almost undetectable at 12 h p.i (Fig. 3.5), probably 
indicating spontaneous uncoating over time. However, levels of pelletable CA at 12 h 
p.i. were also low for the hyperstable E45A mutant, compared with the WT (Fig. 3.5B), 
perhaps due to increased susceptibility to a cellular restriction mechanism for this 
mutant (Rasaiyaah et al, 2013). Nocodazole increased the relative amounts ofpelletable 
CA by ~2 . 8-fold for the WT and ~6.5-fold for the E45A mutant (Fig. 3.5B). However, 
nocodazole did not increase the relative levels ofpelletable K203A CA cOres at 12 h p.i. 
These results confmn the stabilizing effect of nocodazole treatment on CA cores and 
indicate that this drug does not counteract spontaneous uncoating stemming from 
intrinsic instability. 
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Figure 3.5 Nocodazole increases the relative amounts of E45A CA cores in 
infected cells, but has no effect on the intrinsically hypostable CA 
mutant K203A. 
(A) HeLa cells were pretreated or not with 0.25 ).lM of nocodazole and 
infected with equal amounts of VSV G-pseudotyped WT, E45A or 
K203A HIV-1 R%E (normalized by RT assay). Half of the cells were lysed 
at 1 h p.i. and the rest were incubated for an additional Il h in fresh 
medium containing nocodazole if applicable, then lysed. Fate-of-capsid 
was performed, and pellet- and WCL-associated CA were analyzed by 
Western blotting. (B) CAp24 bands were quantified by densitometry and 
plotted as pellet/WCL ratios. 
3.5 Discussion 
Previous articles showed that HIV -1 uncoating could be modulated by CA 
interactions with cellular factors such as CPSF6 (De laco et al, 2013) and cyclophilin A 
(Li et al, 2009). In this article, we demonstrate that functional disruption of the 
microtubule network and dynein motors increases the amounts of HIV -1 CA cores in 
cells, most likely reflecting delayed uncoating caused by inhibition of their transport 
towards the nucleus. As observed using IF microscopy, DHC depletion significantly 
increased the amounts of CA foci and resulted in their accumulation in the cell 
periphery. These results are consistent with the hypothesis that HIV-1 can use dynein. 
motors to translocate on microtubules towards the nucleus (McDonald et al, 2002). 
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Similarly, nocodazole and paclitaxel treatments resulted in an increase in the relative 
distance of CA foci from the nucleus and also increased the frequency of these foci, 
suggesting that fewer cores underwent uncoating. Furthermore, fate-of-capsid 
experiments revealed that DHC depletion and disruption of dynein-dependent transport 
by p50 over-expression transiently increased the amounts of CA cores. Thus, dynein 
motor complexes seem to be involved not only in IllV -1 trafficking but also in 
uncoating. However, neither DHC depletion (not shown) nor p50 over-expression had a 
significant effect on HIV-l infectivity, which is consistent with our previous 
observations (Pawlica et al, 2014) and is explained by the fact that the effect of these 
interventions on uncoating seem to be transient. The effect of nocodazole and paclitaxel 
treatments on IllV -1 uncoating was more prolonged, though our experimental setting 
did not allow us to analyze time points beyond 12 h p.i. These drugs did not significantly 
affect infectivity in the cell lines used here (data not shown), consistent with previous 
reports (Bukrinskaya et al, 1998; Pawlica et al, 2014; Yoder et al, 2011), also suggesting 
that uncoating was delayed by the treatments rather than disrupted altogether. These 
observations can be partly explained by the use of a more stable (nocodazole-resistant) 
sub-population of microtubules by IllV-l , as proposed by others (Sabo et al, 2013). 
Alternatively, IllV -1 CA core retrograde transport could proceed by microtubule-
independent mechanisms, such as translocation on actin micro filaments (Yoder et al, 
20 Il). Thus, we propose that inhibition of dynein- and microtubule-mediated transport 
delays uncoating until the virus reaches the juxtanuclear region by employing alternative 
transportation strategies. 
The uncoating inhibition phenotype reported here stands in sharp contrast with the 
effect of the CA E45A mutation, which enhances the stability of CA cores purified from 
virions, but abrogates IllV-l infectivity (Forshey et al, 2002). We show that despite 
being more stable in infected cells than their WT counterpart when analyzed at 1 h, most 
E45A CA cores are 'lost' by 12 h p.i. , which may reflect their sensitivity to a cellular 
restriction factor, by disruption of interactions between incoming CA cores and cellular 
partners shielding them (Rasaiyaah et al, 2013). Nocodazole treatment increased the 
amounts ofE45A CA cores at 12 h p.i, suggesting that this mutant is not impaired in its 
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interactions with the microtubule network. On the other hand, nocodazole did not. 
stabilize the intrinsically hypostable K203A mutant, suggesting that this mutant 
undergoes spontaneous disassembly independently of its retro grade transport. 
It has been reported that HIV -1 CA cores can reach the vicinity of the nucleus 
within two hours of infection (Arhel, 2010; Arhel et al, 2007; McDonald et al, 2002), 
and uncoating appears to be initiated during this transport (Hulme et al, 20 Il), but is not 
completed before reaching the nuclear pore complex (Arhel et al, 2007; Rasaiyaah et al, 
2013). Our results support the notion that when microtubules/dynein-dependent 
transport is inhibited, both retrograde transport and uncoating are simultaneously 
delayed; longitudinal live microscopy experiments might be needed to definitely prove 
this hypothesis. Interestingly, a member of the PDZ domain-containing family, the 
putative microtubule-interacting protein PDZD8, was recently reported to stabilize 
HIV-1 CA cores (Guth & Sodroski, 2014). In agreement with this report, we propose 
that during dynein-dependent transport along microtubules, the HIV -1 CA core is 
stabilized by PDZD8 and/or other cellular proteins, remaining intact or only partially 
uncoated, and completes its uncoating only after being transferred to actin filaments in 
the vicinity of the nucleus (Arhel et al, 2007; Hulme et al, 2011). Our study suggests 
. that uncoating is functionally linked to intracytoplasmic transport of the CA core. 
3.6 Methods 
Cells, pharmaceuticals and antibodies. Human embryonic kidney 293T 
(HEK293T) cells, epithelial carcinoma HeLa cells and human U373-derived MAGI cells 
(V odicka et al, 1997) were maintained in Dulbecco' s modified Eagle' s medium 
(DMEM) with high glucose, supplemented with 10% fetal bovine serum (FBS) and 
antibiotics at 37°C, 5% C02. AlI cell culture reagents were from HyClone (Thermo 
Scientific, Logan, UT). Nocodazole, paclitaxel and MG132 were from Sigma (St Louis, 
MI), while PF-3450074 was provided by Pfizer (New York, NY). Rabbit polyclonal 
antibodies against dynein heavy chain and p50/dynamitin were from Santa Cruz (Dallas, 
TX) and Millipore (Billerica, MA), respectively. Capsid (CA, p24) was detected using a 
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mouse monoclonal antibody (clone 183, cat#3537) from the AIDS Research and 
Reference Reagent Program. The HRP-conjugated mouse anti-actin antibody was from 
Sigma. HRP-conjugated goat anti-rabbit and goat anti-mouse antibodies used as 
secondary antibodies in Western blots were a11 from Santa Cruz. 
Plasmid DNAs, retrovirus production and reverse transcriptase assay. 
pR9ôEWT, pR9ÔEE45A and pR9ÔEK203A, plasmids encoding Ô env HIV-1 vectors and 
bearing capsid stability mutations, were generously provided by Chistopher Aileen 
(Forshey et al, 2005), while p50/dynamitin-HA was a gift from Tina Schroer (Schrader 
et al, 2000). To produce viral vectors, IO-cm culture dishes or 75-cm flasks of sub-
confluent HEK293T ce11s were co-transfected using polyethylenimine (pEI; MW 
25,000, Polyscience, Niles, IL) with the appropriate plasmids, as fo11ows: for the 
replication-competent mV-1NIA3, 20 f.lg ofpNL4-3; for the viraI vector mV-1CMV-GFP, 
pTRIPcMV-GFP (10 f.lg), pÔR8.9 (10 f.lg) and pMD-G (5 f.lg); for HIV-1NIA3-GFP, pNL-GFP 
(10 f.lg) and pMD-G (5 f.lg); for the envelope-devoid HIV-1NIA3-GFP, pNL-GFP (10 f.lg); 
for the HIV-1R%E constructs, the appropriate pR9ÔE (20 f.lg) and pMD-G (5 f.lg) (Aileen, 
1997; Berthoux et al, 2003; Naviaux et al, 1996; Zufferey et al, 1997). Media were 
changed 16 h post transfection and virus-containing supernatants were co11ected after an 
additional 1.5 d of culture. Viral stocks were clarified by centrifugation for 5 min at 
400 x g. In sorne experiments, reverse transcriptase activity was measured on virus 
stocks using the EnzCheck kit (Molecular Probes, Eugene, OR) according to the 
manufacturer's instructions. 
Viral challenges. Ce11s were seeded in 24-we11 plates at 2 x 105 ce11s per we11 and 
cha11enged the next day with the appropriate GFP-expressing viral vectors. When 
applicable, ce11s were pre-treated for 15 min with nocodazole, paclitaxel or PF-3450074, 
and supernatants were replaced with fresh medium 16 h post infection (p.i.) Ce11s were 
trypsinized 48 h p.i. and fixed in 2% formaldehyde (Fisher Scientific, Waltham, MA). 
The percentages of GFP-positive ce11s were then determined by analyzing 104 to 3 X 104 
ce11s on a FC500 MPL cytometer (Beckman Coulter, Brea, CA) using the CXP Software 
(Beckman Coulter). 
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siRNA and plasmid DNA transfection. For the siRNA treatments, 106 cells were 
seeded in a 10 cm dish in Opti-MEM (Gibco, Carlsbad, CA) and transfected the next day 
with 40 nM of siRNA using DharmaFECT 1 (Dharmacon, Lafayette, CO). The siRNA 
targeting the sequence 5'GATCAAACATGACGGAATT of the dynein heavy 
chain (DHC) , has been described before (Lehmann et al, 2009; Pawlica et al, 2014) 
and was purchased from Qiagen (Venlo, Netherlands). A control siRNA 
(5'CGTACGCGGAATACTTCGATT) targeting the luciferase rnRNA (pawlica et al, 
2014) was purchased from Dharmacon. 48 h post transfection, cells were seeded in 
24-well plates and infected the next day with HIV-l vectors as described above. For 
p50 over-expression, 106 cells seeded in a 10-cm dish were PEI transfected with 5 f..lg of 
p50/dynamitin-HA or an irrelevant plasmid (pMIP). Cells were seeded in 24-well plates 
24 h later and challenged with viral vectors the nextday. 
Immunofluorescence (IF) microscopy. 2 x 105 HeLa or MAGI cells were seeded 
on glass coverslips placed in 3.5-cm wells and were infected the next day at a high 
multiplicity of infection (MOI) of vesicular stomatitis virus glycoprotein (VSV G)-
pseudotyped HIV-lcMV-GFP (HeLa) or replication-competent HIV-INlA3 (MAGI) in the 
presence of 1 f..lg/ml MG 132 and various treatments. For depletion experiments, siRNAs 
were transfected 72 h prior to infection while cells were pre-treated with nocodazole or 
paclitaxel 15 min prior to infection. Infections were carried out for 2 h (HIV-1NlA3) or 
4 h followed by a 2-h incubation in fresh medium (HIV-lcMV-GFP). Cells were then fixed 
for 30 min in 4% formaldehyde-DMEM, followed by 3 washes with ice-cold phosphate 
buffer saline (PBS) and permeabilized for 2 min on ice in 0.1% Triton X-100, 0.1 mM 
sodium citrate. Cells were then washed again three times with PBS and treated with 10% 
normal goat serum (Sigma, St Louis, MI) containing 0.3 M glycine (Sigma) for 30 min 
at room temperature. This was followed by a 4-hours incubation with antibodies against 
CA (1 : 100 dilution) in PBS containing 10% normal goat serum. Cells were washed 
five times and fluorescently stained with AlexaFluor488-conjugated goat anti-mouse 
(Molecular Probes, Eugene, OR) diluted 1 :200 in normal goat serum-containing PBS. 
Cells were then washed five times in PBS before mounting in Vectashield (Vector 
Laboratories, Peterborough, UK). Hoechst33342 (0.8 f..lg/ml; Molecular Probes) was 
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added along with the penultimate PBS wash to reveal DNA. Z-stacks were acquired on 
an AxioObserver Microscope (Carl Zeiss, Jena, Gennany) equipped with an ApoTome 
module, and the median optical slice of a Z-stack was analyzed. 
Fate-of-capsid assay. To analyze post-entry CA uncoating, a protocol adapted 
from Perron et al (perron et al, 2004) was used and has been described in details before 
(Bérubé et al, 2007; Pawlica et al, 2014). 4 x 106 HeLa cells were seeded in lO-cm 
dishes. In sorne cases, HeLa cells were previously transfected with siRNAs or 
p50/dynamitin. The next day, if applicable, cells were pretreated 15 min with 
phannacological agents and infected with IllV-l NIA3-GFP or IllV-IR9ô.E [wild-type (WT) 
or CA-mutated]. The MOI used for IllV-l NIA3-GFP was - 2. WT, CA-E45A and CA-
K203A IllV-IR9L\E vectors were equalized using reverse transcriptase (RT) assay. The 
amounts of envelope-devoid IllV-lNIA3-GFP and its VSV G-pseudotyped counterpart 
were also nonnalized by RT assay. Unless otherwise specified, supernatants were 
replaced with fresh media containing the appropriate drugs 1 h p.i. Cells were collected 
by trypsinization at different time points. Cells were washed in ice-cold PBS and 
resuspended in 1.5 ml ofice-cold lysis buffer [100 ~ Tris-HCI (PH 8.0), 0.4 mM KCl, 
2 !lM EDTA, Roche's Complete protease inhibitor] and disrupted with a Dounce 
homogenizer. Whole-cell Lysate (WCL) samples were collected at this point. Lysates 
were centrifuged for 5 min 1,000 x g, 4°C to remove cell debris and nuclei, and 
supernatants were layered on top of a 50% sucrose cushion prepared in STE buffer [100 
mM NaCI, 10 mM Tris-HCl (pH 8.0), 1 mM EDTA]. Particulate viral cores were 
sedimented by ultracentrifugation in a Sorval WX Ultra 100 ultracentrifuge at 175,000 x 
g for 2 h at 4°C. In sorne experiments, post-ultracentrifugation supernatants were 
collected. Pellets were resuspended in 80 !lI of IX denaturing loading buffer and 
processed for CA Western blotting together with WCLs. 
Statistical analysis. AlI statistical analyses were done in Graph Prism 5 
(GraphPad Software, Inc., La Jolla, CA, USA). The box blot representations in Fig. 3.1 
were generated with the R software (Spitzer et al, 2014). 
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Chapter IV contains a summary and discussion of the results described in 
Chapters II and III. Additionally, in this chapter new directions and perspectives of the 
studies are described. 
CHAPTERIV 
CONCLUSIONS 
4.1 The involvement of microtubules and dynein motor complexes in 
TRIMSa-mediated restriction 
In the study in Chapter II, we examined the importance of micro tubules and 
dynein motors in TRIM5a-mediated restriction. We found that both microtubules and 
dynein motor complexes were relevant for the ability of TRIM5a to fully inhibit 
retroviral infection. To disrupt the microtubule network we used the pharmacological 
agents nocodazole and paclitaxel, white the dynein motor was inhibited either by ERNA 
treatment or by DHC depletion. Perturbation of microtubules and dynein motor 
complexes decreased the ability of TRIM5a to inhibit retroviruses and impaired its 
hallmark feature: the destabilization of viral CA cores. Additionally, these treatments 
affected dynamics of cytoplasmic bodies (CBs) formed by TRIM5a proteins. DHC 
depletion also decreased the co-Iocalization ofthese structures with microtubules. 
4.1.1 How might TRIMSa use microtubules? 
TRIM5a CBs, similarly to IllV-l, most likely use microtubules for their transport 
and/or correct localization. Thus, microtubules are likely a platform for the encounter of 
TRIM5a proteins and incoming restriction-sensitive retroviruses. The hypothesis that 
TRIM5a CBs use microtubules is supported by their altered dynamics following 
disruptions of these filaments. While it appears to be certain that TRIM5a CBs associate 
with microtubules, the role of the dyne in motor complexes as a mediator of this 
association is not fully understood. The effects of DHC depletion on the localization of 
TIRM5a CBs and their co-Iocalization with microtubules were moderate. This can be 
explained by two factors. First, the siRNA-mediated DHC knockdown was not complete 
and thus unaffected dynein motor complexes could still mediate the interaction of 
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TRIM5a CBs with microtubules. Secondly, the dyne in motor complex might be one of 
two, or more, co-factors responsible for these interactions. Indeed, the majority of cargos 
for molecular motors associate simultaneously with kinesins and dyneins (Gross, 2004), 
and sometimes these molecular motors share an adaptor complex, e.g. the dynactin 
complex (Deacon et al, 2003). Of note, the 'tug-of-war' theory (Hendricks et al, 2010; 
Muller et al, 2008) seems to be well illustrated in this study when upon a depletion of 
the dynein motor its cargos (TRIM5a CBs) are probably pulled by the kinesin motor 
towards the cell periphery. 
Interestingly, the treatments targeting either microtubules or dyne in motor 
complexes did not significantly affect the replication of retroviruses in non-restrictive 
conditions. This seems to be counter-intuitive, as both of these cytoskeletal components 
were suggested to be responsible for the transport ofHIV-l virus. However, the base for 
these suggestions were IF observations and were not supported by infectivity data 
(McDonald et al, 2002). On the contrary, initial reports described little or no effects of 
microtubule-targeting drugs on HIV-l infectivity (Bukrinskaya et al, 1998; Daniel et al, 
2005; Yoder et al, 2011). Only recently has it been proposed that for its transport HIV-l 
uses a stable sub-population of microtubules (Sabo et al, 2013). Regardless of the lack 
of an effect of these treatments on HIV -1 transduction, the role of nocodazole- and 
paclitaxel-sensitive microtubules in TRIM5a-mediated restriction is certain, as these 
drugs decrease it. 
Microtubule disruption did not completely abolish the full capacity of TRIM5a to 
restrict retroviruses; the 10ss in the initial restriction potency varied, depending on a cell 
line, and was between 16 and 71 %. This could be explained by several factors. First, the 
pharmacological agents nocodazole and paclitaxel probably do not alter all microtubules 
in the cell and the drug-resistant microtubules are present in the cell following these 
treatments (Bre et al, 1987; Schulze & Kirschner, 1987). While HIV-l likely exploits 
stable microtubules for its transport (Sabo et al, 2013), it remains unknown which types 
of microtubules are used by TRIM5a. The diversity of microtubules in one cell is vast 
and is regulated by the presence of different microtubule-associated proteins and post-
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translational modifications. TRIM5a might use various subsets of microtubules, sorne of 
which could be nocodazole- and paclitaxel-sensitive. Secondly, TRIM5a can block a 
restriction-sensitive virus in more than one way. The microtubules and dynein motor 
complexes could be involved in only one step of TRIM5a-mediated restriction, while 
other steps like activation of the innate immune signaling could still be active (Pertel et 
al, 2011 ; Tareen & Emerman, 2011). 
The results acquired in the fate-of-capsid assay suggest that microtubules and 
dynein mo~or complexes could enable the initial contact between TRIM5a proteins and 
restriction-sensitive viruses. However, the possibility that this contact could still take 
place, but the subsequent proteasome-dependent de gradation of TRIM5a is inhibited 
cannot be ruled out. Nonetheless, proteasome inhibitors restore seemingly normal 
stability of the HIV-l core without greatly rescuing viral infectivity (Anderson et al, 
2006; Diaz-Griffero et al, 2007a; Kutluay et al, 2013), while the treatments targeting 
microtubules and dynein motor complexes significantly increase infectivity. 
4.1.2 Future experiments 
In order to address more completely the role of dynein motor complexes in 
TRIM5a-mediated restriction it would be important to look at the restriction upon 
additional disabling of kinesin motor complexes. As an initial approach it should be 
possible to inhibit the function of the kinesin motor complex by one of many inhibitors 
(Brier et al, 2004; Hewitt et al, 2010; Kapoor & Mitchison, 1999; Kawaguchi & 
Ishiwata, 2001 ; Smith et al, 2013). Although the pharmacological agents could be 
informative, more in-depth studies would be required to determine which of the 
45 kinesins might be involved. To suggest sorne candidates, the knowledge about other 
members from the TRIM family could be helpful, e.g. TRIM601RNF33 associates with 
the kinesin-2 family (KIF3A and KIF3B (Huang et al, 2012)) and TRIM3/BERP 
associates with KIF21B (Labonte et al, 2013). " 
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Experiments aimed at establishing the effects of microtubule/dynein disrupting 
agents on the role of TRIM5a proteasome-dependent degradation should be peerformed. 
TRlM5a CBs were shown to co-Iocalize with many proteins involvedin the proteasomal 
degradation pathway (Campbell et al, 2008; Danielson et al, 2012; Lukic et al, 2011). 
Firstly, it would be interesting to look at the co-Iocalization of these structures 
upon treatments targeting either microtubules or dynein motors. Additionally, as this co-
localization is increased in the presence of a restriction-sensitive virus (Danielson et al, 
2012), it would be also informative to perform similar observations following infection. 
Another experiment relating to the same question would be to look at the turnover of 
TRIM5a. It is known that the turnover of TRIM5a is greatly increased in the presence of 
a restriction-sensitive virus (Diaz-Griffero et al, 2006) and it would be interesting to 
look at this process following disruptions of microtubules and dynein motor complexes. 
Moreover, it would be tempting to investigate whether TRIM5a, like HIV-1, uses 
a stable sub-population of microtubules. It could be informative to look at TRIM5a-
mediated restriction while depleting EB 1, which is responsible for the formation of the 
stable sub-population ofmicrotubules used by HIV-1 (Gouveia & Akhmanova, 2010). 
Additionally, a new small-molecule antagonists of cytoplasmic dynein was 
recently discovered, called ciliobrevin (Firestone et al, 2012). Employing this drug could 
simplify experimental procedures, eliminating the necessity of depleting DHC for each 
experiment. 
Very interesting data could be generated by performing real-time IF imaging. 
TRlM5a CBs are described as dynamic structures constantly undergoing homo- fusions 
and fissions (Campbell et al, 2007a). It would be informative to observe how these 
processes are altered by inhibiting either microtubules or dynein motor complexes. 
Additionally, TRlM5a CBs can sequester incoming restriction-sensitive viruses 
(Campbell et al, 2008) and thus it would be interesting to monitor this process in 
real-time in the presence of treatments modifying either microtubules or molecular 
motors. 
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Interestingly, sorne of the TRIM family members, such as MID1/TRIM18, possess 
a so-called COS box which mediates microtubule binding (Short & Cox, 2006). This 
domain is directly downstream coiled-coil, precedes C-terminal functional domains, and 
is necessary for direct binding to microtubules. TRIM proteins from are known, not only 
to homodimerize, but also to heteredimerize (Reymond et al, 2001). Taking these two 
facts together, it could be interesting to examine if TRIM5a could interact with 
microtubules via one of the proteins from TRIM family that contains the COS box. 
Perhaps an over-expression of e.g. MIDI could inhibit TRIM5-mediated restriction 
through competition for binding to microtubules. 
4.2 The involvement of microtubules and dynein motor complexes in HIV-l 
uncoating 
In Chapter III, we presented a study based upon which we proposed that 
microtubules and dynein motor complexes are important for HIV -1 uncoating. In brief, 
we disrupted microtubules using the pharmacological agents nocodazole and paclitaxel, 
and disabled dynein-mediated transport by either siRNA targeting DHC or by p50 over-
expression. FOllowing these treatments in cells infected with HIV-l we noted increases 
in the amounts of(i) CAfoei observed by IF and (ii) pelletable (particulate) CA cores by 
employing the fate-of-capsid assay. We hypothesize that these results reflect impaired or 
delayed HIV -1 uncoating. 
Intriguingly, we observed that the disruption of nocodazole-sensitive microtubules 
seems to increase the amounts/stability of HIV -1 CA cores, while it was proposed that 
HIV-l uses a stable sub-population of microtubules (Sabo et al, 2013). We can only 
speculate about how to explain this discrepancy. It is not fully understood how HIV-l 
traffics in the cytoplasm. It is likely that it uses, in addition to the stable sub-population 
of microtubules, other cytoskeletal components, e.g. actin microfilaments. It has been 
suggested that HIV -1 associates with actin filaments upon its entry and in the proximity 
of the NPC (Arhel et al, 2006; McDonald et al, 2002; Zamborlini et al, 2007). Sorne 
reports even suggested that HIV -1 might mainly use actin microfilaments for its route to 
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the nucleus (Yoder et al, 2011). It is likely that for its transport to the nucleus HN-l 
could use both actin filaments and microtubules, and this would explain why we 
observed only a delay in RN-l core uncoating. Additionally, the lack of an effect on 
HN -1 infectivity following the disruption of microtubules and dynein motor complexes 
might be explained by the cellular context. HeLa cells used in this study likely lack 
either cytosolic receptors that sense RN -1 cDNA or elements in the downstream 
signaling pathway that would induce type 1 interferon (lFN) response, e.g. cyclic GMP-
AMP synthase cGAS or STING (Rasaiyaah et al, 2013; Yan et al, 2010). These immune 
sensors are present in natural HIV-l targets e.g. macrophages (Lahaye et al, 2013; 
Rasaiyaah et al, 2013). It was reported that N74D and P90A CA mutants, which are 
unable to recruit cellular partners shielding the core and thus enabling the evasion of the 
innate detection, fail to replicate in macrophages, but infect HeLa cells (Fig. 4.1). Thus, 
it would be important to perform experiments in cells that are natural RN -1 targets. It 
would be also very interesting to look at possible uncoating defects of the mutants 
impaired for the recruitment of cellular partners, such as N74D and P90A CA. 
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a) Upon infection of macrophages, WT HIV-1 CA core interacts with 
host-cell proteins, including CPSF6, cyclophilin A and Nup358, which 
prevents the induction of IFN response. b) HIV -1 viruses carrying 
mutations in CA proteins that block the proteins' interactions with ho st 
proteins may traffic differently within the ceIl, and reverse transcription 
may occur prematurely, aIlowing recognition of viral DNA by host-ceIl 
sensors that induce a signaling pathway (involving the transcription 
factors NF-KB and IRF-3) leading to IFN production. 
Image source: (Goff, 2013; Rasaiyaah et al, 2013). 
4.2.1 Trafficking of mv -1 and its uncoating 
Microtubules and dynein motor complexes are thought to be involved in the 
transport of HIV -1 towards the nucleus and the results from the study in Chapter III 
suggest that these structures are also implicated in the uncoating of its CA core. It is thus 
probable that the transport ofHIV-1 and its uncoating are linked. Importantly, uncoating 
might not be initiated during the transport of HIV -1 towards the nucleus, but only after 
this transport is complete. The association of the CA core with microtubules and dyne in 
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complexes could even promote its stabilization. Recent reports have demonstrated that 
cellular components stabilize the post-entry HIV-I CA core (Fricke et al, 2013; Guth & 
Sodroski, 2014), and uncoating might take place after the virus reaches the NPC 
(Ambrose & Aiken, 2014; Arhel et al, 2007; Rasaiyaah et al, 2013; Schaller et al, 2011). 
Many reports evidence that CA pro teins must be present at these later stage, as they 
interact with Nup358 and Nupl53 (Matreyek et al, 2013; Schaller et al, 2011), have a 
role in nuclear entry (Yamashita & Emerman, 2004; Yamashita et al, 2007) and are 
connected with integration site specificity (Schaller et al, 2011). It is possible that, 
similarly to CypA (Li et al, 2009; Shah et al, 2013), CPSF6 (Shah et al, 2013) and 
PDZD8 (Guth & Sodroski, 2014), dynein-dependent transport would promote 
stabilization of CA cores until they reach the NPC. The currently emerging hypothesis 
suggests that in the proximity of the NPC, CPSF6 and CypA would disassociate from 
the CA core, which would be transferred to Nup358 and Nup153, allowing for uncoating 
(Ambrose & Aiken, 2014; Rasaiyaah et al, 2013; Schaller et al, 2011; Shah et al, 2013). 
TNP03 would have a role in sequestering CPSF6 and CypA (De Iaco et al, 2013; Shah 
et al, 2013). This hypothesis would be additionally supported by the fact that these 
proteins share the same CA-binding interface (Price et al, 2012). 
The recently discovered PDZD8 prote in is a moesin-interacting factor and a 
potential regulator of microtubule stability (Henning et al, 2010). This protein has been 
shown to stabilize the HIV-I CA core (Guth & Sodroski, 2014). It is also possible that 
this protein could be involved in HIV -1 transport towards the nucleus. Interestingly, in 
neurons, a trimetric complex of PDZ proteins, mLin-2, mLin-7 and mLin-lO, mediates 
binding of N-methyl-D-aspartate (NMDA) receptors to the kinesin family member 17 
(KIF 17) (Fig. 4.2) (Setou et al, 2000). Thus, maybe PDZD8 could take part in the HIV-I 
CA core binding to the dynein motor complex? 
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Figure 4.2 Model of the NMDA receptor transporting machinery. 
NRI and NR2B - subunits ofNMDA (N-methyl-D-aspartate) receptor. 
Image source: (Setou et al, 2000). 
In conclusion, the relationship between HIV -1 uncoating and its transport to the 
nucleus remains unclear. Very likely they are linked, as the disruptions of microtubules 
and dynein motor complexes seem to affect uncoating. Additional experiments must be 
performed in order to outline a more precise model of how these structures are involved 
in RIV -1 uncoating. 
4.2.2 Future experiments 
In order to provide more conclusive answers referring to the involvement of 
microtubules and dynein motor complexes in RIV -1 uncoating a few additional 
experiments should be considered. 
First, it would be very important to look at HIV -1 uncoating and infectivity in its 
natural cellular targets: macrophages, dendritic cells and lymphocytes. We might have 
missed an important consequence of microtubule and dynein disruptions on HIV-l 
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infectivity due to the employment of ReLa cells. Similarly, CA mutants N74D and P90A 
were thought not to impair RIV -1 infectivity until monocyte-derived macrophages 
(MDM) were used (Rasaiyaah et al, 2013). 
Secondly, as actin microfilaments also have a role in HIV-l transport (Arhel et al, 
2006; McDonald et al, 2002; Yoder et al, 2011; Zamborlini et al, 2007) it would be 
important to look at HIV -1 uncoating upon disrupting these structures. There are many 
available pharmacological agents targeting actin filaments, such as cytochalasin D 
(Casella et al, 1981) or latrunculin B (Coue et al, 1987). It would be especially 
interesting in the case of T -cells as they do not have a robust microtubule cytoskeleton 
(Y oder et al, 20 Il) and it is possible that HIV -1 transport towards the nucleus might be 
more dependent on actin filaments. Additionally, simultaneous disruption ofmicrotubule 
and actin filaments could be very interesting. 
Furthermore, a possible effect of disrupting microtubules and dyne in motor 
complexes on the fusion of the HIV -1 Env with the plasma membrane should be 
investigated. It is possible that interfering with the cytoskeleton might affect this step. 
These experiments might be especially significant, when VSV G-pseudotyped virions 
are used as they enter via endosomes which requires microtubules for their maturation 
(Lakadamyali et al, 2006). 
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Figure 4.3 Schematic overview of viral fusion assay. 
Producer cells are co-transfected with plasmids encoding HIV -1 provirus 
and ~-lactamase-Vpr (BlaM-Vpr) chimera. Target cells are infected with 
BlaM-Vpr virions and then loaded with self-quenching CCF2/AM dye, 
which diffuses passively into cells. In the ce 11 , excitation of the dye at 
409 nm leads to fluorescent resonance energy transfer (FRET) producing 
green emission (520 nm). However, if ~-lactam ring (green) is cleaved by 
BlaM, FRET is blocked and blue emission (447 nm) is detected. Cells can 
be discriminated by IF or FACS. 
Image source: (Cavrois et al, 2002). 
Already established assays would enable looking at fusion of the viral and plasma 
membranes (Cavrois et al, 2002; Smith et al, 2014), and an example of such an assay 
is shown in Fig. 4.3. In principle, a successful fusion is detected by a cleavage of a 
fluorescent dye localized in the cytoplasm by a ~-lactamase enclosed inside an incoming 
vIrlon. 
An interesting insight in uncoating could be obtained through another approach, 
the 'CsA washout assay' (Fig. 4.4) (Hulme & Hope, 2014). This assay employs owl 
monkey cells (OMK) that endogenously express TRIMCyp. Normally, TRIMCyp binds 
the post-entry HIV-1 CA core and destabilizes it, resulting in loss of infectivity. When 
CsA is present, it binds TRIMCyp and prevents its activity against mv -1. In theory, this 
assay should allow tracking uncoating by removing CsA at different times post 
infection; coated viral complexes are still restricted by TRIMCyp, while uncoated 
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particles are able to infect the cell. The advantage of this assay is that it detects only the 
cores that enter the cytoplasm. 
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• • Uninfected cell 
OMKcelis • • Uncoating • • ) 
TRIM-CypA 
CsA 
• • Infected cell 
Figure 4.4 Tbe principle of CsA wasbout assay. 
HIV -1 uncoats and infects HeLa cells which can be detected by F ACS. In 
owl monkey OMK cells TRIM-CypA (TRIMCyp) binds to the CA core 
and restricts HIV-l infection (middle panel). HIV-l can infect OMK ce Us 
in the presence of cyclosporine A (CsA) which binds TRIM-CypA and 
prevents its binding to the HIV-l capsid (bottom panel). 
Image source: (Hulme & Hope, 2014). 
Moreover, while in the study presented in Chapter III the IF observations were 
performed with a virus bearing autologous HIV-l Env, aU subsequent fate-of-capsid 
experiments were performed with a VSV G-pseudotyped virus. It would be of extreme 
interest to perform these experiments with HIV-l bearing its autologous Env. This, 
however, might cause certain difficulties as working with a replication-competent virus 
requires the use of minimum Biosafety Level II+ (BSLII+) facilities, which in the 
case of fate-of-capsid would have to contain an the necessary equipment, e.g. an 
ultracentrifuge. Altematively, this kind of experiment could be done with a replication-
impaired vector produced with in trans encoded HIV-l Env. However it must be noted 
that viruses using HIV -1 Env for their entry have significantly lower infectivity yield 
than those pseudotyped with VSV G. To our knowledge an published fate-of-capsid 
assays were done with VSV G-pseudotyped vectors. 
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Finally, in the future it would also be of interest to try to determine how HIV-l 
interacts with the dyne in motor complex - whether this is a direct or indirect interaction, 
through adaptor complexes. If HIV -1 interacts directly with the dynein motor complex it 
would be important to characterize the nature of this interaction, e.g. which chain of the 
dynein motor interacts with which HIV -1 protein. Although HIV -1 CA appears to be a 
valid candidate for this interaction, sorne preliminary results presented last year at the 
9th International Retroviral Nucleocapsid Protein and Assembly Symposium in Montreal 
by Yao et al. indicated that HIV -1 might associate with dynein light chain 1 (LC8- type 
1) via integrase (Yao et al, 2013). 
4.3 Perspectives: Gene therapy targeting HIV-l using TRIM5a 
The case of the Berlin patient (described in the section 1.1.3) provided a proof-of-
concept of the possibility that replacing the patient's cens permissive to HIV-l with cens 
resistant to it can result in a sterilizing cure. Recently, the first clinical trial studying an 
autologous T -cell transplant, with ex vivo disrupted CCR5 genes, was completed, 
proving the safety ofthat approach, though with a moderate efficacy (Tebas et al, 2014). 
The patients, following the infusion of modified cells, were subjected to a cessation of 
antiretroviral therapy, and while none ofthem was able to control the virus, the modified 
T -cens had longer survival times when compared with the autologous ones (Tebas et al, 
2014). TRlM5a is thought to be a great candidate for gene therapy aimed at treating 
HIV-l infection (Anderson, 2013). It could be accomplished by modifying the existing 
human TRlM5 gene (pham et al, 2010; Yap et al, 2005) or introducing a human version 
of TRIMCyp (Neagu et al, 2009). 
4.4 Perspectives: development of new classes of drugs 
Sorne small molecules, e.g. PF-3450074 (PF74) were shown to destabilize the 
post-entry HIV-l CA core inhibiting HIV-l infectivity (Blair et al, 2010; Shi et al, 
2011). Other molecules binding to the same CA site, BI-l and BI-2, that in vitro 
stabilized CA-NC tubes also inhibited HIV-l infectivity (Lamorte et al, 2013). The 
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effects of these drugs on mv -1 replication confinned that uncoating can be a new area 
of investigation for antiviral therapeutics targeting HIV -1. U ncoating remains one of the 
least explored aspects of HIV -1 replication, thus it is important to obtain more detailed 
knowledge about this process. 
4.5 Final conclusions 
The studies presented in this thesis offer novel and important input into the field of 
HIV-l pathogen-host interaction. This research contributes to the state of knowledge 
about the replication of mv -1 and the mechanism of action of the restriction factor 
TRIM5a. Hopefully, these studies will contribute to future development of new 
approaches to treat mv -1 infection. 
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A.2 Abstract 
Retroviral capsid (CA) cores undergo uncoating during their retro grade transport 
(toward the nucleus), and/or after reaching the nuclear membrane. However, whether 
HIV -1 CA core uncoating is dependent upon its transport is not understood. There is 
sorne evidence that HIV -1 cores retro grade transport involves cytoplasmic dyne in 
complexes translocating on microtubules. Here we investigate the role of dynein-
dependent transport in HIV-l uncoating. To interfere with dynein function, we depleted 
dynein heavy chain (DHC) using RNA interference, and we over-expressed 
p50/dynamitin. In immunofluorescence microscopy experiments, DHC depletion caused 
an accumulation of CA foci in HIV-l infected cells. Using a biochemical assay to 
monitor HIV -1 CA core disassembly in infected cells, we observed an increase in 
amounts of intact (pelletable) CA cores upon DHC depletion or p50 over-expression. 
Results from these two complementary assays suggest that inhibiting dynein-mediated 
transport interferes with HIV -1 uncoating in infected cells, indicating the existence of a 
functionallink between HIV -1 transport and uncoating. 
Keywords: HIV -1; uncoating; capsid; microtubules; dyne in 
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A.3 Introduction 
The mature CA core of human immunodeficiency virus 1 (HIV -1) is a ~60 nm x 
120 nm (Briggs et al, 2003) cone-shaped prote in lattice, encasing viral genomic RNA, 
enzymes (integrase and reverse transcriptase) and other viral proteins [reviewed in 
(Briggs & Krausslich, 2011)]. It is composed of ~1,000 CA monomers (pornillos et al, 
2011) arranged in ~ 170 hexamers and 12 pentamers through interactions involving their 
N-terminal domains (pornillos et al, 2009), whereas the C-terminal domains are 
important for homodimerization that connects the rings into a lattice (GambIe et al, 
1997). Following receptor-mediated entry into the cytoplasrn, HIV-1 undergoes tightly 
regulated processes that prepare the virus for nuclear import and integration of its 
genetic material into host DNA. The nucleoprotein complex formed before completing 
reverse transcription (RT) is usually referred to as the reverse transcription cornplex 
(RTC), which is later transformed into the pre-integration complex. RT is thought to be 
initiated within 30 minutes post virus entry (Goff, 2001) by a still unknown mechanism. 
Before, during or after R T, the CA core must be disassembled in a process called 
'uncoating'. The precise timing and location of uncoating remain unclear; sorne reports 
propose that it occurs in the cytoplasrn (Hulme et al, 20 Il; McDonald et al, 2002), while 
others suggest that uncoating takes place at the nuclear pore (Arhel et al, 2007; 
Rasaiyaah et al, 2013; Schaller et al, 2011). It is possible that a small fraction of CA 
proteins remain associated with pre-integration complexes and are transported to the 
nucleus (Zhou et al, 2011). These hypotheses are not mutually exclusive considering 
that uncoating could take place through several sequential steps rather than through a 
rapid single-step process (Ambrose & Aiken, 2014). Additionally, recent lines of 
evidence indicate that uncoating is linked with RT (Hulme et al, 2011; Roa et al, 2012; 
Yang et al, 2013) and that RT may even trigger uncoating (Hulme et al, 2011; Zhang et 
al, 2000). However, RT initiation itselfmay depend on prior destabilization or increased 
permeability of the CA core after entry into the cytoplasm (Zhang et al, 1998). 
Altematively, uncoating could be triggered by an as yet unknown cellular factor 
(Auewarakul et al, 2005). 
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Numerous studies indicate that CA is the main viral determinant for uncoating. 
Mutations resulting in either hypostable or hyperstable CA cores almost completely 
abolish viral infectivity despite normal virion protein content (Forshey et al, 2002). 
Additionally, the retroviral restriction factors TRIM5a and TRIMCyp inhibit viral 
infection (Sayah et al, 2004; Stremlau et al, 2004) through binding to and destabilization 
of incoming CA cores, in essence causing 'premature uncoating' (Stremlau et al, 2006). 
Furthermore, the HIV-l small-molecule inhibitor PF-3450074 (PF74) inhibits HIV-l 
infectivity specifically by destabilizing the CA core (Shi et al, 2011). Uncoating is also 
likely dependent on cellular factors, but these remain mostly elusive (Ambrose & Aiken, 
2014). A few cellular partners that interact with the HIV-l CA core were characterized 
and sorne were proposed to modulate uncoating, such as cyclophilin A (CypA) (Li et al, 
2009b; Shah et al, 2013), nucleoprotein RanBP2/Nup358 (Schaller et al, 2011), 
transportin 3 (TNP03) (Shah et al, 2013), cleavage and polyadenylation specific factor 6 
(CPSF6) (De Iaco et al, 2013) and PDZ Domain-containing 8 (Guth & Sodroski, 2014). 
Similarly to other viruses [reviewed in (Slonska et al, 2012)], HIV-l hijacks the 
cell ' s cytoskeleton and associated molecular motors for its trafficking towards the 
nucleus [reviewed in (Gaudin et al, 2013)]. The microtubule network and microtubule-
associated dynein motor complexes were proposed to transport HIV -1 R TCs toward the 
nucleus (McDonald et al, 2002). Specifically, HIV-l translocation on microtubules was 
evidenced by live microscopy, and was inhibited by micro-injection of anti-dynein 
antibodies (McDonald et al, 2002). Recently, it was reported that HIV-l induces the 
formation of and co-Iocalizes with a stable sub-population of microtubules whose 
disruption abolishes infectivity (Sabo et al, 2013). Thus, the microtubule network seems 
to be important for HIV-l trafficking and infectivity. 
In this study, we hypothesized that uncoating of the HIV -1 CA core and its 
trafficking towards the nucleus were linked mechanisms. Our results suggest a role for 
dynein motor complexes in HIV -1 uncoating. 
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A.4 ResuUs 
Disruption of the Dynein Motor Complex Causes an Accumulation of CA 
Foci in Infected Cells. We used immunofluorescence (IF) microscopy to analyze the 
presence of CA foci, visualized using a CA monoclonal antibody, in human HeLa cells 
infected with IllV-1cMV-GFP pseudotyped with the glycoprotein of the vesicular 
stomatitis virus (VSV G) or in human MAGI cells infected with HIV-1 NIA3 • Such CA 
foci detected in acute infection conditions are thought to be individual viruses that are 
not or only partially uncoated (Arhel et al, 2007; Campbell et al, 2007; Hulme et al, 
20 Il; McDonald et al, 2002). HeLa cells transfected with siRNAs targeting either the 
dynein heavy chain (DHC) mRNA (Lehmann et al, 2009; Pawlica et al, 2014) or the 
non-relevant luciferase (Luc) mRNA (pawlica et al, 2014) were infected with 
HIV-1cMV-GFP for 2 h, at which point supernatants were removed and cells were 
incubated for an additional 4 hours. This timing was previously determined to allow for 
the efficient detection of cytoplasmic, unenveloped HIV -1 CA cores (data not shown 
and (Campbell et al, 2008». DHC depletion was efficient as assessed by Western 
blotting, since transfection ofDHC siRNA led to a reduction of ~85.4% ± 6.7% (n = 10) 
in protein levels (Figure lA), which is consistent with previous observations that a large 
proportion of cells showed altered dynein-dependent transport in these conditions as 
seen by LAMP-I staining (pawlica et al, 2014). Upon staining infected ce Ils using an 
anti-CA antibody, we detected distinct foci that were absent from mock-infected cells, as 
expected (Figure lB). We analyzed the median slice from a Z-stack for each field, which 
removed the cytoplasm present on top of or underneath the nucleus from the analysis. 
DHC depletion caused an increase in the amounts of CA foci. Specifically, the average 
number of CA foci per cell increased ~2.5-fold following DHC depletion, from 6.98 ± 
0.82 in control cells (n = 71 cells analyzed) to 17.4 ± 2.9 in DHC-depleted cells (n = 57) 
(P = 0.0038) (Figure IC). Moreover, CA foci tended to accumulate in the cell periphery, 
as evidenced by measuring relative distances to the nucleus. The median relative 
distance to the nucleus changed significantly (P < 0.0001) from 0.44 (95% CI, 0.39-
0.52) for the Luc siRNA-transfected control cells (P = 10) to 0.83 (95% CI, 0.79-0.84) 
for cells (n = 16) transfected with DHC siRNA (Figure ID). A similar accumulation of 
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viral RTCs in the cell periphery was observed upon transfection of anti-dynein 
antibodies prior to infection (McDonald et al, 2002). 
HIV -1 virions pseudotyped with VSV Gare delivered through clathrin-mediated 
endocytosis (Sun et al, 2005) and are further released into the cytoplasm following 
acidification of endosomes (Blumenthal et al, 1987). Clathrin-medüited entry relies 
mainly on actin filaments (Cureton et al, 2009), while maturation of endosomes involves 
microtubules (Lakadamyali et al, 2006) and possibly the dynein motor complex 
(Lehmann et al, 2009). Therefore, in order to confirm that the effects observed in 
Figure 1B-D were not stemming from pseudotyping, we repeated the experiment using a 
virus harboring an autologous HIV-1 envelope. U373-derived MAGI cells (Vodicka et 
al, 1997) were infected with the replication-competent HIV-1NIA3 . MAGI cells were 
transfected with the DHC-targeting siRNA or with the control siRNA and later infected 
with HIV-1 NIA3, or left uninfected (Figure lE). We used a shorter duration for the 
infection, as these non-pseudotyped viruses fuse primarily at the surface of cells and do 
not need to escape endosomes. We observed a significant increase in the amount of CA 
foci per cell following DHC depletion (Figure IF). Specifically, the average number of 
CA foci per cell was 16.1 ± 2.3 in cells (n = 77) transfected with DHC siRNA compared 
to 5.4 ± 0.4 in control cells (n = 84) (P = 0.0001). CA foci were predominantly found in 
the vicinity of the nucleus in control cells (Luc siRNA), with a median relative distance 
to the nucleus of 0.30 (95% confidence interval, 0.26-0.37; n = 29 cells analyzed) 
(Figure 1G). As previously, DHC depletion caused a significant (P < 0.0001) shift in the 
distribution of CA cores towards the cell periphery; CA foci were found at a median 
relative distance of 0.70 (95% confidence interval, 0.63-0.75; n = 12 cells analyzed). 
These observations confirm that the effects reported in Figure 1B-D did not result from 
pseudotyping, and suggest that the dynein motor complex might not only be involved in 
the intracellular transport of CA cores (as reflected by the shift in relative distance) but 
a1so in their uncoating (as evidenced by their increased numbers). Collectively, the 
results shown in Figure 1 suggest that dynein motor complexes influence both HIV-1 
retrograde transport and CA core stability in infected cells, irrespective of the mode of 
viral entry. 
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Dynein heavy chain (DHC) depletion causes the accumulation of 
HIV-l CA cores in infected cells and alters their subcellular 
distribution. 
(A) HeLa cells were transfected with siRNAs targeting either dynein 
heavy chain (siDHC) or luciferase (siLuc) as a control, and DHC 
expression was analyzed 2 days later by Western blotting; 
(B) Immunofluorescence microscopy observations of CA foci following 
infection with VSV G-pseudotyped HIV -1. HeLa cells were transfected 
with the indicated siRNAs and 72 h later were infected or not with VSV 
G-pseudotyped HIV-lcMV.GFP in the presence of MG132. At 4 h p.i., 
supernatants were replaced with virus-free medium. Cells were tixed 6 h 
p.i. and stained to detect CA (green) or DNA (blue). The outline of cells 
was revealed by low-exposure bright-field microscopy. Representative 
images are shown. The white bar represents 10 !lm; (C) Box plots 
showing total amounts of CA foci per cell. The total numbers of CA foci 
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and nuclei in 10 randornly chosen fields were counted and the CA 
foci/nuclei ratios were calculated. 375 and 1047 CA foci were counted for 
siLuc and siDHC, respectively. Center green lines show the medians; box 
limits indicate the 25th and 75th percentiles as determined by R software; 
whiskers extend 1.5 times the interquartile range from the 25th and 
75th percentiles; and red crosses represent sample means. ** indicates 
p ~ 0.001 in a Student t-test analysis; (D) Box plots showing the relative 
localization of CA foci in 10 randornly chosen cells, ca1culated using the 
formula x/(x + y) where x is the shortest distance to the nucleus edge and 
y is the shortest distance to the cell' s edge in the two-dimensional cellular 
cross-section analyzed. Data points are plotted as open circles; center 
green lines show the medians; box. limits indicate the 25th and 75th 
percentiles as determined by R software; whiskers extend 1.5 times the 
interquartile range from the 25th and 75th percentiles; and red crosses 
represent sample means. *** indicates P ~ 0.0001 in a Student t-test 
analysis; (E) Immunofluorescence microscopy observation of CA foci 
following infection with IllV -1 bearing an autologous envelope. MAGI 
cells were transfected with siDHC or siLuc prior to infection, and 72 h 
later were infected with IllV-1NIA3 in the presence ofMG132. Cells were 
fixed 2 h later and stained as in (B); The white bars represent 10 J..I1Il; 
(F) The total amounts of CA foci per cell were ca1culated as in (C); At 
least 250 CA foci were counted for each condition (*** indicates P ~ 
0.0001); (G) Relative cellular distribution of CA foci, analyzed as in (D) 
(*** indicates P ~ 0.0001). 
DHC Depletion Alters HIV-l Uncoating, As Analyzed Using the Fate-of-
Capsid Assay. As an independent, biochemical approach to analyze uncoating, we used 
the well described fate-of-capsid biochemical assay (perron et al, 2004; Stremlau et al, 
2006) that allows isolation of post-entry CA cores from infected cells, by 
ultracentrifugation of pre-cleared cell lysates through a sucrose cushion. This assay has 
been mostly used to study the destabilization of IllV -1 cores caused by TRIM5 proteins 
(Bérubé et al, 2007; Pawlica et al, 2014; Strernlau et al, 2006), but several reports 
established that it was a suitable tool to analyze uncoating in other contexts (Fricke et al, 
2014; Li et al, 2009a; Lukic et al, 2014). In order to gain insight into the timing of 
HIV -1 uncoating and how it is affected by DHC depletion, a time-course fate-of-capsid 
assay was performed (Figure 2). HeLa cells transfected with siRNAs targeting either 
DHC or Luc were infected with equal amounts of VSV G-pseudotyped IllV-1 NIA3-GFP 
for a short period of time (1 h) and then lysed immediately or placed in virus-free 
medium and lysed at 3, 6, 12 and 24 h post infection (p.i.). This allowed us to analyze 
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uncoating in quasi-synchronized conditions. To track relative changes in the amounts of 
particulate (pelletable) CA core, samples from different time points were analyzed side 
by side by CA Western blotting. The CAp24 content in whole celllysates, as analyzed at 
3 h p.i., confmned equal input (Figure 2A). To enable comparison between control and 
DHC-depleted conditions, equal amounts of a CAp24-containing reference sample were 
loaded on the different gels (Figure 2A). The amounts of particulate CAp24 determined 
by densitometry were then normalized to the reference sample and plotted (Figure 2B). 
These amounts of particulate CA likely reflect a balance between the dynamics of CA 
core release from endosomes and its uncoating. In the control cells transfected with Luc 
siRNA, the relative amounts ofparticulate CA peaked at 6 h p.i. but were smaller at 12 h 
p.i. (Figure 2A,B), suggesting that uncoating had taken place for most RTCs by that 
time, as expected (Arhel et al, 2007; Hulme et al, 2011). Increased levels ofpelletable 
CA were observed at 6 h p.i. in cells transfected with DHC siRNA (Figure 2A,B). 
Specifically, DHC depletion increased CAp24 content in the pelletable fraction by 
~ 1.5-fold (P = 0.059) relative to the control cells (Figure 2B). This is consistent with our 
previous report showing an increase in relative amounts of CA cores 6 h p.i. following 
DHC depletion or treatment with nocodazole and paclitaxel (pawlica et al, 2014). 
Interestingly, the increase in amounts of particulate CA caused by DHC depletion 
appeared to be transient, suggesting that uncoating was delayed rather than fully 
impaired. 
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DHC depletion affects lllV-l uncoating as analyzed using the fate-of-
capsid assay. 
(A) Time-course fate-of-capsid assay. HeLa cells were transfected with 
siRNAs targeting DHC (siDHC) or luciferase (siLuc) and then infected 
with HIV-l NIA3-GFP for 1 h. Pelletable CA cores were isolated by 
ultracentrifugation at the indicated times after infection and analyzed by 
Western blotting (upper panels). Aiso shown is a Western blot analysis of 
CAp24 in whole cell lysates (WCLs) at 3 h p.i. (lower panel). Identical . 
amounts of a control CAp24-containing sample were inc1uded in each gel 
as an internaI standard ('Std'); (B) Bands corresponding to pelletable 
CAp24 were quantified by densitometry up to 12 h p.i. and plotted after 
normalization to the standard. Mean values from two independent 
experiments are shown, with standard errors of the mean (SEM). 
Disruption of the dynactin complex interferes with lllV-l uncoating. As an 
additional approach to disrupt dynein-dependent transport, we over-expressed 
p50/dynamitin (P50), a subunit of the dynactin complex responsible for binding cargos 
to the dynein motor. p50 over-expression results in the disassembly of the dynactin 
complex, thereby disrupting cargo binding to the dynein motor and inhibiting dynein-
dependent transport (Burkhardt et al, 1997; Melkonian et al, 2007). The efficiency of 
p50 transfection was confirmed by Western blotting (Figure 3A). We analyzed the effect 
ofp50 over-expression on HIV-l uncoating at 6 h p.i., since the maximal effect ofDHC 
depletion on CA cores was observed at this time point (Figure 2). As a control, we used 
the small-molecule CA inhibitor PF-3450074 (PF74) , known to disrupt HIV-l 
infectivity through destabilization of the CA core (Shi et al, 2011). p50 transfection 
resulted in increased amounts of pelletable CA cores isolated at 6 h p.i. from cells 
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infected with HIV-1NIA3-GFP (Figure 3B). The pellet/whole celllysate ratio was 2.3-fold 
(± 0.097, n = 2) higher than for control cells transfected with an irrelevant plasmid 
(Figure 3C). As expected, PF-3450074 caused a decrease (3.7-fold) in the amounts 
of pelletable CA (Figure 3B,C). p50 transfection had no significant effect on HIV-1 
infectivity, while PF-3450074 decreased perrnissiveness to HIV -1 by ~ 150- to 
~550-fold, depending on the MOI used (Figure 3D) and as previously reported (Blair et 
al, 2010). These results confirrn that disruption of dynein-dependent transport 
counteracts uncoating, but the lack of an effect on infectivity suggests that uncoating is 
delayed rather than permanently impaired. 
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Over-expression of p50/dynamitin affects HIV-l uncoating. 
(A) Western blot analysis of p50 and actin expression in HeLa cells 
2 days after transfection with a plasmid encoding p50 or an irrelevant 
plasmid (pMIP; 0); ,,(B,C) Fate-of-capsid analysis; (B) HeLa cells 
transfected with a p50 expression construct or with pMIP (0), or treated 
with 10 IlM of PF-3450074 (PF74), were infected two days later with 
HIV-1NIA3-GFP. Supernatants were replaced with virus-free media, 
containing PF-3450074 where applicable, at 1 h p.i. and fate-of-capsid 
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was performed at 6 h p.i. Shown are Western blot analyses of CAp24 in 
pellets and whole cell lysates (WCLs). Levels of actin in whole cell 
lysates were also analyzed; (C) CAp24 bands were quantified by 
densitometry in two independent experiments, and pelletable/whole cell 
lysate ratios were calculated and are shown as -fold changes relative to 
the untreated control, with standard deviations; (D) Infectivity. HeLa cells 
treated as in (B) were infected with increasing amounts ofHIV-1 NIA3-GFP. 
Supernatants were replaced with virus-free, drug-free medium 16 h p.i. 
The percentages of GFP-expressing cells were analyzed 2 days p.i. by 
flow cytometry. 
Dynein Depletion Reduces HIV-l cDNA Levels. HIV-l RT was suggested to be 
linked to uncoating of its CA core, as increased stabilization of CA cores was observed 
following inhibition of RT (Hulme et al, 2011; Yang et al, 2013). We therefore asked 
whether RT would be affected by treatments that have a stabilizing effect on CA cores. 
Quantitative PCR (qPCR) was performed on DNA isolated at various times from HeLa 
cells subjected or not to DHC depletion and infected with HIV-1NIA3-GFP. GFP DNA was 
quantified as a marker for late viral reverse transcribed DNA (Figure 4A). In control 
cells transfected with Luc siRNA, RT product levels peaked at 6 to 9 h p.i. , which is 
consistent with previous reports (Butler et al, 2001 ; Kim et al, 1989; Zennou et al, 
2000). In cells expressing owl monkey TRIMCyp, or treated with nevirapine, viral RT 
products were undetectable as expected (Bérubé et al, 2007) (Figure 4A). RT product 
levels in DHC-depleted cells at 6 hours p.i. were 0.65-fold ± 0.027 those in the control 
cells, a small but significant decrease. However, no reduction was apparent at 12 h p.i., 
suggesting that the defect in RT was transient, consistent with the uncoating results in 
Figure 2. We also analyzed 2-LTR circular RT products, which are a marker for nuclear 
reverse transcribed HIV-l DNA (pauza et al, 1994). Less 2-LTR products were detected 
in DHC-depleted cells compared with the control cells at early time-points, but no 
difference was seen at 12 h p.i. (Figure 4B). Altogether, our results suggest that a 
transient decrease (or delay) in uncoating is associated with a transient RT defect. 
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DHC depletion reduces levels ofHIV-l reverse transcribed DNA. 
(A,B) HeLa cells transfected with siRNAs targeting DHC (siDHC) or 
luciferase (siLuc), or treated with the RT inhibitor nevirapine (nevi; 
20 J..LM), or stably expressing TRlMCyp (TCyp) were infected with 
HIV -1 NIA3-GFP . Supematants were removed 3 h p.i. and replaced with 
virus-free media containing the appropriate drugs; Total DNAs were 
extracted at 3, 6, 9, 12 and 24 h p.i. and quantitative PCR (qPCR) was 
performed to detect GFP as a marker for RT (A), or 2-LTR circles as a 
marker for nuclear transport (B). GAPDH DNA was quantified for 
normalization purposes. The results are presented as ratios of GFP 
copies/GAPDH copies or 2-LTR copies/GAPDH copies. Shown are the 
means with SEM for each time point, from triplicate infections. 
A.5 Discussion 
Previous articles showed that HIV -1 uncoating could be modulated by CA 
interactions with cellular factors such as CPSF6 (De Iaco et al, 2013) and cyclophilin A 
(Li et al, 2009b). In this article, we present data suggesting that functional disruption of 
cytoplasmic dynein transiently increases the amounts of HIV -1 CA cores in cells, most 
likely reflecting delayed uncoating caused by inhibition of their transport towards the 
nucleus. These observations are in agreement with a recent report by the Campbell 
laboratory (Lukic et al, 2014). In this latter study, the authors similarly observed a delay 
in uncoating when dynein was targeted using siRNAs, as analyzed using a fate-of-capsid 
assay and also using an elegant 'CsA withdrawal' assay that takes advantage of the fact 
that only intact CA cores can be inhibited by the restriction factor TRIMCyp in Owl 
monkey cells (Hulme et al, 2011 ; Hulme et al, 2014; Yufenyuy et al, 1013). Our p50 
over-expression experiment provides additional evidence for the involvement of dynein 
. 
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m HIV-l uncoating. As observed usmg irnmunofluorescence rrncroscopy, DHC 
depletion significantly increased the amounts of CA foci and resulted in their 
accumulation in the cell's periphery. These results are consistent with the hypothesis that 
HIV -1 can use dynein motors to translocate on microtubules towards the nucleus 
(McDonald et al, 2002). Furthermore, fate-of-capsid experiments revealed that DHC 
depletion and disruption of dynein-dependent transport by p50 over-expression 
transiently increased the amounts of CA cores. Thus, dynein motor complexes seem to 
be involved in both HIV -1 trafficking and in its uncoating, supporting the idea that the 
two processes are related (Ambrose et al, 2014; Fassati et al, 2012; Arhel, 2010). Along 
these lines, other authors previously reported that decreased uncoating resulting from 
mutations in CA correlated with decreased nuclear transport (De Iaco et al, 2014; 
Dismuk:e et al, 2006). Consistently, mutations in CA affect the process of nuclear 
transport or the involvement of specific cellular factors in this process (Dismuk:e et al, 
2006; Krishnan et al, 2010; Meehan et al, 2014). Binding of the HIV-l CA prote in, as 
part of intact CA cores, to the nucleopore prote in NUP358 could trigger an uncoating 
step (Bichel et al, 2013). Collectively, these observations suggest that dynein complexes 
contribute indirectly to uncoating by transporting the HIV -1 CA core to the vicinity of 
nucleopores where key uncoating steps occur. Interestingly, a member of the PDZ 
domain-containing family, the putative microtubule-interacting protein PDZD8, was 
recently reported to stabilize HIV-l CA cores (Guth & Sodroski, 2013), raising the 
possibility that HIV -1 uncoating is actively inhibited during transport. Whether dynein 
complexes are involved in this stabilization remains to be investigated. 
Neither DHC depletion (not shown) nor p50 over-expression (Figure 3) had a 
significant effect on HIV -1 infectivity in HeLa cells, as we previously reported (pawlica 
et al, 2014) and consistent with the fact that the effects of these interventions on 
uncoating and RT seem to be transient (Figures 2 and 4). Although the effect of 
counteracting dynein on HIV -1 transport has long been known from live microscopy-
based evidence (Mcdonald et al, 2002), it was not clear whether inhibiting dynein 
completely disrupts HIV -1 transport, and our results suggest that it does not. In their 
recent paper, however, Lukic et al. (2014) showed that pharmacological inhibition of 
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cytoplasmic dynein by Ciliobrevin D does decrease infectivity. Why does this drug have 
an effect on infectivity while two genetic approaches (DHC knockdown and p50 over-
expression) do not, is unclear, but one could propose off-target effects of the drug on 
infectivity, independent of its effect on dynein. It is equally possible, however, that our 
genetic interventions did not fully disrupt dynein function and that low levels of 
cytoplasmic dynein complexes are sufficient to achieve transport, although in a delayed 
fashion. Alternatively, it is possible that HIV-1 CA core retro grade transport can 
proceed in the absence of functional dynein, albeit less efficiently, by dynein-
independent or even microtubule-independent mechanisms, such as translocation on 
actin microfilaments (Yoder et al, 20 Il). 
A.6 Methods 
Cells, pharmaceuticals and antibodies. Human embryonic kidney 293T 
(HEK293T) cells, epithelial carcinoma HeLa cells and human U373-derived MAGI cells 
(Vodicka et al, 1997) were maintained in Dulbecco's modified Eagle's medium 
(DMEM) with high glucose, supplemented with 10% fetal bovine serum (FBS) and 
antibiotics at 37 oC, 5% CO2. HeLa cells retrovirally transduced to stably express owl 
monkey TRIMCyp were described before before (Bérubé et al, 2007; Nepveu-Traversy 
et al, 2009). AlI cell culture reagents were from HyClone (Thermo Scientific, Logan, 
UT, USA). MG132 was from Sigma (St Louis, MI, USA), nevirapine (cat#4666) was 
from the AIDS Research and Reference Reagent Program, while PF-3450074 was 
provided by Pfizer (New York, NY, USA). Rabbit polyclonal antibodies against dynein 
heavy chain and p50/dynamitin were from Santa Cruz (Dallas, TX, USA) and Millipore 
(Billerica, MA, USA), respectively. Capsid (CA, p24) was detected using a mouse 
monoclonal antibody (clone 183, cat#3537) from the AIDS Research and Reference 
Reagent Program. The HRP-conjugated mouse anti-actin antibody was from Sigma. 
HRP-conjugated goat anti-rabbit and goat anti-mouse antibodies used as secondary 
antibodies in Western blots were from Santa Cruz. 
168 
Plasmid DNAs and retrovirus production. p50/dynamitin-HA was a gift 
from Tina Schroer (Schrader et al, 2000). To produce viral vectors, 10-cm culture dishes 
or 75-cm flasks of sub-confluent HEK293T cells were co-transfected using 
polyethylenimine (PEI; MW 25,000, Polyscience, Niles, IL, USA) with the appropriate 
plasmids, as follows: for the replication-competent HIV-lNIA3, 20 Ilg ofpNL4-3; for the 
viral vector HIV-lcMV-GFP, pTRIP-CMV-GFP (10 Ilg), pllR8.9 (10 Ilg) and pMD-G 
(5 Ilg); for HIV-lNIA3-GFP, pNL-GFP (10 Ilg) and pMD-G (5 Ilg) (Berthoux et al, 2003; 
He et al, 1997; Naviaux et al, 1996; Zufferey et al, 1997). Media were changed 16 h 
post transfection and virus-containing supematants were collected after an additional 
1.5 days of culture. Viral stocks were clarified by centrifugation for 5 min at 400 x g. 
Viral challenges. 106 cells seeded in a 10-cm dlsh were PEI transfected with 5 Ilg 
of p50/dynamitin-HA or an irrelevant plasmid (PMIP). 24 h later cells were seeded in 
24-well plates at 2 x 105 cells per well and challenged with GFP-expressing viral vectors 
the next day. Where applicable, cells were pre-treated for 15 min with PF-3450074, and 
supematants were replaced with fresh medium 16 h post infection (p.i.) Cells were 
trypsinized 48 h p.i. and flXed in 2% formaldehyde (Fisher Scientific, Waltham, MA, 
USA). The percentages of GFP-positive cells were then determined by analyzing 104 to 
3 x 104 cells on a FC500 MPL cytometer (Beckman Coulter, Brea, CA, USA) using the 
CXP Software (Beckman Coulter). 
siRNA transfection. 106 cells were seeded in a 10-cm dish in Opti-MEM (Gibco, 
Carlsbad, CA, USA) and transfected the next day with 40 nM of siRNA using 
DharmaFECT 1 (Dharmacon, Lafayette, CO, USA). The siRNA targeting the sequence 
5'GATCAAACATGACGGAATT of (DHC) , has been described before (Lehmann et al, 
2009; Pawlica et al, 2014) and was purchased from Qiagen (Venlo, The Netherlands). A 
control siRNA (5'CGTACGCGGAATACTTCGATT) targeting the luciferase rnRNA 
(pawlica et al, 2014) was purchased from Dharmacon. 48 h post transfection, cells were 
seeded for the experiments. 
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Immunofluorescence (IF) microscopy. HeLa and MAGI cells were siRNA-
transfected as detailed above. 72 h later, 2 x 105 cells were seeded on glass coverslips 
placed in 3.5-cm wells and were infected the next day at a multiplicity of infection 
(MOI) of ~ 1 with vesicular stomatitis virus glycoprotein (VSV G)-pseudotyped 
HIV-1cMV-GFP (HeLa) or replication-competent HIV-1NIA3 (MAGI) in the presence of 
1 /lg/mL MG132. Infections were carried out for 2 h (HIV-1 NIA3) or 4 h followed by a 
2-h incubation in fresh medium (HIV-1cMV-GFP). Cells were then fIxed for 30 min in 4% 
formaldehyde-DMEM, followed by 3 washes with ice-cold phosphate buffer saline 
(PBS) and permeabilized for 2 min on ice in 0.1 % Triton X-100, 0.1 mM sodium citrate. 
Cells were then washed again three times with PBS and treated with 10% normal goat 
serum (Sigma, St Louis, MI) containing 0.3 M glycine (Sigma) for 30 min at room 
temperature. This was followed by a 4-h incubation with antibodies against CA 
(1 : 100 dilution) in PBS containing 10% normal goat serum. Cells were washed fIve 
times and fluorescently stained with AlexaFluor488-conjugated goat anti-mouse 
(Molecular Probes, Eugene, OR, USA) diluted 1 :200 in normal goat serum-containing 
PBS. Cells were then washed fIve times in PBS before mounting in Vectashield (Vector 
Laboratories, Peterborough, UK). Hoechst33342 (0.8 /lg/mL; Molecular Probes) was 
added along with the penultimate PBS wash to reveal DNA. Z-stacks were acquired on 
an AxioObserver Microscope (Carl Zeiss Canada, Jena, Germany) equipped with the 
ApoTome module, and the median optical slice of each Z-stack was analyzed. For the 
calculation of relative distances to the nucleus, we proceeded as described previously 
(Pawlica et al, 2014). The nucleus edge was defIned using Hoechst33342 staining, while 
the cell's edge was visualized by bright fIeld microscopy. The shortest distances to the 
nucleus edge and to the cell' s edge were calculated in 2D images of median optical 
slices and thus represent apparent, rather than real, shortest distances. 
Fate-of-capsid assay. To analyze post-entry CA uncoating, a protocol adapted 
from Perron et al (perron et al, 2004) was used and has been described in details before 
(Bérubé et al, 2007; Pawlica et al, 2014). 4 x 106 HeLa cells, previously transfected with 
siRNAs or p50 as described above, were seeded in 10-cm dishes. The next day, if 
applicable, cells were pretreated 15 min with PF-3450074 and infected with 
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HIV-1NIA3-GFP at a MOI of ~2 and in presence or absence of PF-3450074. Supernatants 
were rep1aced with fresh media, containing PF-3450074 or not, 1 h p.i. Cells were 
collected by trypsinization at different time points, washed in ice-cold PBS and 
resuspended in 1.5 mL of ice-cold lysis buffer (1 00 ~ Tris-HCI (pH 8.0), 0.4 mM KCI, 
2 ~M EDTA, Roche's Complete protease inhibitor) and disrupted with a Dounce 
homogenizer. Whole cell lysate samples were collected at this point. Lysates were 
centrifuged for 5 min 1000 x g, 4°C to remove cell debris and nuclei, and supernatants 
were 1ayered on top of a 50% sucrose cushion prepared in STE buffer (100 mM NaCI, 
10 mM Tris-HCl (pH 8.0), 1 mM EDTA). Particulate viral cores were sedimented by 
ultracentrifugation in a Sorval WX Ultra 100 ultracentrifuge at 175,000 x g for 2 h at 
4 oC. Pellets were resuspended in 80 ~L of IX denaturing loading buffer and processed 
for CA Western blotting together with whole celllysates. 
Quantitative PCR of HIV-l DNA. Cells were seeded in 12-well plates at 
3 x 105 cells/well and infected with HIV-1NIA3-GFP (MOI ~0.03 as calculated on the 
control permissive cells) depleted or not of DHC, as detailed above. Prior to infection, 
viral stocks were passed through 0.45-~m filters and pretreated for 1 h at 37 oC with 
20 U/mL DNAse 1 (New England Biolabs) to prevent contamination by carry-over 
plasmid DNA. After 3 h, supernatants were ' replaced with fresh media, and cellular 
DNAs were isolated at various tirnes using the DNeasy Blood and Tissue Kit (Qiagen, 
CA, USA). Purified DNAs were digested with 0.25 ~L of DpnI (20 U/~L, New England 
Biolabs) for 1 h at 37 oC to help remove any remaining plasmid DNA. The absence of 
such contaminant DNA was verified by performing control infections in the presence of 
80 ~M of the R T inhibitor nevirapine. The primers and reaction conditions for detecting 
OFP, 2-LTR and OAPDH have been previously described (Veillette et al, 2013). In each 
experiment, a standard curve of the amplicon being measured was run in duplicates 
ranging from 30 to 3 x 105 copies plus a no-template control. Reactions contained lx 
SensiF AST SYBR Lo-Rox (Bioline, UK), 300 nM forward and reverse primers, and 
100-300 ng template DNA. Results were analyzed with the MxPro software (Agilent 
Technologies, CA, USA). Computed values for OFP and 2-LTR copy numbers were 
normalized to the amounts of OAPDH copy numbers for each sample. 
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Statistical analysis. AlI statistical analyses were done usmg GraphPad Prism 
version 5.00 for Windows, GraphPad Software, San Diego California USA, 
www.graphpad.com. The box blot representations in Figure 1 were generated using the 
R software (Spitzer et al, 2014). 
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The following study, published in Journal of general virology, demonstrates that 
the involvement of microtubules and dynein motor complexes in the restriction mediated 
by owl monkey TRIMCyp is cellular context-specific. 
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B.2 Summary 
Interferon-induced restriction factors can significantly affect the replicative 
capacity ofretroviruses in mammals. Tripartite motifprotein 5, isoform a (TRIM5a) is a 
restriction factor that acts at early stages of the virus life cycle by intercepting and 
destabilizing incoming retroviral cores. Sensitivity to TRIM5a maps to the N-terminal 
domain of the retroviral capsid (CA) proteins. In several New World and Old World 
monkey species, independent events of retrotransposon-mediated insertion of the 
cyclophilin A (CypA) coding sequence in the trim5 gene have given rise to TRIMCyp 
(also called TRIM5-CypA), a hybrid prote in that is active against sorne lentiviruses in a 
species-specific fashion. In particular, TRIMCyp from the owl monkey (omkTRIMCyp) 
very efficiently inhibits HIV-l. Previously, we showed that disrupting the integrity of 
microtubules (MTs) and of cytoplasmic dynein complexes partially rescued replication 
of retroviruses, including HIV -1 , from restriction mediated by TRIM5a. Here we show 
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that efficient restriction of HIV-1 by ornkTRIMCyp is similarly dependent on the MT 
network and on dyne in complexes, but in a context-dependent fashion. When 
ornkTRIMCyp was expressed in human HeLa cells, restriction was partially 
counteracted by pharmacological agents targeting MTs or by siRNA-mediated inhibition 
of dynein. The same drugs (nocodazole and paclitaxel) also rescued mV-1 from 
restriction in cat CRFK cells, although to a lesser extent. Strikingly, neither nocodazole, 
paclitaxel nor depletion of the dynein heavy chain (DHC) had a significant effect on the 
restriction of HIV -1 in an owl monkey cell line. These results suggest the existence of 
cell-specific functional interactions between MTs/dynein and TRIMCyp. 
B.3 Introduction 
The replication of retroviruses and retrotransposons is inhibited by a diverse 
family of type 1 interferon (IFN) stimulated gene products commonly called restriction 
factors (Harris et al, 2012; Malim & Bieniasz, 2012; Zheng et al, 2012). The replication 
of human immunodeficiency virus type 1 (HIV -1) is reduced by IFN treatment of cells 
in vitro (Ho et al, 1985; Yamamoto et al, 1986) and in vivo (Skillman et al, 1996). At 
least sorne of the restriction factors that mediate the IFN-induced restriction of HIV-1 
have been uncovered. For instance, the interferon-induced transmembrane proteins 
2 and 3 (IFITM2 and IFITM3) can affect entry or immediate post-entry steps of HIV-l 
replication (Lu et al, 20 Il). If the virus reaches the cytoplasm, it can then be inhibited 
by myxovirus resistance prote in 2 (Mx2, also called MxB) (Goujon et al, 2013; Kane et 
al, 2013). Mx2 binds CA proteins that are part of the 'intact' (not-yet-disassembled) 
HIV-l core, and interferes with core disassembly (uncoating) (Fricke et al, 2014; Liu et 
al, 2013). TRIM5a is another IFN-inducible factor that intercepts incoming retroviruses 
in the cytop1asm of infected cells (Strernlau et al, 2004). Restriction is host- and virus-
specifie, and HIV -1 is generally insensitive to human TRIM5a, as its CA is not 
recognized by the human version of the protein (Hatziioannou et al, 2004; Keckesova et 
al, 2004; Sebastian & Luban, 2005; Strernlau et al, 2004; Strernlau et al, 2006; Yap et 
al, 2004). However, HIV-1 is efficiently inhibited by TRIM5a expressed in several 
monkey species (up to ~100-fold in single-cycle assays), including macaques and the 
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African green monkey (Hatziioannou et al, 2003). TRIM5a belongs to the tripartite 
motif (TRIM) family of proteins, a very large family (close to 100 members) of 
ubiquitin ligases that function in various pathways including antiviral defense (Han et al, 
2011; Reymond et al, 2001). TRIM proteins contain, starting at the N-terminal domain, 
a RING domain, one or two B-boxes, and a Coiled-Coil domain. Most ofthem also have 
an additional functional domain at the C-terminus (Sardiello et al, 2008); in the case of 
TRIM5a, this additional domain is a PRYSPRY motif, also called SPRY or B30.2 (Song 
et al, 2005). The PRYSPRY domain is responsible for the specificity of restriction, by 
mediating direct interactions with surface patches present in the N-terminal region of 
retroviral CA proteins (Biris et al, 2013; Sebastian & Luban, 2005; Yang et al, 2014). In 
several independent instances, retrotransposition events have led to the insertion of the 
CypA coding sequence into the trim5 locus of New World or Old World primate 
species, leading to the expression of various TRlMCyp hybrid proteins. TRIMCyp 
expressed in the ow 1 monkey (Aotus trivirgatus) very efficiently decreases HIV-l 
infectivity (~100- to 500-fold in single cycle assays) (Nisole et al, 2004; Sayah et al, 
2004). Among the other TRIMCyp hybrid proteins discovered, those expressed in pig-
tailed macaques (Macaca nemestrina) and in sorne rhesus macaques (Macaca mulatta) 
do not restrict RIV-l, but target other lentiviruses like RIV-2 (Brennan et al, 2008; 
Newman et al, 2008; Virgen et al, 2008; Wilson et al, 2008). 
Restriction of HIV -1 by omkTRIMCyp seems to occur by a mechanism similar to 
that of TRlM5a and is initiated by the direct binding of the CypA domain of TRIMCyp 
to CA proteins that are part ofincoming cores (Black & Aiken, 2010; Price et al, 2009; 
Shi et al, 2013). This interaction occurs relatively quickly, within an hour following 
virus entry into the cytoplasm (Hulme et al, 20 Il) and results in the destabilization of 
the retroviral core, a process sometimes referred to as premature decapsidation (Bérubé 
et al, 2007; Diaz-Griffero et al, 2007; Diaz-Griffero et al, 2006b). Over-expression of 
omkTRIMCyp in human cells results in an HIV -1 inhibition as potent as what is 
observed in owl monkey cell lines such as OMK cells, showing that the HIV-l 
restriction-null endogenous human TRIM5a does not interfere with restriction in this 
context (Berthoux et al, 2005a). Interestingly, TRIM5 proteins are expressed at very 
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low levels endogenously in the absence ofIFN (Carthagena et al, 2008), as illustrated by 
the difficulty to detect them by immunoblotting or immunofluorescence microscopy. 
Moreover, restriction by TRlM5a or TRlMCyp involves their aggregation or 
multimerization on the targeted retro viral core, as seen in various imaging studies 
(Campbell et al, 2008; Ganser-Pornillos et al, 2011 ; Zhao et al, 2011). Taken together, 
these observations raise an intriguing question: how can a sparsely expressed restriction 
factor quickly and efficiently intercept incoming retro viral cores in a process that may 
require hundreds or thousands of TRlM5 molecules? To address this question, we have 
hypothesized that TRlM5 proteins associate with cytoskeleton components used by 
retroviruses for their transport toward the nucleus, which would dramatically enhance 
the probability of successfu1 interception. omkTRlMCyp, like TRlM5a, forms 
cytoplasmic bodies (CBs) whose sizes are dependent on expressIon levels (perez-
Caballero et al, 2005). TRlM5a CBs co-Iocalize with ubiquitin (Campbell et al, 2008) 
and proteasomal subunits (Danielson et al, 2012; Lukic et al, 2011), which supports a 
functional role for CBs since the proteasome is invo1ved in TRlM5a-mediated 
restriction (Anderson et al, 2006). On the other hand, CBs and proteasome were found to 
be dispensable for HIV-1 restriction by omkTRlMCyp (perez-Caballero et al, 2005), 
pointing to the possibility of differences between the precise mechanisms of action for 
the se two restriction factors. TRlM5a CBs associate with MTs and their movements 
along these filaments have been reported (Campbell et al, 2007). HIV-1 and other 
viruses are thought to recruit dynein motor complexes translocating on MTs for their 
retrograde transport (toward the nucleus) [reviewed in (Dodding & Way, 2011 ; Hsieh et 
al, 2010; Mouland & Milev, 2012)]. In a previous report, we showed that restriction of 
HIV-l and N-tropic murine leukemia virus (N-MLV) by TRlM5a could be significantly 
attenuated by pharmacological treatments that affect the integrity and dynamics of 
MTs (pawlica et al, 2014). TRlM5a-mediated restriction was also inhibited by 
pharmacological or RNAi-mediated disruption of dynein complexes (pawlica et al, 
2014). Because of the reported differences between TRlM5a and omkTRlMCyp in 
restricting HIV -1, we investigated whether the MT network and dynein complexes were 
relevant to omkTRlMCyp-mediated restriction. 
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B.4 Results 
The size and localization of TRIMCyp CBs are modulated by MTs and 
cytoplasmic dynein. Previously, we showed that treatment of HeLa cens with 
nocodazole, a drug that inhibits MT polymerization (Luduena & Roach, 1991), 
increased the size of TRlM5a CBs and caused them to localize closer to the nucleus, on 
average (Pawlica et al, 2014). Depleting DHC also caused TRIM5a CBs to be larger, 
and they were found to localize closer to the plasma membrane, on average (pawlica et 
al, 2014). We used the same approach to analyze the effect ofthese two interventions on 
omkTRIMCyp CBs. HeLa cens stably expressing omkTRIMCyp or transduced with the 
empty vector where stained with a monoclonal anti-FLAG antibody. cens were treated 
with nocodazole at a concentration (2 J.lM) previously determined to result in efficient 
MTs disassembly (pawlica et al, 2014), or left untreated (Fig. la). Altematively, cens 
were transfected with a DHC siRNA under conditions leading to a ~85% decrease in 
DHC protein expression levels (pawlica et al, 2014), or were transfected with a control 
(luciferase-targeting) siRNA (Fig. lb). No staining was detected in the empty vector-
transduced cens under the conditions used (Fig. la,b). The size of omkTRlMCyp CBs, 
as represented by the area on the two-dimensional images recorded, was calculated, 
along with their relative localization as previously described (Pawlica et al, 2014). In the 
absence of drug and in the cells transfected with the luciferase-targeting siRNA, 
omkTRIMCyp CBs had a median area of ~0.12 J.lm2, while the mean area was of 
~0.13 J.lm2 (Fig. lc). Treatment with nocodazole increased the median and mean size of 
CBs by 16.7% and 20.3%, respectively (Fig. lc, left panel). DHC depletion increased 
the median size of omkTRlMCyp by 16.7% but had a bigger effect on their mean size, 
compared with the control siRNA (a 67.0% increase, indicating that the effect was much 
more pronounced on a minority of CBs). The effect was significant in both experiments 
(P = 0.01 and P = 0.002, respectively) and showed that the dynamics of TRlMCyp 
bodies are affected by treatments that disrupt MTs or interfere with cytoplasmic dynein 
function, similar to TRIM5a (Diaz-Griffero et al, 2006a; Pawlica et al, 2014). 
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Dynein heavy chain (DHe) depletion and MTs perturbation alter the 
size and/or distribution of omkTRIMCyp CBs. 
(a, b) immunofluorescence microscopy. HeLa ceUs transduced with 
FLAG-tagged omkTRIMCyp and control ceUs transduced with the empty 
vector were (a) seeded on glass coverslips and 24 hours later treated or 
not with 2 ~M of nocodazole (noc) for 6 h, or (b) transfected with 40 nM 
of siRNAs targeting DHC or luciferase and 48 hours later seeded on glass 
coverslips and incubated for an additional 24 h. CeUs were fixed and 
immunostained for FLAG (red). DNA was stained with Hoechst33342 
(blue). Representative images are shown with outlined ceU edges. 
(c) Sizes of CBs. AU CBs were outlined in ceUs from a minimum of 
5 randomly chosen fields and their area was calculated using image 
analysis software (Axio Vision). Red bars show the means with SEM 
and green bars show the medians. P values were calculated using Student 
t-test analysis. (d) The relative localization of aU TRIMCyp CBs from a 
minimum of 5 randomly chosen cells was calculated using the formula 
x/(x+y), where x is the shortest distance to the nucleus and y is the 
shortest distance to the ceU's edge. Red bars show the mean with SEM 
and green bars, the median. 
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The relative intracytoplasmic position of omkTRIMCyp CBs was determined 
according to their closest distance to the nuclear membrane and the cytoplasmic 
membrane (Pawlica et al, 2014). Treatment with nocodazole caused omkTRIMCyp CBs 
to localize closer to the nucleus, relative to the untreated control (Fig. 1 d, left panel). 
This effect was highly significant (P = 0.001) and mirrored our previous observations 
with TRIM5a (Pawlica et al, 2014). In contrast, DHC depletion had no significant effect 
on omkTRIMCyp relative localization (Fig. 1c, right panel). This stands in contrast to 
what was observed with TRIM5a CBs, which were found to be closer to the cen's edge 
upon DHC depletion (Pawlica et al, 2014). Altogether, results in Fig. 1 show that the 
dynamics of omkTRIMCyp are sensitive to perturbation of MTs and cytoplasmic 
dynein, but the specific effects are different from what is observed with TRIM5a, 
hinting at differences in their interactions with the cytoskeleton. 
Nocodazole and paclitaxel partially rescue HIV-l from restriction by 
omkTRIMCyp in HeLa cells. The fact that nocodazole treatment a1tered the dynamics 
of omkTRIMCyp CBs prompted us to analyze whether disrupting MTs would affect 
restriction. In addition to nocodazole, we also tested the effect of paclitaxel, a drug that 
prevents the disassembly of MTs (Jordan et al, 1992; Schiff et al, 1979). HeLa cens 
stably expressing omkTRIMCyp or transduced with the parental construct were treated 
with two different concentrations of nocodazole (Fig. 2a) or paclitaxel (Fig. 2b) and then 
infected with increasing amounts of an HIV-1 vector, HIV-1cMV-GFP. We previously 
showed that nocodazole and paclitaxel at these concentrations had the expected effects 
on the MT network in HeLa cens and were not strongly cytotoxic (paw1ica et al, 2014). 
In the absence of drug, HIV-I cMV-GFP was restricted 300- to 400-fold by omkTRIMCyp 
(Fig. 2a, 2b), which is comparable to previous observations (Bérubé et al, 2007). 
Nocodazole increased infectivity of HIV-IcMV-GFP in HeLa cens expressing 
omkTRIMCyp by ~50-fold, while only slightly increasing infectivity in the permissive 
cens transduced with the empty vector (Fig.2a). Thus, nocodazole counteracted 
omkTRIMCyp-mediated restriction, and this effect was seen at an virus doses tested and 
at both drug concentrations. Likewise, paclitaxel increased HIV-IcMV-GFP infectivity by 
~30-fold in HeLa cens expressing omkTRIMCyp, while slightly decreasing infectivity 
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in the empty vector-transduced control cens (Fig. 2b). In the reciprocal experiment, we 
infected the same cen lines with HIV -1 CMV-GFP in the presence of increasing nocodazole 
concentrations and using fixed virus doses. Nocodazole increased infectivity in HeLa-
omkTRIMCyp cens by up to ~80-fold, compared with the untreated control, and this 
effect was observed at a wide range of nocodazole concentrations (Fig.2c; see non-
normalized data in Fig. Sla,b). Like before, nocodazole slightly increased HIV-IcMV-GFP 
infectivity in the control cens, by up to ~2-fold at 1 f.lM (Fig.2c). We did a similar 
experiment with increasing concentrations of paclitaxel and fixed virus doses. Paclitaxel 
treatment increased HIV-lcMV-GFP infectivity in omkTRIMCyp-expressing cens by up to 
15-fold compared to the untreated control (Fig.2d; see non-normalized data in 
Fig. SI d). The magnitude of this effect was identical at an the drug concentrations 
tested. In contrast, paclitaxel decreased HIV-lcMV-GFP infectivity in the empty vector-
transduced control cens by up to 2.5-fold (Fig. 2d; see non-normalized data in Fig. SIc). 
If the effect of nocodazole and paclitaxel was calculated relatively to the effect seen in 
control vector-transduced cens treated, rather than relatively to the untreated control, 
then both drugs were found to stimulate infectivity by roughly the same magnitude, 
~50-fold. This observation mirrors previously published findings that nocodazole and 
paclitaxel both rescue N-MLV and HIV-I from restriction by endogenous human 
TRIM5a and exogenous rhesus TRIM5a, respectively, in HeLa cens, and the effects of 
the two drugs were also of similar magnitude (Pawlica et al, 2014). 
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Pharmacological perturbation of MTs partially counteracts HIV-l 
restriction by omkTRIMCyp in HeLa cells. 
(a, b) Effect ofnocodazole (noc) and paclitaxel (pxl) on restriction. HeLa 
cens transduced with FLAG-tagged omkTRIMCyp or the empty vector 
were infected with multiples doses of HIV-lcMV-GFP in the presence or 
absence of indicated concentrations of either nocodazole (a) or paclitaxel 
(b). Infections were performed for 16 hours. Infected (GFP-expressing) 
cens were detected by · flow cytometry at 2 days post-infection. 
(c, d) Dose-dependent effect of nocodazole or paclitaxel on restriction. 
Human HeLa cens transduced with FLAG-tagged omkTRIMCyp or the 
empty vector were infected for 16 hours with a single dose ofHIV-I CMV_ 
GFP in the presence of increasing concentrations of either nocodazole (c) 
or paclitaxel (d). The percentages of infected cens were determined by 
flow cytometry 2 days postinfection, and the results are presented as the 
fold changes in infectivity relative to the relevant untreated controls. 
Higher amounts of input virus were used in omkTRIMCyp-expressing 
ceUs than in the control cens, so . that an values fan within the dynamic 
range for this assay. The ratio of infected ceUs in the absence of drug 
were 0.06% (TRIMCyp, panel c), 0.16% (TRIMCyp, panel d), 2.15% 
(empty vector, panel c) or 7.93% (empty vector, panel d). 
188 
Depletion of DHC partially rescues HIV-l from omkTRIMCyp-mediated 
restriction in HeLa cells. Previously, we found that DHC depletion partially suppressed 
the restriction of HIV -1 by rhesus TRIM5a expressed in HeLa cens (Pawlica et al, 
2014). On the other hand, DHC depletion had a milder effect on the size and position of 
omkTRIMCyp CBs, compared to rhesus TRIM5a CBs (Fig. 1). To investigate whether 
the presence of DHC would be important to restriction mediated by TRIMCyp, we used 
a siRNA to suppress its expression in HeLa cens that were transduced with 
omkTRIMCyp or the empty vector. DHC knockdown was efficient (>90%), as shown in 
Fig.3a. Then, cells were challenged with HIV-1cMV-GFP using virus doses leading to 
~0.49% infected cells (empty vector-transduced) and 0.17% infected cells 
(omkTRIMCyp-transduced). When cells were transfected with the DHC-targeting 
siRNA, infectivity in omkTRIMCyp-expressing cens increased by 34.8-fold ± 1.3 
compared to cells transfected with a control siRNA against luciferase (Fig. 3b; see non-
normalized data in Fig. S2a). In contrast, the DHC-targeting siRNA had no effect in 
control cells transduced with the empty vector. Thus, DHC depletion counteracted 
omkTRIMCyp-mediated restriction, and the magnitude seen was comparable to what 
was observed with nocodazole and pac1itaxel (Fig. 2). To determine whether the 
pharmacological disruption of MTs (using nocodazole or paclitaxel) and the siRNA-
mediated disruption of cytoplasmic dynein counteracted omkTRIMCyp · through the 
same mechanism or by acting independently, HeLa cells expressing omkTRIMCyp were 
infected with HIV-lcMV-GFP in the presence of an siRNA targeting DHC or luciferase, 
and in presence or not of nocodazole or pac1itaxel (Fig. 3c; see non-normalized data in 
Fig. S2b). Like before, pac1itaxel (alone or in combination with DHC knockdown) 
slightly decreased HIV-lcMV-GFP infectivity (~1.5-fold), while nocodazole and DHC 
depletion had no significant effect (Fig. 3c). Compared to the untreated control, 
treatment with nocodazole and pac1itaxel increased infectivity in omkTRIMCyp-
expressing cens by 27.0-fold (± 2.4) and 59.2-fold (± 3.7), respectively. DHC depletion 
alone increased infectivity by 16.9-fold (± 0.7) in omkTRIMCyp-expressing cells. 
Combining DHC depletion with nocodazole and pac1itaxel increased infectivity by 
32.3-fold (± 6.9) and 53.9-fold (± 4.98), respectively (Fig. 3c). Thus, the effects are 
aImost identical to those obtained with the drugs alone, strongly suggesting that DHC 
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depletion and MTs perturbation rescued HIV -1 from omkTRIMCyp by interfering with 
the same pathway. Of note, in this experiment, only 0.14% omkTRIMCyp-expressing 
cens were infected in the absence of drug, which implies that we would have been able 
to observe 100-fold increases (or more) in infectivity if they had occurred. Thus, the 
absence of an additive effect in Fig. 3c is not due to saturated infection. 
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DHC depletion partially counteracts HIV-l restriction by 
omkTRIMCyp in HeLa cells. 
(a) Western blot analysis ofDHC expression in HeLa cens 48 hours after 
transfection of the siRNAs against DHC (siDHC) or against luciferase 
(siLuc) as a control. Actin was analyzed as a loading control. (b) HeLa 
cens transduced with omkTRIMCyp or the empty vector were transfected 
with the indicated siRNAs and infected 72 ho urs later in triplicates with 
single doses of HIV-lcMV-GFP for 16 h. Infected cens were detected by 
flow cytometry 2 days postinfection and results are presented as -fold 
changes relative to the relevant untreated controls (relative change in 
infectivity). Higher amounts of input virus were used in omkTRIMCyp-
expressing cens than in the control cens, so that an values fan within the 
dynamic range for this assay. The ratio of infected cens in the absence of 
drug were 0.17% (TRIMCyp) and 0.49% (empty vector). ***, P :::; 0.0001 
(Student t-test). (c) Effect of combining DHC depletion and microtubule 
perturbation on TRIMCyp-mediated HIV -1 restriction. HeLa cens 
transduced with omkTRIMCyp or the empty vector were transfected with 
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40 nM of siRNA against DHC or Luc, then treated or not with either 
0.2 ~M of nocodazole or 0.1 ~M of pac1itaxel and infected with 
HIV-l cMV-GFP. Infection yields were analyzed as above. The ratio of 
infected cells in the absence of drug were 0.14% (TRIMCyp) and 5.77% 
(empty vector). ** and *** indicate respectively P ~ 0.005 and 
P ~ 0.0001 compared with the untreated omkTRIMCyp-transduced cells, 
as calculated using the Student t-test. 
Over-expression of p50/dynamitin partially counteracts omkTRIMCyp-
mediated restriction. As an alternative approach to analyze the importance of dynein-
mediated transport in omkTRIMCyp-mediated restriction, we over-expressed 
p50/dynamitin in control and omkTRIMCyp-expressing HeLa cells (Fig. 4a). p50 is a 
subunit of the dynactin complex that is responsible for binding cargos to the dynein 
complex. Its over-expression results in the disassembly of dynactin complexes, thereby 
disrupting cargo biiJ.ding to dynein (Burkhardt et al, 1997; Melkonian et al, 2007). Over-
expression of p50 increased HIV-l cMV-GFP infectivity in TRIMCyp-expressing cells by 
2.3-fold (± 0.35), while replication in the control permissive cells was not affected 
(Fig. 4b; see non-normalized data in Fig. S2c). Altogether, the data in Fig. 3 and Fig. 4 
strongly suggest that functional dynein complexes are important, but not absolutely 
necessary, to omkTRIMCyp-mediated restriction. 
Figure 4. 
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Over-expression of p50/dynamitin decreases omkTRIMCyp-
mediated restriction ofHIV-l in HeLa cells. 
(a, b) HeLa cells transduced with omkTRIMCyp or the empty vector were 
transfected with p50/dynamitin-HA or an irrelevant control plasmid. 
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(a) Detection of p50 in the transfected cells by Western blotting. (b) 
48 hours after transfection, cells were infected in triplicates with HIV-
lcMV-GFP. Infected cells were counted by flow cytometry 2 days post 
infection and results are presented as -fold changes in infectivity relative 
to the relevant mock-transfected control. Higher amounts of input virus 
were used in omkTRIMCyp-expressing cens than in the control cens, so 
that an values fan within the dynamic range for this assay. The ratio of 
infected cens in the mock-transfected cens were 0.25% (for TRIMCyp) 
apd 0.42% (for the empty vector). ** indicates P ~ 0.005 in a Student 
t-test. 
Nocodazole and paclitaxel partially rescue HIV-l from omkTRIMCyp-
mediated restriction in cat cells. The experiments in Figs 1-4 were an performed in 
HeLa cens. To analyze whether nocodazole and paclitaxel could also interfere with 
omkTRIMCyp function in another cellline, we used CRFK cat cens stably expressing 
omkTRIMCyp, or transduced with the empty vector as a control. Cats, like other feline 
species, apparently do not have a TRIM5a or TRIMCyp ortholog (McEwan et al, 2009), 
and thus, using this cenline also insured that endogenous TRIM5a did not play a role in 
the effects seen in HeLa cens. First, CRFK cens were transfected with a construct 
expressing GFP-a-tubulin and then treated with nocodazole or paclitaxel before being 
processed for immunofluorescence microscopy. In the absence of drug, individual MTs 
were clearly visible (Fig. 5a, left panel). Nocodazole prevents polymerization of MTs 
(Luduena & Roach, 1991) and consequently, MTs appeared shortened and/or 
disassociated; most of the signal was diffuse and distributed throughout the cytoplasm 
(Fig. 5a). Paclitaxel, on the other hand, binds to MT polymers to prevent their 
disassembly (Jordan & Wilson, 2004), resulting in the formation of abnormal MT 
bundles (Hornick et al, 2008), a phenotype that was observed as expected in CRFK cens 
(Fig. 5a). Next, we analyzed the effect of these pharmacological treatments on HIV-l 
infectivity under restriction by omkTRIMCyp. In the absence of treatment, 
HIV-lcMV-GFP infectivity in CRFK cens expressing omkTRIMCyp was reduced by 
~100-fold compared to the control cens (Fig. 5b-c), which is smaner than what was seen 
in HeLa cens transduced with the same omkTRIMCyp-expressing construct (Fig. 2a-b). 
Treatment with nocodazole (Fig.5b) and paclitaxel (Fig. 5c) increased HIV-ICMV-GFP 
infectivity by ~6-fold while having no effect in control permissive cens. Thus, 
perturbing MTs partially inhibits omkTRIMCyp function in CRFK cells, similar to what 
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was observed in HeLa cens, although the effect is smaner in CRFK cens. Moreover, the 
magnitudes of the effects of the two drugs in CRFK cens were similar, as was the case 
in HeLa cells. 
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Pharmacological perturbation of MTs partially counteracts mv-1 
restriction by omkTRIMCyp in CRFK cells. 
(a) Immunofluorescence microscopy analysis of microtubules. CRFK 
cens were transfected with GFP-a-tubulin and 2 days later were left 
untreated or subjected to 2-hour treatments using either 2 !-lM nocodazole 
(noc) or 1 !-lM paclitaxel (pxl) and then flxed. GFP fluorescence was 
observed by immunofluorescence microscopy, along with DNA which 
was stained using Hoechst33342 (blue). A representative image from 
each condition is presented. (B, C) Effect of nocodazole (noc) and 
paclitaxel (pxl) on restriction. CRFK cens transduced with omkTRIMCyp 
or with the empty vector were infected with multiples doses of 
HIV -1 CMV-GFP in the presence or absence of 2 !-lM nocodazole (b) or 1 !-lM 
paclitaxel (c). Infections were performed for 16 hours and infected cens 
were detected by flow cytometry 2 days later. 
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Disrupting MTs dynamics or dynein function do es not counteract restriction 
of HIV-l in owl monkey OMK cells. Finally, we tested whether MTs and cytoplasmic 
dyne in were important to omkTRIMCyp function when expressed endogenously in owl 
monkey cells. For this, we used OMK cells, which are kidney epithelial cells known to 
be very poorly permissive to HIV-l (Sayah et al, 2004; Towers et al, 2003). 
GFP-u-tubulin transfection allowed us to analyze the effect of nocodazole and paclitaxel 
on the MT network in this cell line (Fig. 6a). Similar to what was seen in CRFK cells, 
treatment with 2 ~M nocodazole resulted in GFP-u:-tubulin to be more diffuse in the 
cytoplasm of cells (Fig. 6a), consistent with inhibition of MT polymerization by this 
drug. Conversely, treatment with 1 ~M paclitaxel caused the formation of abnormal MT 
bundles that were found close to the cell's edge (Fig. 6a). OMK cells were then infected 
with HIV-1 NIAJ-GFP, a VSV G-pseudotyped HIV-l vector devoid of an HIV-l envelope 
and expressing GFP in place of Nef (He et al, 1997). As a non-restricted control, we 
used SIV mac-GFP, a similarly constructed vector derived from the omkTRIMCyp-
insensitive SIV strain mac239 (Berthoux et al, 2005b). OMK cells were infected with 
multiple doses of HIV-1NIA3-GFP and SIVmac-GFP, in absence of drug or in presence of 
nocodazole (Fig. 6b) or paclitaxel (Fig. 6c). After normalization of the virus amounts 
used according to their titers in the non-restrictive CRFK cells, we found that as 
expected, HIV -1 NIA3-GFP infectivity was ~500-fold smaller than that of SIV mac-GFP 
in these cells (Fig. 6b-c). Addition of nocodazole at 0.1 or 1 ~M slightly increased 
HIV-1NIA3-GFP infectivity, but this drug also had a small positive effect on SIVmac-GFP 
infectivity (Fig. 6b). Likewise, treatment with paclitaxel slightly increased infectivity of 
SIVmac-GFP and also that of HIV-1NIA3-GFP, at least at sorne virus doses (Fig. 6c). Thus, 
HIV-1NIA3-GFP is not rescued from TRIMCyp-mediated restriction in OMK cells by 
nocodazole or paclitaxel treatment. The discrepancy between this result and what was 
observed in HeLa and CRFK cells could possibly be due to differences in restriction 
sensitivity between the vectors used, HIV-lcMV-GFP and HIV-1NIA3-GFP. To exclude that 
possibility, we infected OMK cells with several doses of HIV-ICMV-GFP in absence or 
presence of nocodazole or paclitaxel. As shown Fig. 6d, neither drug could rescue this 
vector from restriction by TRIMCyp in OMK cells. As additional evidence that 
TRIMCyp was expressed and functional in these cells, we tested whether inhibition of 
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its interaction with IllV-1 capsid would rescue IllV-1 infectivity (Sayah et al, 2004). 
Treatment with 5 JlM cyclosporine A during infection and introducing the G89V 
mutation in IllV-1 capsid both increased HIV-1 infectivity by ~200-fold in OMI<. cens 
(Fig. 6e), thus completely disrupting restriction. 
It is conceivable, albeit unlikely (since dynein complexes translocate on MTs), that 
cytoplasmic dynein could have a role in TRIMCyp function in OMI<. cens even if the 
MT network does not. To test this possibility, we depleted DHC in OMK cens using the 
same siRNA that was used in human cens. We found that DHC knockdown by this 
siRNA was as efficient in OMK cens as in human cens (>90%; Fig. 6f). DHC depletion 
had no significant effect on HIV -1 NL43-GFP, even decreasing infectivity at one of the virus 
doses compared to the cens transfected with the control (luciferase-targeting) siRNA 
(Fig. 6g). SIV mac-GFP infectivity was similarly not significantly affected by DHC 
depletion (Fig. 6g). Thus, IllV -1 infectivity in OMI<. cens is not rescued by interfering 
with the integrity of the MT network or by targeting DHC, suggesting the existence of 
cen context specificity for the involvement of MTs and cytoplasmic dynein in the 
restriction process. 
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Pharmacological perturbation of MTs and DHC depletion do not 
rescue HIV-l from TRIMCyp-mediated restriction in OMK cells. 
(a-d) Effect of nocodazole (noc) and pac1itaxel (pxl) on restriction. 
(a) Immunofluorescence microscopy analysis ofmicrotubules. OMK cells 
were transfected with GFP-a-tubulin and 2 days later were left untreated 
or subjected to 2-hours treatments using either 2 ~ nocodazole or 1 ~ 
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paclitaxel and then fixed. GFP fluorescence was observed by 
immunofluorescence microscopy, along with DNA which was stained 
using Hoechst33342 (blue). A representative image from each condition 
is presented. (b-d) OMK cells were infected with multiples doses of 
HIV-1NIA3-GFP (b, c), SlVmac-GFP (b, c) or HIV-lcMV-GFP (d) in the presence 
or absence of nocodazole (b, d) or paclitaxel (c, d) at the indicated 
concentrations. Infections were performed for 16 hours and infected cells 
were detected by flow cytometry 2 days later. (e) Abrogation of 
restriction by CsA treatement or CA mutation. OMK cells were infected 
with increasing amounts of wild-type (WT) HIV-l cMV-GFP or the G89V 
CA mutant ,and in presence or absence ofCsA (5 ~M). The x-axis shows 
the amounts of virus used fof both G89V and WT virus as determined by 
their titers in CRFK cells in the absence of drug. The % of GFP-positive 
cells were determined by flow cytometry 2 days post-infection. 
(t) Western blot analysis of DHC expression in OMK cells 48 hours after 
transfection of the siRNAs targeting DHC (siDHC) or, as a control, 
luciferase (siLuc). Actin was analyzed as a loading control. (g) OMK 
cells were transfected with the indicated siRNAs and infected 72 hours 
later infected with muliple doses of either HIV -INIA3-GFP or SIV mac-GFP for 
16 h. Infected cells were detected by flow cytometry 2 days postinfection. 
B.S Discussion 
Previously, we showed that full restriction by TRIM5a. required the presence of a 
functional MT network, as well as functional dynein complexes (Pawlica et al, 2014). 
This was true whether TRIM5a. was expressed endogenously or over-expressed by 
retro viral transduction. Moreover, the phenotype was observed in human cells and in 
rhesus macaque cells, and whether the restricted virus was a lentivirus (HIV -1) or an 
oncoretrovirus (N-ML V). Here, we show that the antiretroviral function of TRIMCyp, a 
TRIM5 protein bearing a CypA domain instead of a PR YSPRY domain, can be similarly 
sensitive to inhibition of MTs or dynein complexes. All viruses used in this study were 
VSV G-pseudotyped, and we cannot totally exclude that such pseudotyping modulates 
the involvement of microtubules or dynein in omkTRIMCyp-mediated restriction. 
However, this seems unlikely considering that the mode of virus entry was previously 
shown to be irrelevant for the involvement of microtubules in TRIM5a.-mediated 
restriction of HIV-l (Pawlica et al, 2014). Interestingly, the MT/dynein dependency of 
omkTRIMCyp varied between the celllines use d, being high in HeLa cells, relatively 
less so in CRFK cells, and absent in OMK cells. Endogenous TRIMCyp in OMK cells is 
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expressed at much lower levels compared to over-expression in HeLa or CRFK cells, 
but this is unlikely to explain the differences seen here, considering that (i) the 
magnitude of omkTRIMCyp-mediated HIV-1 restriction is similar in OMK and in 
TRIM5a-transduced HeLa cells (100-fold or more) and (ii) microtubules and dynein 
were shown to be important for restriction mediated by both endogenous and over-
expressed TRIM5a (pawlica et al, 2014). However, we cannot totally exclude this 
possibility. Of note, none of the experimental approaches used here had a significant 
effect on omkTRIMCyp expression levels in HeLa cells (not shown), ruling out such a 
putative unspecific effect as the cause for the loss of restriction. Because cytoplasmic 
dynein complexes translocate on MTs (Rook & Vallee, 2006), it appears likely that 
paclitaxel and nocodazole inhibit TRIM5a and TRIMCyp in~irectly, by preventing 
dynein-mediated transport. In support of this conclusion is the observation that 
combining DHC depletion with paclitaxel or nocodazole treatment has no additional 
effect on restriction in cells, and this has been shown for rhesus TRIM5a (pawlica et al, 
2014) and now for omkTRIMCyp as well. The fact that neither TRIM5a or TRIMCyp 
are completely dependent on the presence of an intact MT network or functional dynein, 
regardless of the cellular context, leads us to conclude that dynein complexes have a 
function in TRIM5aJTRIMCyp-mediated restriction that is not absolutely required or, 
possibly, this function can be accomplished by another transporter complex that does not 
translocate on MTs. This hypothesis helps make sense of the fact that neither DHC 
depletion nor pharmacological disruption of MTs could rescue HIV -1 infection of owl 
monkey OMK cells. We speculate that the endogenous omkTRIMCyp expressed in 
these cells does not require MTs or dynein to make initial contact with the incoming 
virus capsid core, and elucidating the molecular basis for this behavior will require 
additional investigations. Altematively, the discrepancy of results between the celllines 
used in this study could stem from different effects of inhibiting MTs and dynein on 
virus uncoating in these cell lines. Targeting MTs and dynein may delay uncoating, as 
has been shown recently by us (pawlica & Berthoux, 2014; Pawlica et al, 2014) and by 
others (Lukic et al, 2014), and perhaps this has a greater impact on restriction in some 
cell lines than in others. Interestingly, Lukic et al also included data showing that 
nocodazole treatment did not rescue HIV -1 from restriction by rhesus TRIM5a or 
198 
omkTRIMCyp expressed in HeLa ceIls, apparently conflicting with our previous report 
(Pawlica et al, 2014) and the present one. However, HeLa cells have been shown to be a 
highly heterogeneous cell line (Carson & PirrucceIlo, 2013) including clones with 
various permissiveness toward HIV-l infection (De Iaco & Luban, 2014) and it is also 
known that the magnitude of restriction by TRIM5a. and TRIMCyp proteins can vary 
widely between ceIllines (Bérubé et al, 2007; Gong et al, 2011). Altogether, it appears 
likely that a cellular context effect explains the different results obtained by Lukic et al. 
In conclusion, the MT network and dyne in complexes can potentiate the antiretroviral 
activity of not only TRIM5a. but also TRIMCyp, but is not strictly required. 
. B.6 Methods 
CeUs, pharmaceuticals and antibodies. Human embryonic kidney 293T 
(HEK293T) ceIls, human epithelial carcinoma HeLa ceIls, feline renal CRFK cells, owl 
monkey kidney (OMK) cells were maintained in Dulbecco's modified Eagle's medium 
(DMEM) with high glucose, supplemented with 10% fetal bovine serum (FBS) and 
antibiotics at 37°C, 5% C02. AIl cell culture reagents were from HyClone (Thermo 
Scientific, Logan, UT). Nocodazole, paclitaxel and cyclosporine A were from Sigma 
(St Louis, MI). HeLa and CRFK cells retrovirally transduced to stably express 
omkTRIMCyp were described before (Bérubé et al, 2007; Nepveu-Traversy et al, 2009). 
Rabbit polyclonal antibodies against dynein heavy chain and p50/dynamitin were from 
Santa Cruz (Dallas, TX) and Millipore (Billerica, MA), respectively. The FLAG epitope 
was detected using the M2 mouse monoclonal antibody (Sigma). The HRP-conjugated 
mouse anti-actin antibody was from Sigma. HRP-conjugated goat anti-rabbit and goat 
anti-mouse antibodies used as secondary antibodies in Western blots were from Santa 
Cruz. 
Plasmid DNAs and retrovirus production. p50/dynamitin-HA was a gift from 
Tina Schroer (Schrader et al, 2000). To produce viral vectors, lü-cm culture dishes of 
sub-confluent HEK293T cells were co-transfected using polyethylenimine (MW 25,000; 
Polyscience, Niles, IL) with the appropriate plasmids, as follows: for the viral vector 
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HIV-1CMV-GFP, TRIP-CMV-GFP (10 Ilg), pÔR8.9 (WT or G89V; 10 Ilg) and pMD-G 
(5Ilg) ; for HIV-1NIA3-GFP, pNL-GFP (10 Ilg) and pMD-G (5 Ilg); for SIVmac-GFP, 
pSIV mac-GFP (10 Ilg) and pMD-G (5 Ilg) (Berthoux et al, 2003; He et al, 1997; Zuffereyet 
al, 1997). Media were changed 16 hours post transfection and virus-containing 
supematants were collected after an additional 1.5 days of culture. Viral stocks were 
clarified by centrifugation for 5 min at 400 x g. 
Viral challenges. Cells were seeded in 24-well plates at 105 cells/well (CRFK and 
HeLa cells) or 5 x 104 cells/well (OMK cells) and challenged the next day with the 
appropriate GFP-expressing viral vectors. When applicable, cells were pre-treated for 
15 min with nocodazole, paclitaxel or cyclosporine A, and supematants were replaced 
with fresh medium 16 hours post infection (p.i.). Cells were trypsinized 48 hours p.i. and 
fixed in 2% formaldehyde (Fisher Scientific, Waltham, MA). The percentages of GFP-
positive cells were then determined by analyzing 104 to 105 cells on a FC500 MPL 
cytometer (Beckman Cou1ter, Brea, CA) using the CXP Software (Beckman Coulter). 
siRNA and plasmid transfections. For the siRNA treatments, 106 cells were 
seeded in a 10 cm dish in Opti-MEM (Gibco, Carlsbad, CA) and transfected the next day 
with 40 nM of siRNA using DharmaFECT 1 (Dharmacon, Lafayette, CO). The siRNA 
targeting the sequence 5'GATCAAACATGACGGAATT of the dynein heavy 
chain (DHC), has been described before (Lehmann et al, 2009; Pawlica et al, 2014) 
and was purchased from Qiagen (Venlo, Netherlands). A control siRNA 
(5'CGTACGCGGAATACTTCGATT) targeting the luciferase mRNA (pawlica et al, 
2014) was purchased from Dharmacon. 48 hours post transfection, cells were seeded in 
24-well plates and infected the next day with HIV-1 vectors as described above. For p50 
over-expression, 106 cells seeded in a 10-cm dish were polyethyleneimine-transfected 
with 5 Ilg of p50/dynamitin-HA or an irrelevant plasmid (pMIP). Cells were seeded in 
24-well plates 24 hours later and challenged with viral vectors the next day. 
Immunofluorescence (IF) microscopy. For siRNA treatments, HeLa cells in 
3.5-cm wells were transfected 48 hours prior to seeding as described above. For the cells 
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expressmg GFP-tubulin, 2 Ilg of the plasmid were transfected per well usmg 
polyethyleneimine 24 hours prior to seeding on coverslips. 2 x 105 cells were seeded on 
glass coverslips placed in 3.5-cm wells. 24 hours later, the cells were treated or not with 
nocodazole for 2 hours and then fixed and processed for IF staining. Fixation was done 
for 10 min in 4% formaldehyde-DMEM in 37°C, followed by three washes with ice-cold 
PBS. Cells were then permeabilized by treatrnent with 0.1 % Triton X-100, 0.1 mM 
sodium citrate for 1-2 min on ice. Cells were then washed again three times with PBS 
and treated with 10% normal goat serum (Sigma, St Louis, MI) containing 0.3 M glycine 
(Sigma) for 30 min at RT. This was followed by a 4-hours incubation with a murine 
antibody against the FLAG epitope diluted 1 :400 in PBS containing 10% normal goat 
serum. Ce1ls were washed five times and fluorescently stained with the Alexa594-
conjugated goat anti-mouse antibody (Molecular Probes) at a 1:200 dilution. Ce1ls were 
washed five times in PBS before mounting in Vectashield CV ector Laboratories, 
Burlington, Ontario). Hoechst33342 (0.8 Ilg/ml; Molecular Probes) was added along 
with the penultimate PBS wash to reveal DNA. Z-stacks were acquired on the 
AxioObserver Microscope (Carl Zeiss, Jena, Germany) equipped with the Apotome 
module and median Z-stacks were retained for analysis. For the analysis ofTRIM5a CB 
sizes, FLAG foci in a given cell were manua1ly outlined in the Axio Vision software for 
calculation of the surface. A minimum of 80 and up to 180 CBs from 10 randomly 
chosen cells were included in the analysis. For the analysis of TRIM5a CB localization, 
the cell's edge was outlined and for each FLAG foci in a given cell, we measured the 
closest distance to the nuclear membrane and the closest distance to the plasma 
membrane, using Axiovision. A minimum of 170 and up to 320 CBs from a minimum of 
5 randomly chosen cells were included in the analysis. 
Statistical analysis. AlI statistical analyses were done m Graph Prism 5 
(GraphPad Software, Inc., La Jolla, CA, USA). 
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